<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virus Res</journal-id><journal-id journal-id-type="iso-abbrev">Virus Res</journal-id><journal-title-group><journal-title>Virus Research</journal-title></journal-title-group><issn pub-type="ppub">0168-1702</issn><issn pub-type="epub">1872-7492</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7260533</article-id><article-id pub-id-type="publisher-id">S0168-1702(20)30293-8</article-id><article-id pub-id-type="doi">10.1016/j.virusres.2020.198040</article-id><article-id pub-id-type="publisher-id">198040</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5&#x00394;32 on viral diseases</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Ellwanger</surname><given-names>Joel Henrique</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Kulmann-Leal</surname><given-names>Bruna</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Kaminski</surname><given-names>Val&#x000e9;ria de Lima</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Rodrigues</surname><given-names>Andressa Gon&#x000e7;alves</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0025"><name><surname>Bragatte</surname><given-names>Marcelo Alves de Souza</given-names></name><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="aut0030"><name><surname>Chies</surname><given-names>Jos&#x000e9; Artur Bogo</given-names></name><email>jabchies@terra.com.br</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="cor0005" ref-type="corresp">*</xref></contrib><aff id="aff0005"><label>a</label>Laborat&#x000f3;rio de Imunobiologia e Imunogen&#x000e9;tica, Departamento de Gen&#x000e9;tica, Universidade Federal do Rio Grande do Sul &#x02013; UFRGS, Porto Alegre, Brazil</aff><aff id="aff0010"><label>b</label>Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Gen&#x000e9;tica e Biologia Molecular, Departamento de Gen&#x000e9;tica, Universidade Federal do Rio Grande do Sul &#x02013; UFRGS, Porto Alegre, Brazil</aff><aff id="aff0015"><label>c</label>Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Biotecnologia, Laborat&#x000f3;rio de Imunologia Aplicada, Instituto de Ci&#x000ea;ncia e Tecnologia - ICT, Universidade Federal de S&#x000e3;o Paulo - UNIFESP, S&#x000e3;o Jos&#x000e9; dos Campos, S&#x000e3;o Paulo, Brazil</aff><aff id="aff0020"><label>d</label>N&#x000fa;cleo de Bioinform&#x000e1;tica do Laborat&#x000f3;rio de Imunobiologia e Imunogen&#x000e9;tica, Departamento de Gen&#x000e9;tica, Universidade Federal do Rio Grande do Sul &#x02013; UFRGS, Porto Alegre, Brazil</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: Laborat&#x000f3;rio de Imunobiologia e Imunogen&#x000e9;tica (Pr&#x000e9;dio 43323, Laborat&#x000f3;rio 212), Departamento de Gen&#x000e9;tica, Instituto de Bioci&#x000ea;ncias, Universidade Federal do Rio Grande do Sul &#x02013; UFRGS, Av. Bento Gon&#x000e7;alves, 9500, Campus do Vale, 91501-970, Porto Alegre, RS, Brazil. <email>jabchies@terra.com.br</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>30</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>5</month><year>2020</year></pub-date><volume>286</volume><fpage>198040</fpage><lpage>198040</lpage><history><date date-type="received"><day>26</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>27</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>&#x02022;</label><p id="par0005">CCR5 regulates multiple cell types (<italic>e.g.</italic>, T regulatory and Natural Killer cells) and immune responses.</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p id="par0010">The effects of CCR5, CCR5&#x00394;32 (variant associated with reduced CCR5 expression) and CCR5 antagonists vary between infections.</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p id="par0015">CCR5 affects the pathogenesis of flaviviruses, especially in the brain.</p></list-item><list-item id="lsti0020"><label>&#x02022;</label><p id="par0020">The genetic variant CCR5&#x00394;32 increases the risk of symptomatic West Nile virus infection.</p></list-item><list-item id="lsti0025"><label>&#x02022;</label><p id="par0025">The triad &#x0201c;CCR5, extracellular vesicles and infections&#x0201d; is an emerging topic.</p></list-item></list></p></abstract><abstract id="abs0010"><p>The interactions between chemokine receptors and their ligands may affect susceptibility to infectious diseases as well as their clinical manifestations. These interactions mediate both the traffic of inflammatory cells and virus-associated immune responses. In the context of viral infections, the human C-C chemokine receptor type 5 (CCR5) receives great attention from the scientific community due to its role as an HIV-1 co-receptor. The genetic variant CCR5&#x00394;32 (32 base-pair deletion in <italic>CCR5</italic> gene) impairs CCR5 expression on the cell surface and is associated with protection against HIV infection in homozygous individuals. Also, the genetic variant CCR5&#x00394;32 modifies the CCR5-mediated inflammatory responses in various conditions, such as inflammatory and infectious diseases. CCR5 antagonists mimic, at least in part, the natural effects of the CCR5&#x00394;32 in humans, which explains the growing interest in the potential benefits of using CCR5 modulators for the treatment of different diseases. Nevertheless, beyond HIV infection, understanding the effects of the CCR5&#x00394;32 variant in multiple viral infections is essential to shed light on the potential effects of the CCR5 modulators from a broader perspective. In this context, this review discusses the involvement of CCR5 and the effects of the CCR5&#x00394;32 in human infections caused by the following pathogens: West Nile virus, Influenza virus, Human papillomavirus, Hepatitis B virus, Hepatitis C virus, Poliovirus, Dengue virus, Human cytomegalovirus, Crimean-Congo hemorrhagic fever virus, Enterovirus, Japanese encephalitis virus, and Hantavirus. Subsequently, this review addresses the impacts of <italic>CCR5</italic> gene editing and CCR5 modulation on health and viral diseases. Also, this article connects recent findings regarding extracellular vesicles (<italic>e.g.</italic>, exosomes), viruses, and CCR5. Neglected and emerging topics in &#x0201c;CCR5 research&#x0201d; are briefly described, with focus on Rocio virus, Zika virus, Epstein-Barr virus, and Rhinovirus. Finally, the potential influence of CCR5 on the immune responses to coronaviruses is discussed.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>C-C chemokine receptor type 5</kwd><kwd>Chemokine</kwd><kwd>Host-pathogen interactions</kwd><kwd>Immunogenetics</kwd><kwd>Inflammation</kwd><kwd>Viral infection</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0030">Inflammatory cells play a crucial role in protecting the host from viral infections. Leukocyte migration is a fundamental step of the inflammatory response to viruses, a process regulated by the interaction between chemokines and their receptors. Therefore, dysregulations in the chemokine-mediated inflammatory process may contribute to viral pathogenesis (<xref rid="bib0530" ref-type="bibr">Glass et al., 2003</xref>). The C-C chemokine receptor type 5 (CCR5) interacts primarily with the chemokines CCL3 (MIP-1&#x003b1;), CCL4 (MIP-1&#x003b2;), and CCL5 (RANTES), which act as CCR5 agonists by stimulating cell migration and mediating inflammatory responses. On the other hand, the chemokine MCP-3/CCL7 is the main CCR5 antagonist ligand (<xref rid="bib0140" ref-type="bibr">Blanpain et al., 1999</xref>; <xref rid="bib1705" ref-type="bibr">Zlotnik and Yoshie, 2000</xref>; <xref rid="bib0530" ref-type="bibr">Glass et al., 2003</xref>; <xref rid="bib0055" ref-type="bibr">Alkhatib, 2009</xref>).</p><p id="par0035">In addition to regulating the migration of non-specific leukocytes during inflammatory responses, CCR5 controls the action of specific cell types, including natural killer (NK) cells (<xref rid="bib0735" ref-type="bibr">Khan et al., 2006</xref>; <xref rid="bib1610" ref-type="bibr">Weiss et al., 2011</xref>) and regulatory T (Treg) cells (<xref rid="bib1630" ref-type="bibr">Wysocki et al., 2005</xref>; <xref rid="bib1455" ref-type="bibr">Tan et al., 2009</xref>; <xref rid="bib0350" ref-type="bibr">Dobaczewski et al., 2010</xref>). CCR5 is also expressed by tissue-resident memory T cells. These CCR5<sup>+</sup> cells support barrier immunity (<xref rid="bib0320" ref-type="bibr">Davis et al., 2019</xref>).</p><p id="par0040">The CCR5 is a G-protein-coupled receptor (GPCR), containing seven transmembrane &#x003b1;-helices, three extracellular loops, and three intracellular loops (<xref rid="bib1460" ref-type="bibr">Tan et al., 2013</xref>). <xref rid="fig0005" ref-type="fig">Fig. 1</xref>
shows the structure of CCR5, highlighting its transmembrane domains and extra and intracellular loops. The specificity of interaction between CCR5 and chemokines is mediated by the second extracellular loop (<xref rid="bib1285" ref-type="bibr">Samson et al., 1997</xref>). Helices 2 and 3 have a fundamental role in chemokine-induced CCR5 activation (<xref rid="bib0550" ref-type="bibr">Govaerts et al., 2003</xref>). The steps required from ligand binding culminating in cell migration encompass a series of intracellular interactions, including the G-protein heterotrimer and downstream effectors (<xref rid="bib0815" ref-type="bibr">Lacalle et al., 2017</xref>). After stimulation by chemokines or natural reactive antibodies and subsequent triggering of chemotaxis, CCR5 is phosphorylated and internalized in the cytoplasm (<xref rid="bib1370" ref-type="bibr">Signoret et al., 2000</xref>; <xref rid="bib1555" ref-type="bibr">Venuti et al., 2015</xref>, <xref rid="bib1560" ref-type="bibr">2016</xref>; <xref rid="bib0815" ref-type="bibr">Lacalle et al., 2017</xref>; <xref rid="bib1565" ref-type="bibr">Venuti et al., 2017</xref>, <xref rid="bib1570" ref-type="bibr">2018</xref>).<fig id="fig0005"><label>Fig. 1</label><caption><p><bold>Crystal structure of CCR5.</bold> Crystal structure of CCR5 from RCSB PDB data bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/" id="intr0005">https://www.rcsb.org/</ext-link>) presented with ChimeraX molecular visualization program. A) 4MBS (CCR5, resolution 2.71 Angstroms) molecule, without contact with any ligand/inhibitor, display of the entire domain is shown in cartoon mode and colored in blue. The surface with transparency in red highlights only transmembrane regions of CCR5. B) 5UIW (CCR5 in complex with high potency HIV entry inhibitor 5P7&#x02212;CCL5, resolution 2.20 Angstroms) molecule display of the entire domain is shown in cartoon mode and colored in purple. The surface with transparency (colored in orange) emphasizes subtle changes in the spatial conformation of the molecule when in contact with the inhibitor colored in green. Crystallography: <xref rid="bib1460" ref-type="bibr">Tan et al. (2013)</xref> for 4MBS and <xref rid="bib1690" ref-type="bibr">Zheng et al. (2017)</xref> for 5UIW.</p></caption><alt-text id="at0060">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="par0045">The number of available receptors on the cell surface is related to the rate of internalization and recycling of CCR5, which affects the activation of CCR5 and consequent signaling of specific pathways that culminate in chemotaxis processes (<xref rid="bib1050" ref-type="bibr">Mueller et al., 2002</xref>). Of note, intracellular pools of CCR5 can be detected in the cells. These pools are probably formed by internalized or immature/precursor forms of CCR5 molecules (<xref rid="bib1020" ref-type="bibr">Mirzabekov et al., 1999</xref>; <xref rid="bib0770" ref-type="bibr">Kohlmeier et al., 2008</xref>; <xref rid="bib0010" ref-type="bibr">Achour et al., 2009</xref>; <xref rid="bib0580" ref-type="bibr">Guglielmi et al., 2011</xref>; <xref rid="bib1360" ref-type="bibr">Shirvani et al., 2011</xref>) that can be rapidly expressed on the cell surface in response to viral stimuli and inflammatory responses (<xref rid="bib0770" ref-type="bibr">Kohlmeier et al., 2008</xref>). In other words, CCR5 molecules are recycled by cells. Specifically, CCR5 recycling can be mediated by degradation followed by <italic>de novo</italic> synthesis (in response to stimulation by natural antibodies) or occur in the classic short-term system without <italic>de novo</italic> synthesis (in response to stimulation by CCL5, for example) (<xref rid="bib1555" ref-type="bibr">Venuti et al., 2015</xref>, <xref rid="bib1560" ref-type="bibr">2016</xref>). The traffic of CCR5 between the plasma membrane and the intracellular medium is mediated by different molecules, including clathrins, &#x003b2;-arrestin 2, and extracellular signal-regulated kinase (ERK) 1 (<xref rid="bib1555" ref-type="bibr">Venuti et al., 2015</xref>, <xref rid="bib1560" ref-type="bibr">2016</xref>; <xref rid="bib1570" ref-type="bibr">Venuti et al., 2018</xref>). Also, intracellular CD4 regulates the expression of CCR5 on the cell surface (<xref rid="bib0010" ref-type="bibr">Achour et al., 2009</xref>).</p><p id="par0050">The human CCR5 protein (352 residues) is encoded by the <italic>CCR5</italic> gene [Chromosome 3 (3p.21.31)], which is very polymorphic (<xref rid="bib0145" ref-type="bibr">Blanpain et al., 2000</xref>; <xref rid="bib0635" ref-type="bibr">Hoover, 2018</xref>). Among polymorphisms of the <italic>CCR5</italic>, the CCR5&#x00394;32 (rs333) has been intensively studied in different human populations. The frequency of the CCR5&#x00394;32 is quite variable. In general, the &#x00394;32 allele frequency is high in European-derived populations (for example, 16 % in Norway and 11 % in Germany) and low or absent in African and Asian populations (<xref rid="bib1405" ref-type="bibr">Solloch et al., 2017</xref>). However, although the &#x00394;32 allele is more frequent in European populations, there are exceptions due to migratory events. For example, the frequency of the &#x00394;32 allele is high in South Africa (13 %) and Chile (12 %) (<xref rid="bib1405" ref-type="bibr">Solloch et al., 2017</xref>). Also, the frequency of the &#x00394;32 allele can be quite variable within the same country. In Brazil, the frequency of the allele in the general population is around 4&#x02013;5 % (<xref rid="bib1380" ref-type="bibr">Silva-Carvalho et al., 2016</xref>; <xref rid="bib1405" ref-type="bibr">Solloch et al., 2017</xref>). In the southern region of the country, the frequency can reach up to 9% due to the past migration of European populations to this region (<xref rid="bib0150" ref-type="bibr">Boldt et al., 2009</xref>; <xref rid="bib1130" ref-type="bibr">Pena et al., 2011</xref>; <xref rid="bib1305" ref-type="bibr">Schauren et al., 2013</xref>). <xref rid="fig0010" ref-type="fig">Fig. 2</xref>
summarizes basic aspects of CCR5 and shows the frequency of the &#x00394;32 allele in various countries.<fig id="fig0010"><label>Fig. 2</label><caption><p><bold>Fundamental aspects of CCR5 (panel A) and frequency of the &#x00394;32 allele in selected countries (panel B).</bold> This figure was created using Servier Medical Art illustrations (available at <ext-link ext-link-type="uri" xlink:href="https://smart.servier.com" id="intr0010">https://smart.servier.com</ext-link>, under a Creative Commons Attribution 3.0 Unported License). The bar chart was plotted using GraphPad Prism 5.01 software (GraphPad Software, Inc., San Diego, CA, USA). The &#x00394;32 allele frequencies were obtained from <xref rid="bib1405" ref-type="bibr">Solloch et al. (2017)</xref>.</p></caption><alt-text id="at0065">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><p id="par0055">The CCR5&#x00394;32 is the most studied genetic variant of the <italic>CCR5</italic> gene because of its strong protective effect against HIV infection (considering susceptibility to CCR5-tropic strains). HIV entry into CD4<sup>+</sup> T cells is mediated by the interaction of the virus with CD4 and with a co-receptor, usually CCR5. The CCR5&#x00394;32 variant is a 32 base-pair deletion in the <italic>CCR5</italic> coding region, which causes a frameshift, resulting in a truncated protein that is not directed to the cell surface. CCR5&#x00394;32 in heterozygosis promotes a decrease in the expression of functional CCR5 on the cell surface compared to <italic>CCR5</italic> wild-type cells. Therefore, individuals with heterozygous genotype for CCR5&#x00394;32, if infected with HIV, have a small protection against disease progression due to the reduced expression of CCR5 on the surface of CD4<sup>+</sup> T cells (reduced HIV&#x02212;CCR5 interaction). In CCR5&#x00394;32 homozygous cells, no CCR5 is expressed in the plasmatic membrane. Therefore, homozygous individuals for this polymorphism (&#x00394;32/&#x00394;32) show virtually total protection against HIV type 1 infection, since no CCR5 expression is verified on cell surface (no HIV&#x02212;CCR5 interaction at cell surface is possible) (<xref rid="bib0330" ref-type="bibr">Deng et al., 1996</xref>; <xref rid="bib0365" ref-type="bibr">Dragic et al., 1996</xref>; <xref rid="bib0650" ref-type="bibr">Huang et al., 1996</xref>; <xref rid="bib1280" ref-type="bibr">Samson et al., 1996</xref>; <xref rid="bib1620" ref-type="bibr">Wu et al., 1997</xref>; <xref rid="bib1180" ref-type="bibr">Proudfoot, 2002</xref>; <xref rid="bib1550" ref-type="bibr">Venkatesan et al., 2002</xref>; <xref rid="bib1150" ref-type="bibr">Picton et al., 2012</xref>). <xref rid="fig0015" ref-type="fig">Fig. 3</xref>
illustrates the phenotypic effects of CCR5&#x00394;32 in human cells.<fig id="fig0015"><label>Fig. 3</label><caption><p><bold>Phenotypic effects of the polymorphism CCR5&#x00394;32 in human cells.</bold> WT/WT: wild-type homozygous genotype. WT/&#x00394;32: heterozygous genotype. &#x00394;32/&#x00394;32: variant homozygous genotype. This figure was created using Servier Medical Art illustrations (available at <ext-link ext-link-type="uri" xlink:href="https://smart.servier.com" id="intr0015">https://smart.servier.com</ext-link>, under a Creative Commons Attribution 3.0 Unported License).</p></caption><alt-text id="at0070">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p><p id="par0060">The main results involving the triad &#x0201c;CCR5, HIV, and CCR5&#x00394;32&#x02033; were published in 1996 in <italic>Nature</italic>, <italic>Cell</italic> and <italic>Science</italic> papers by different groups (<xref rid="bib1120" ref-type="bibr">Parmentier, 2015</xref>). Since then, the research involving CCR5 has explored the role of the CCR5 protein and CCR5&#x00394;32 polymorphism in different diseases, as well as the therapeutic potentials of CCR5 blockade. Currently, the physical interaction of CCR5 with HIV is known in detail (<xref rid="bib1340" ref-type="bibr">Shaik et al., 2019</xref>) and the research involving the impacts of CCR5&#x00394;32 on HIV infection has led to the development of CCR5 antagonists: quite effective drugs used in the treatment of HIV-infected individuals, especially the licensed drug Maraviroc (Pfizer, Inc.), an allosteric modulator approved for clinical use in 2007 (<xref rid="bib1535" ref-type="bibr">Van Der Ryst, 2015</xref>; <xref rid="bib0840" ref-type="bibr">Latinovic et al., 2019</xref>). Also, a recent study has shown that molecules that inhibit CCR5 trafficking to the plasma membrane also have a therapeutic potential against HIV infection (<xref rid="bib0155" ref-type="bibr">Boncompain et al., 2019</xref>). Research involving CCR5 has also brought other important advances in combating HIV infection. Of note, there are already two cases of sustained remission of HIV infection following stem-cell transplantation using CCR5&#x00394;32 homozygous donor, the &#x0201c;Berlin Patient&#x0201d; (<xref rid="bib0670" ref-type="bibr">H&#x000fc;tter et al., 2009</xref>) and the &#x0201c;London Patient&#x0201d; (<xref rid="bib0595" ref-type="bibr">Gupta et al., 2019</xref>, <xref rid="bib0600" ref-type="bibr">2020</xref>). <xref rid="fig0020" ref-type="fig">Fig. 4</xref>
summarizes the effects of CCR5&#x00394;32 (homozygous genotype) on HIV infection and the main achievements of the research involving CCR5 and HIV infection.<fig id="fig0020"><label>Fig. 4</label><caption><p><bold>Effects of the CCR5&#x00394;32 (homozygous genotype) on HIV infection (upper panel) and the main achievements of the research involving CCR5 and HIV infection (bottom panel).</bold> This figure was created using Servier Medical Art illustrations (available at <ext-link ext-link-type="uri" xlink:href="https://smart.servier.com" id="intr0020">https://smart.servier.com</ext-link>, under a Creative Commons Attribution 3.0 Unported License).</p></caption><alt-text id="at0075">Fig. 4</alt-text><graphic xlink:href="gr4_lrg"/></fig></p><p id="par0065">Beyond the effects of CCR5/CCR5&#x00394;32 on HIV infection, CCR5&#x00394;32 impacts non-viral infectious diseases (<xref rid="bib1520" ref-type="bibr">Ungv&#x000e1;ri et al., 2007</xref>; <xref rid="bib1275" ref-type="bibr">Salnikova et al., 2013</xref>) and inflammation-related conditions (<xref rid="bib0245" ref-type="bibr">Chies and Nardi, 2001</xref>; <xref rid="bib0095" ref-type="bibr">Balistreri et al., 2009</xref>; <xref rid="bib1060" ref-type="bibr">Muntinghe et al., 2012</xref>; <xref rid="bib0700" ref-type="bibr">Kaminski et al., 2019a</xref>; <xref rid="bib0810" ref-type="bibr">Kulmann-Leal et al., 2020</xref>). Therefore, both the CCR5 molecule <italic>per se</italic> as well as the CCR5&#x00394;32 variant, through the interference on the interaction of CCR5 with its ligands, may impact CCR5-mediated antiviral cellular activity and inflammatory reactions during host response against pathogens. Indeed, the CCL5&#x02212;CCR5 axis influences virus-associated immune responses (<xref rid="bib1515" ref-type="bibr">Tyner et al., 2005</xref>; <xref rid="bib0560" ref-type="bibr">Grayson et al., 2007</xref>; <xref rid="bib0230" ref-type="bibr">Chen et al., 2017</xref>). Although the effects of CCR5&#x00394;32 on CCR5 expression are clear, CCR5 and CCR5&#x00394;32 have varied and even contrasting roles in different diseases. Due to interactions with other genetic variants as well as with environmental factors, the role of CCR5&#x00394;32 may differ even within the same disease, depending on the ethnic group or population assessed (<xref rid="bib1200" ref-type="bibr">Rautenbach and Williams, 2020</xref>). Studying the involvement of CCR5 and the effects of CCR5&#x00394;32 on infectious diseases may contribute to the understanding of the genetic factors involved in the susceptibility and progression of multiple viral diseases. Also, these studies can shed light on the use of CCR5 modulators/blockers in a broader perspective, beyond HIV infection. In this context, the aim of this review is to discuss the involvement of CCR5 and the effects of the CCR5&#x00394;32 in human viral infections, covering West Nile virus, Influenza viruses, Human papillomavirus, Hepatitis B virus, Hepatitis C virus, Poliovirus, Dengue virus, Human cytomegalovirus, Crimean-Congo hemorrhagic fever virus, Enterovirus, Japanese encephalitis virus, and Hantavirus. This review also addresses the impacts of <italic>CCR5</italic> gene editing and the CCR5 modulation on health and viral diseases. Recently, the role of extracellular vesicles has brought complexity to the fields of both immunology and virology. Therefore, this article connects recent findings regarding extracellular vesicles, viruses, and CCR5. In the last part of the review, neglected and emerging topics in &#x0201c;CCR5 research&#x0201d; are briefly discussed, with a focus on Rocio virus, Zika virus, Epstein-Barr virus, and Rhinovirus.</p><p id="par0070">Studies involving HIV will not be included in this article because different aspects of the relationship between HIV and CCR5/CCR5&#x00394;32 are well established and have already been intensely explored in different reviews (<xref rid="bib0060" ref-type="bibr">Allen et al., 2018</xref>; <xref rid="bib0170" ref-type="bibr">Brelot and Chakrabarti, 2018</xref>; <xref rid="bib1090" ref-type="bibr">Ndung&#x02019;u et al., 2019</xref>). Also, the impacts of CCR5 and CCR5&#x00394;32 on tick-borne encephalitis virus (TBEV) infection will not be addressed in this article because our group has recently reviewed these topics in a recent publication (<xref rid="bib0380" ref-type="bibr">Ellwanger and Chies, 2019a</xref>).</p></sec><sec id="sec0010"><label>2</label><title>Methodological notes</title><p id="par0075">This article is characterized as a narrative review. The selection of the articles was carried out from an initial search on PubMed (<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/" id="intr0030">https://pubmed.ncbi.nlm.nih.gov/</ext-link>), using the terms &#x0201c;CCR5&#x0201d;, &#x0201c;CCR5&#x00394;32&#x0201d;, &#x0201c;virus&#x0201d;, &#x0201c;viral infection&#x0201d;, &#x0201c;exosomes&#x0201d;, and &#x0201c;extracellular vesicles&#x0201d; (separately and in association). After extensive analysis of article abstracts, it was established that the review would address the following viruses: West Nile virus, Influenza viruses, Human papillomavirus, Hepatitis B virus, Hepatitis C virus, Poliovirus, Dengue virus, Human cytomegalovirus, Crimean-Congo hemorrhagic fever virus, Enterovirus, Japanese encephalitis virus, Hantavirus, Rocio virus, Zika virus, Epstein-Barr virus, and Rhinovirus. All original articles that evaluated the involvement of CCR5 or CCR5&#x00394;32 in the infections caused by the mentioned viruses were analyzed. Subsequently, the Google Scholar (<ext-link ext-link-type="uri" xlink:href="https://scholar.google.com.br/" id="intr0035">https://scholar.google.com.br/</ext-link>) was consulted to detect relevant papers that were not indexed in PubMed, using the terms &#x0201c;CCR5&#x0201d; in association with the name of each of the viruses covered in the review. The authors of this review tried to include the largest number of original articles that addressed the topic covered in this work, intending to write a broad and complete article. However, some papers were not included because it was not possible to obtain clear conclusions from the studies. The reference lists of the consulted articles were also used to complement the selection of articles for this review.</p><p id="par0080">As previously mentioned in the introduction, a discussion addressing the involvement of CCR5 in TBEV infection was not included in this work. Articles addressing the involvement of CCR5 and CCR5&#x00394;32 in HIV infection were included only to present to the reader some basic and historical aspects related to such topics, cited mainly in the introduction section and figures, but not included as a major section of the article. Considering the importance of the coronavirus disease 19 (COVID-19) pandemic, a section addressing the potential influence of CCR5 on the immune responses to coronaviruses was included in this article. Review articles were also selected in PubMed and Google Scholar for writing the sections and paragraphs that address the basic aspects of viruses, exosomes, and diseases (<italic>e.g.</italic>, epidemiological, molecular, clinical aspects). Exceptionally, review articles with outstanding discussions regarding the role of CCR5 in viral infections were also cited in this work. Regarding tables, it is important to note that the data available in the &#x0201c;Population&#x0201d; columns are limited and often represent only general characteristics of the evaluated population. In many studies, a population can be composed of individuals from various ethnic groups. This limitation must be taken into account when evaluating the results of the studies cited in the tables. Finally, also in &#x0201c;Population&#x0201d; columns, &#x0201c;information not available&#x0201d; was used when this information was not clearly described in the cited article.</p></sec><sec id="sec0015"><label>3</label><title>CCR5&#x00394;32 and viral infections</title><sec id="sec0020"><label>3.1</label><title>West Nile virus</title><p id="par0085">West Nile virus (WNV) is a neurotropic positive-sense single-stranded RNA flavivirus endemic in various parts of the world. WNV transmission to humans occurs through the bite of infected mosquitoes, especially species of the <italic>Culex</italic> genus (<xref rid="bib1440" ref-type="bibr">Suthar et al., 2013</xref>). Although different animals can participate in the WNV transmission cycle, birds are the classic amplifier hosts. Humans, horses and other mammals are dead-end hosts (<xref rid="bib0785" ref-type="bibr">Kramer et al., 2008</xref>; <xref rid="bib0205" ref-type="bibr">CDC, 2018</xref>). Among humans, blood transfusion, organ transplantation, and breast milk can also transmit the virus. Vertical transmission may also occur. However, compared to transmission by mosquito bites, these routes of transmission are rare (<xref rid="bib0785" ref-type="bibr">Kramer et al., 2008</xref>).</p><p id="par0090">About 25 % of WNV-infected individuals develop West Nile fever, a clinical condition with variable symptoms and severity. In less than 1% of the infected individuals, WNV invades the central nervous system (CNS), causing neurological manifestations (neuroinvasive disease), including meningitis, encephalitis, and acute flaccid paralysis. Of note, West Nile neuroinvasive disease shows a 10%&#x02013;20% fatality rate. Severe illness is associated with older age and other factors, including genetic traces (<xref rid="bib1140" ref-type="bibr">Petersen et al., 2013</xref>; <xref rid="bib1320" ref-type="bibr">Sejvar, 2016</xref>). WNV infection is considered the leading cause of arboviral encephalitis in the world (<xref rid="bib0265" ref-type="bibr">Ciota, 2017</xref>). The treatment of WNV infection is supportive (<xref rid="bib1140" ref-type="bibr">Petersen et al., 2013</xref>).</p><p id="par0095">It is known that the CCR5 protein interferes in the clinical course of WNV infection (<xref rid="bib0535" ref-type="bibr">Glass et al., 2005</xref>; <xref rid="bib0345" ref-type="bibr">Diamond, 2009</xref>; <xref rid="bib1015" ref-type="bibr">Michlmayr and Lim, 2014</xref>), but the effects of CCR5&#x00394;32 on the susceptibility to this infection and disease progression are different. According to <xref rid="bib0910" ref-type="bibr">Lim et al. (2010)</xref> and <xref rid="bib0315" ref-type="bibr">Danial-Farran et al. (2015)</xref>, CCR5&#x00394;32 has no important effect on susceptibility to WNV infection. In accordance, <xref rid="bib0940" ref-type="bibr">Loeb et al. (2011)</xref> found no association between CCR5&#x00394;32 and WNV infection. Conversely, there is robust population-based data showing a strong association between the CCR5&#x00394;32 homozygous genotype and increased risk of developing symptomatic WNV infection (<xref rid="bib0540" ref-type="bibr">Glass et al., 2006</xref>; <xref rid="bib0905" ref-type="bibr">Lim et al., 2008</xref>, <xref rid="bib0910" ref-type="bibr">2010</xref>). Also, <xref rid="bib0125" ref-type="bibr">Bigham et al. (2011)</xref> showed that the CCR5&#x00394;32 variant was associated with symptomatic WNV infection when the dominant model of inheritance was considered in the analysis. A recent meta-analysis confirmed the role of the <italic>CCR5</italic> gene in WNV infection, specifically the association between the CCR5&#x00394;32 with severe disease (<xref rid="bib0185" ref-type="bibr">Cahill et al., 2018</xref>). <xref rid="tbl0005" ref-type="table">Table 1</xref>
summarizes the results of the studies that evaluated the CCR5&#x00394;32 genetic variant in the context of human WNV infection.<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Impacts of CCR5&#x00394;32 on West Nile virus (WNV) infection.</p></caption><alt-text id="at0085">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Population</th><th align="left">Sample</th><th align="left">Main findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">American</td><td align="left">395 symptomatic WNV&#x0202f;+&#x0202f;individuals; 145 symptomatic but non-infected individuals; 1318 controls (blood donors)</td><td align="left">The CCR5&#x00394;32 homozygous genotype was strongly associated with increased risk of symptomatic WNV infection</td><td align="left"><xref rid="bib0540" ref-type="bibr">Glass et al. (2006)</xref></td></tr><tr><td align="left">American</td><td align="left">224 symptomatic WNV&#x0202f;+&#x0202f;individuals; 1318 controls (blood donors)</td><td align="left">Corroborating data from <xref rid="bib0540" ref-type="bibr">Glass et al. (2006)</xref>, the CCR5&#x00394;32 homozygous genotype was strongly associated with increased risk of symptomatic WNV infection</td><td align="left"><xref rid="bib0905" ref-type="bibr">Lim et al. (2008)</xref></td></tr><tr><td align="left">American</td><td align="left">634 WNV&#x0202f;+&#x0202f;individuals; 422 non-infected individuals</td><td align="left">CCR5&#x00394;32 homozygous genotype was associated with clinical symptoms of WNV infection; No association between CCR5&#x00394;32 and susceptibility to WNV infection</td><td align="left"><xref rid="bib0910" ref-type="bibr">Lim et al. (2010)</xref></td></tr><tr><td align="left">American, Canadian</td><td align="left">385 symptomatic WNV&#x0202f;+&#x0202f;individuals; 328 asymptomatic WNV&#x0202f;+&#x0202f;individuals; 1318 controls [blood donors from <xref rid="bib0540" ref-type="bibr">Glass et al. (2006)</xref>]</td><td align="left">No association of CCR5&#x00394;32 and WNV infection considering symptomatic and asymptomatic WNV&#x0202f;+&#x0202f;individuals; Considering a dominant model of inheritance of CCR5&#x00394;32 and using controls from <xref rid="bib0540" ref-type="bibr">Glass et al. (2006)</xref>, the CCR5&#x00394;32 was associated with symptomatic WNV infection and infection risk</td><td align="left"><xref rid="bib0125" ref-type="bibr">Bigham et al. (2011)</xref></td></tr><tr><td align="left">American, Canadian</td><td align="left">821 WNV&#x0202f;+&#x0202f;individuals with severe infection; 1233 individuals with non-severe infection</td><td align="left">No association between CCR5&#x00394;32 and WNV infection severity</td><td align="left"><xref rid="bib0940" ref-type="bibr">Loeb et al. (2011)</xref></td></tr><tr><td align="left">Israeli (Ashkenazi Jews)</td><td align="left">39 symptomatic WNV&#x0202f;+&#x0202f;individuals; 61 non-infected individuals</td><td align="left">No association between CCR5&#x00394;32 and WNV infection</td><td align="left"><xref rid="bib0315" ref-type="bibr">Danial-Farran et al. (2015)</xref></td></tr></tbody></table></table-wrap></p><p id="par0100">In agreement with studies showing that CCR5&#x00394;32 homozygous genotype is a risk factor for symptomatic WNV infection in humans, <italic>Ccr5</italic>-/- WNV-infected mice showed a reduced capacity of viral control, increased disease severity, impaired leukocyte trafficking towards the brain, and high mortality rates than <italic>Ccr5</italic> wild-type mice. These findings reinforce that Ccr5 is a key molecule in the immune response against WNV (<xref rid="bib0535" ref-type="bibr">Glass et al., 2005</xref>; <xref rid="bib0370" ref-type="bibr">Durrant et al., 2015</xref>). Taking together, these pieces of evidence robustly support the role of CCR5 as a protective molecule on WNV pathogenesis. Specifically, CCR5+ leukocytes play a fundamental role in combating WNV in the brain (<xref rid="bib0535" ref-type="bibr">Glass et al., 2005</xref>; <xref rid="bib0900" ref-type="bibr">Lim et al., 2006</xref>; <xref rid="bib1015" ref-type="bibr">Michlmayr and Lim, 2014</xref>; <xref rid="bib0370" ref-type="bibr">Durrant et al., 2015</xref>). In this sense, CCR5 plays a specific and non-redundant role in controlling WNV infection (<xref rid="bib0895" ref-type="bibr">Lim and Murphy, 2011</xref>; <xref rid="bib0370" ref-type="bibr">Durrant et al., 2015</xref>; <xref rid="bib0425" ref-type="bibr">Ellwanger et al., 2020a</xref>).</p><p id="par0105">Based on the data mentioned above, the lack of CCR5 expression linked to CCR5&#x00394;32 homozygosis is an important risk factor for increased severity of WNV-associated disease. The opposite effects of the CCR5&#x00394;32 genetic variant on both HIV and WNV infections are summarized in <xref rid="fig0025" ref-type="fig">Fig. 5</xref>
. Hereupon, individuals homozygous for CCR5&#x00394;32 and living in endemic areas of the WNV should take additional care to prevent WNV infection (<italic>e.g.</italic>, use of repellents, mosquito nets). Also, the use of CCR5 blockers to treat HIV infection may have a negative impact on populations living in WNV-endemic areas. To avoid this negative impact, HIV-infected individuals who live in such areas and who use CCR5 blockers must apply robust measures against mosquito bites (<xref rid="bib0540" ref-type="bibr">Glass et al., 2006</xref>; <xref rid="bib0900" ref-type="bibr">Lim et al., 2006</xref>; <xref rid="bib0895" ref-type="bibr">Lim and Murphy, 2011</xref>).<fig id="fig0025"><label>Fig. 5</label><caption><p><bold>Effects of the polymorphism CCR5&#x00394;32 on HIV and WNV infections.</bold> Upper panel: effects observed in individuals with the wild-type homozygous genotype (WT/WT). Bottom panel: effects observed in individuals with the homozygous genotype variant (&#x00394;32/&#x00394;32). This figure was created using Servier Medical Art illustrations (available at <ext-link ext-link-type="uri" xlink:href="https://smart.servier.com" id="intr0025">https://smart.servier.com</ext-link>, under a Creative Commons Attribution 3.0 Unported License).</p></caption><alt-text id="at0080">Fig. 5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p></sec><sec id="sec0025"><label>3.2</label><title>Influenza virus</title><p id="par0110">Influenza infection affects humans seasonally, causing recurrent epidemics and even pandemics in some years. In humans, the infection is caused basically by influenza A and influenza B, both enveloped negative-sense single-stranded RNA viruses belonging to <italic>Orthomyxoviridae</italic> family (<xref rid="bib0790" ref-type="bibr">Krammer et al., 2018</xref>; <xref rid="bib1145" ref-type="bibr">Petrova and Russell, 2018</xref>). Influenza A is a zoonotic disease, and influenza B circulates primarily in humans. Influenza infection affects mainly the respiratory tract, which can cause mild to severe disease depending on viral and host characteristics. Secondary bacterial infection may also occur (<xref rid="bib0790" ref-type="bibr">Krammer et al., 2018</xref>). Human co-infection with multiple influenza types is an important neglected problem (<xref rid="bib0570" ref-type="bibr">Gregianini et al., 2019</xref>). Influenza is a prevalent infection worldwide, and new vaccines are produced annually, based on strains circulating each year in the Northern and Southern hemispheres (<xref rid="bib0790" ref-type="bibr">Krammer et al., 2018</xref>; <xref rid="bib1145" ref-type="bibr">Petrova and Russell, 2018</xref>). Antivirals can be used in the treatment of influenza infection (<xref rid="bib0790" ref-type="bibr">Krammer et al., 2018</xref>). Investments in new vaccines, antiviral drugs, and surveillance systems are needed to reduce the global burden associated with influenza infection (<xref rid="bib1145" ref-type="bibr">Petrova and Russell, 2018</xref>).</p><p id="par0115">The severity of influenza infection is related to the intensity of proinflammatory responses and the predominant profile of cytokine production by the host (<xref rid="bib0930" ref-type="bibr">Liu et al., 2016</xref>). A body of evidence has shown that both CCL5 and CCR5 participate in the modulation of the immune response to influenza virus infection (<xref rid="bib1005" ref-type="bibr">Matsukura et al., 1998</xref>; <xref rid="bib1515" ref-type="bibr">Tyner et al., 2005</xref>; <xref rid="bib1400" ref-type="bibr">Sl&#x000e1;dkov&#x000e1; and Kostolansk&#x000fd;, 2006</xref>; <xref rid="bib0770" ref-type="bibr">Kohlmeier et al., 2008</xref>; <xref rid="bib1110" ref-type="bibr">Oslund and Baumgarth, 2011</xref>). Of note, CCR5 mediates the recruitment of NK cells to the lungs in influenza A infection (<xref rid="bib0195" ref-type="bibr">Carlin et al., 2018</xref>) and participates in neutrophil action in the lungs during influenza pneumonia (<xref rid="bib1235" ref-type="bibr">Rudd et al., 2019</xref>).</p><p id="par0120">Although flow cytometry data did not indicate significant changes regarding CCR5 expression on the surface of human monocytes after experimental influenza A infection (<xref rid="bib1265" ref-type="bibr">Salentin et al., 2003</xref>), various studies have shown that, in mice, the lack of CCR5 expression is associated with a higher risk of death by influenza infection (<xref rid="bib0325" ref-type="bibr">Dawson et al., 2000</xref>; <xref rid="bib1515" ref-type="bibr">Tyner et al., 2005</xref>; <xref rid="bib0450" ref-type="bibr">Fadel et al., 2008</xref>; <xref rid="bib1470" ref-type="bibr">Tavares et al., 2020</xref>). Based on these findings, it was postulated that pharmacological CCR5 blockade may have some undesirable effect on the immune response against the influenza virus in humans (<xref rid="bib0450" ref-type="bibr">Fadel et al., 2008</xref>). Importantly, more research on this aspect is needed since this data suggests that, in humans, the CCR5 absence due to the CCR5&#x00394;32 polymorphism could affect pathogenesis and the lethality rate of influenza infection.</p><p id="par0125">
<xref rid="bib0455" ref-type="bibr">Falcon et al. (2015)</xref> evaluated the frequency of the CCR5&#x00394;32 in pandemic H1N1-infected Spanish individuals and revealed an association between the polymorphism with fatal outcome. The CCR5&#x00394;32 was also associated with increased disease severity in other studies (<xref rid="bib0725" ref-type="bibr">Keynan et al., 2010</xref>; <xref rid="bib1210" ref-type="bibr">Rodriguez et al., 2013</xref>). However, these results should be interpreted with caution since both studies were based on very small sample sizes (<xref rid="bib0725" ref-type="bibr">Keynan et al., 2010</xref>; <xref rid="bib1210" ref-type="bibr">Rodriguez et al., 2013</xref>). Importantly, other studies addressing humans reported no association between CCR5&#x00394;32 and severity of influenza infection (<xref rid="bib1395" ref-type="bibr">Sironi et al., 2014</xref>; <xref rid="bib0960" ref-type="bibr">Maestri et al., 2015</xref>; <xref rid="bib1000" ref-type="bibr">Matos et al., 2019</xref>). Taking together, the body of evidence suggests that CCR5&#x00394;32 has little influence on severity of influenza infection (<xref rid="tbl0010" ref-type="table">Table 2</xref>
). Results described by <xref rid="bib0455" ref-type="bibr">Falcon et al. (2015)</xref> seem to be specific to that studied population, composed of individuals from 13 regions of Spain.<table-wrap position="float" id="tbl0010"><label>Table 2</label><caption><p>Impacts of CCR5&#x00394;32 on Influenza virus infection.</p></caption><alt-text id="at0090">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Population</th><th align="left">Sample</th><th align="left">Main findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Canadian</td><td align="left">20 individuals infected with 2009 pandemic H1N1</td><td align="left">The CCR5&#x00394;32 allele was considered a risk factor for severe infection among Caucasian individuals</td><td align="left"><xref rid="bib0725" ref-type="bibr">Keynan et al. (2010)</xref></td></tr><tr><td align="left">Spanish</td><td align="left">1 fatal case and 1 mild disease case (2009 pandemic H1N1)</td><td align="left">The patient who died from the infection had CCR5&#x00394;32 homozygous genotype</td><td align="left"><xref rid="bib1210" ref-type="bibr">Rodriguez et al. (2013)</xref></td></tr><tr><td align="left">Mostly European</td><td align="left">29 individuals (27 Italian; 1 Spanish; 1 Chinese) infected with 2009 pandemic H1N1</td><td align="left">No association between the CCR5&#x00394;32 and H1N1 infection</td><td align="left"><xref rid="bib1395" ref-type="bibr">Sironi et al. (2014)</xref></td></tr><tr><td align="left">Spanish</td><td align="left">171 individuals infected with 2009 pandemic H1N1</td><td align="left">The CCR5&#x00394;32 was associated with increased risk for fatal outcome</td><td align="left"><xref rid="bib0455" ref-type="bibr">Falcon et al. (2015)</xref></td></tr><tr><td align="left">Brazilian</td><td align="left">156 infected/hospitalized individuals; 174 infected (mild symptoms) but non-hospitalized individuals (2009 pandemic Influenza A H1N1)</td><td align="left">No association between the CCR5&#x00394;32 and H1N1 infection severity</td><td align="left"><xref rid="bib0960" ref-type="bibr">Maestri et al. (2015)</xref></td></tr><tr><td align="left">Brazilian</td><td align="left">153 influenza-like illness cases; 173 severe acute respiratory infection cases; 106 fatal cases (2009 pandemic H1N1)</td><td align="left">No association between the CCR5&#x00394;32 and H1N1 infection severity or mortality</td><td align="left"><xref rid="bib1000" ref-type="bibr">Matos et al. (2019)</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0030"><label>3.3</label><title>Human papillomavirus</title><p id="par0130">Human papillomavirus (HPV) is a double-stranded DNA virus belonging to the papillomavirus family. HPV is transmitted by direct contact (for example, through sexual intercourse). The HPV infection is quite common worldwide, and is usually controlled by the immune system. Viral clearance occurs in most cases within 1&#x02013;2 years after infection. However, if the infection is not controlled, HPV can cause non-cancerous mucosal lesions or different types of malignant lesions such as anal cancer, penile cancer, vulvar cancer, head cancer, neck cancer, and especially cervical cancer. HPV is an oncogenic pathogen because it inhibits the activity of p53 and Prb (retinoblastoma protein) tumor suppressor molecules through the action of E6 and E7 viral proteins, respectively. These proteins also exhibit other oncogenic mechanisms. Worldwide, between 5&#x02013;10 % of all cancers in women are due to HPV infection (<xref rid="bib1310" ref-type="bibr">Schiffman et al., 2016</xref>; <xref rid="bib1295" ref-type="bibr">Sanjos&#x000e9; et al., 2018</xref>). There are several HPV genotypes (&#x0003e;200), and those most associated with cancer are: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and probably 68 (<xref rid="bib1310" ref-type="bibr">Schiffman et al., 2016</xref>). Of note, the genotype 16 (HPV16) has a prominent role in cancer development. Vaccination is one of the most effective ways to prevent HPV infection, having important positive impacts on multiple aspects of population health. HPV vaccine protects the vaccinated individual from infection <italic>per se</italic> and from HPV-related cancer (<xref rid="bib1310" ref-type="bibr">Schiffman et al., 2016</xref>; <xref rid="bib1295" ref-type="bibr">Sanjos&#x000e9; et al., 2018</xref>).</p><p id="par0135">The expression of CCR5 is increased in cervical cancer tissues (<xref rid="bib1270" ref-type="bibr">Sales et al., 2014</xref>; <xref rid="bib0215" ref-type="bibr">Che et al., 2016</xref>). Also, <italic>in vitro</italic> growth, proliferation, and invasive capacity of cervical cancer cells can be inhibited through CCR5 downregulation (<xref rid="bib0215" ref-type="bibr">Che et al., 2016</xref>). These findings suggest the involvement of CCR5 in the development of cervical lesions. In a study performed with Indian individuals (<xref rid="bib1390" ref-type="bibr">Singh et al., 2008</xref>), the genotype and allele frequencies of CCR5&#x00394;32 were not different between cervical cancer patients and controls. However, when the patients were stratified by cancer stage (stages 1B to 4), the CCR5 heterozygous genotype was associated with stage 1B of cervical cancer. The HPV positivity rate among the evaluated patients was not described (<xref rid="bib1390" ref-type="bibr">Singh et al., 2008</xref>).</p><p id="par0140">The relationship between CCR5&#x00394;32, HPV infection, and cervical lesions is addressed in other studies (<xref rid="tbl0015" ref-type="table">Table 3</xref>
). CCR5&#x00394;32 homozygous genotype was associated with increased susceptibility to HPV infection in a study performed with Swedish individuals (<xref rid="bib1685" ref-type="bibr">Zheng et al., 2006</xref>). <xref rid="bib0975" ref-type="bibr">Mangieri et al. (2019)</xref> investigated the potential influence of CCR5&#x00394;32 on susceptibility to HPV infection and cervical lesions in Brazilian women. However, the genetic variant was not significantly associated with susceptibility to HPV infection (considering allele frequency, codominant model and dominant model) or HPV-associated lesions (<xref rid="bib0975" ref-type="bibr">Mangieri et al., 2019</xref>). In accordance, previous studies performed with Brazilian women did not find an association between CCR5&#x00394;32 and susceptibility to HPV infection (<xref rid="bib1445" ref-type="bibr">Suzuki et al., 2008</xref>) or between the polymorphism and HPV-related cervical lesions (<xref rid="bib1445" ref-type="bibr">Suzuki et al., 2008</xref>; <xref rid="bib1300" ref-type="bibr">Santos et al., 2016</xref>). Lastly, CCR5&#x00394;32 did not affect susceptibility to HPV infection in Lithuanian individuals with laryngeal cancer (<xref rid="bib1425" ref-type="bibr">Stumbryt&#x00117;-Kaminskien&#x00117; et al., 2020</xref>). In conclusion, although tissue analysis and evidence obtained <italic>in vitro</italic> suggest that the CCR5 is potentially involved in the pathogenesis of HPV, most studies point to a lack of involvement of CCR5&#x00394;32 in susceptibility to HPV infection or HPV-associated diseases.<table-wrap position="float" id="tbl0015"><label>Table 3</label><caption><p>Impacts of CCR5&#x00394;32 on Human papillomavirus (HPV) infection.</p></caption><alt-text id="at0095">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Population</th><th align="left">Sample</th><th align="left">Main findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Swedish</td><td align="left">126 HPV-infected individuals; 173 non-infected individuals</td><td align="left">CCR5&#x00394;32 homozygous genotype was associated with increased risk of HPV infection</td><td align="left"><xref rid="bib1685" ref-type="bibr">Zheng et al. (2006)</xref></td></tr><tr><td align="left">Brazilian</td><td align="left">74 HPV-infected individuals; 43 non-infected individuals</td><td align="left">No association between CCR5&#x00394;32 and HPV infection; No association between CCR5&#x00394;32 and HPV-related cancer</td><td align="left"><xref rid="bib1445" ref-type="bibr">Suzuki et al. (2008)</xref></td></tr><tr><td align="left">Brazilian</td><td align="left">139 HPV-infected individuals with cervical intraepithelial neoplasia or cervical cancer; 151 HPV-infected individuals without cervical lesions</td><td align="left">No association between CCR5&#x00394;32 and HPV-related lesions; No association between CCR5&#x00394;32 and HPV genotypes</td><td align="left"><xref rid="bib1300" ref-type="bibr">Santos et al. (2016)</xref></td></tr><tr><td align="left">Brazilian</td><td align="left">164 HPV-infected individuals; 185 non-infected individuals</td><td align="left">No statistically significant effect of CCR5&#x00394;32 on susceptibility to HPV infection or HPV-related cervical lesions (low&#x02010;grade squamous intraepithelial lesion or high&#x02010;grade squamous intraepithelial lesion)</td><td align="left"><xref rid="bib0975" ref-type="bibr">Mangieri et al. (2019)</xref></td></tr><tr><td align="left">Lithuanian</td><td align="left">49 laryngeal squamous cell carcinoma patients (21 HPV-infected patients and 28 non-infected patients)</td><td align="left">No statistically significant effect of CCR5&#x00394;32 on susceptibility to HPV infection, clinical-pathological characteristics or surviving rates</td><td align="left"><xref rid="bib1425" ref-type="bibr">Stumbryt&#x00117;-Kaminskien&#x00117; et al. (2020)</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0035"><label>3.4</label><title>Hepatitis B virus</title><p id="par0145">The Hepatitis B virus (HBV) is a hepatotropic DNA virus member of the <italic>Hepadnaviridae</italic> family. In adults, approximately 95 % of HBV infections are resolved naturally (viral clearance). Individuals who have not cleared the virus after acute infection become chronic HBV carriers. Of note, chronic HBV infection affects 3.5 % of the world population. A portion of individuals who develop chronic infection have a variety of liver diseases: different levels of inflammation and fibrosis, cirrhosis, and cancer. The outcome of the infection (acute or chronic) as well as the course of liver diseases, depends on the interaction between host and viral factors. The pharmacological therapies available to treat HBV are not satisfactory, since frequently the infection is only controlled, and cure is rarely achieved. There is, therefore, a need to develop new anti-HBV therapies. Currently, HBV infection can be prevented through vaccination (<xref rid="bib1655" ref-type="bibr">Yuen et al., 2018</xref>; <xref rid="bib0820" ref-type="bibr">Lang et al., 2019</xref>; <xref rid="bib0865" ref-type="bibr">Lee and Banini, 2019</xref>).</p><p id="par0150">The CCR5 and its ligands regulate the action of T cells and other leukocytes in the liver. Thus, CCR5 regulates liver inflammation and participates in the local immune response against viruses (<xref rid="bib0050" ref-type="bibr">Ajuebor et al., 2006</xref>; <xref rid="bib1290" ref-type="bibr">Sanchooli et al., 2014</xref>). In mice models of hepatitis, CCR5 deficiency was associated with increased liver inflammation, tissue injury, and liver failure (<xref rid="bib0045" ref-type="bibr">Ajuebor et al., 2005</xref>; <xref rid="bib1035" ref-type="bibr">Moreno et al., 2005</xref>; <xref rid="bib1420" ref-type="bibr">Stevens et al., 2019</xref>). Deficiency of CCR5 expression is generally associated with reduced migration of inflammatory cells, which would translate into less inflammation. This reasoning is correct and applies to different situations and tissues (<xref rid="bib0160" ref-type="bibr">Braunersreuther et al., 2007</xref>; <xref rid="bib1055" ref-type="bibr">Muntinghe et al., 2009</xref>; <xref rid="bib0700" ref-type="bibr">Kaminski et al., 2019a</xref>). However, CCR5 is an immunoregulatory molecule (<xref rid="bib0360" ref-type="bibr">Doodes et al., 2009</xref>; <xref rid="bib0350" ref-type="bibr">Dobaczewski et al., 2010</xref>; <xref rid="bib0260" ref-type="bibr">Christmann et al., 2011</xref>; <xref rid="bib0675" ref-type="bibr">H&#x000fc;tter et al., 2011</xref>) and therefore its deficiency can also cause deregulation in the action of various immune cell types (<italic>e.g.</italic>, NK and Treg cells), increasing the inflammatory status in some tissues. In humans, multiple evidence has shown the involvement of CCR5 (protein and gene) in distinct aspects of HBV infection (<xref rid="bib0035" ref-type="bibr">Ahn et al., 2006</xref>; <xref rid="bib1505" ref-type="bibr">TrehanPati et al., 2009</xref>; <xref rid="bib0030" ref-type="bibr">Ahmadabadi et al., 2013</xref>; <xref rid="bib1645" ref-type="bibr">Yang et al., 2018</xref>). Interestingly, CCR5&#x00394;32 and other host genetic factors can affect the immunogenicity of the HBV vaccine (<xref rid="bib0485" ref-type="bibr">Ganczak et al., 2017</xref>; <xref rid="bib0385" ref-type="bibr">Ellwanger and Chies, 2019b</xref>). Considering these aspects, the influence of the CCR5&#x00394;32 on susceptibility/resistance to HBV and disease severity is quite plausible.</p><p id="par0155">Several studies investigated the role of the CCR5&#x00394;32 polymorphism in HBV infection. Some of them found no association between those variables (<xref rid="bib0075" ref-type="bibr">Arababadi et al., 2010</xref>; <xref rid="bib0740" ref-type="bibr">Khorramdelazad et al., 2013</xref>; <xref rid="bib1250" ref-type="bibr">Safari et al., 2017</xref>; <xref rid="bib1675" ref-type="bibr">Zhang et al., 2018</xref>; <xref rid="bib1040" ref-type="bibr">Moudi et al., 2019</xref>). In other studies, the absence of CCR5&#x00394;32 allele in the sample, due to ethnic features of the evaluated population, precluded the analysis concerning the potential impact of this genetic variant on HBV infection (<xref rid="bib0035" ref-type="bibr">Ahn et al., 2006</xref>; <xref rid="bib0870" ref-type="bibr">Li et al., 2011</xref>).</p><p id="par0160">Some authors have observed significant influences of CCR5&#x00394;32 on HBV infection. <xref rid="bib1430" ref-type="bibr">Suneetha et al. (2006)</xref> reported an association between the CCR5&#x00394;32 heterozygous genotype and chronic HBV infection. In contrast, <xref rid="bib1480" ref-type="bibr">Thio et al. (2007)</xref> found an association between the CCR5&#x00394;32 allele and infection recovery in a study that analyzed individuals with persistent HBV infection and individuals who recovered from the infection. Subsequently, <xref rid="bib1485" ref-type="bibr">Thio et al. (2008)</xref> associated the HBV infection recovery with an epistatic effect between the CCR5&#x00394;32 and the <italic>RANTES</italic>-403A promoter polymorphisms. Finally, <xref rid="bib0005" ref-type="bibr">Abdolmohammadi et al. (2016)</xref> found a protective effect of the CCR5&#x00394;32 genetic variant against HBV infection, once the &#x00394;32 allele was more frequent in controls compared to HBV-infected individuals.</p><p id="par0165">Recently, we investigated the frequency of CCR5&#x00394;32 in HBV mono-infected and HBV/HIV co-infected Brazilian individuals (<xref rid="bib0430" ref-type="bibr">Ellwanger et al., 2020b</xref>). A control group and HIV mono-infected individuals were also evaluated in our study. A total of 1113 individuals were studied, which represents the largest study involving CCR5&#x00394;32 and HBV infection to date (see <xref rid="tbl0020" ref-type="table">Table 4</xref>
for comparisons with other studies). We found a significant protective effect of CCR5&#x00394;32 on HBV/HIV co-infection, a result probably due to the partial protective effect of CCR5&#x00394;32 against HIV infection since no important impact of CCR5&#x00394;32 on susceptibility to HBV mono-infection was observed (<xref rid="bib0430" ref-type="bibr">Ellwanger et al., 2020b</xref>).<table-wrap position="float" id="tbl0020"><label>Table 4</label><caption><p>Impacts of CCR5&#x00394;32 on HBV infection.</p></caption><alt-text id="at0100">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Population</th><th align="left">Sample</th><th align="left">Main findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Korean</td><td align="left">349 chronic HBV-infected individuals; 243 individuals with spontaneous recover; 106 non-infected individuals</td><td align="left">The CCR5&#x00394;32 allele was not found in any studied individual</td><td align="left"><xref rid="bib0035" ref-type="bibr">Ahn et al. (2006)</xref></td></tr><tr><td align="left">Information not available</td><td align="left">214 chronic HBV-infected individuals; 408 non-infected individuals</td><td align="left">The CCR5&#x00394;32 heterozygous genotype was associated with chronic HBV infection; The CCR5&#x00394;32 wild-type allele was associated with severe liver disease when analyzed in combination with other genetic variants (a/a-T/T-Wt/Wt model from VDR-Apa1/Taq1/CCR5&#x00394;32 polymorphisms)</td><td align="left"><xref rid="bib1430" ref-type="bibr">Suneetha et al. (2006)</xref></td></tr><tr><td align="left">American</td><td align="left">190 individuals with persistent HBV infection; 336 individuals with infection recover</td><td align="left">The CCR5&#x00394;32 allele was associated with recovery from the infection</td><td align="left"><xref rid="bib1480" ref-type="bibr">Thio et al. (2007)</xref></td></tr><tr><td align="left">American</td><td align="left">181 individuals with persistent HBV infection; 316 individuals with infection recover</td><td align="left">Infection recovery was associated with an epistatic interaction between the CCR5&#x00394;32 and the <italic>RANTES</italic>-403A polymorphism</td><td align="left"><xref rid="bib1485" ref-type="bibr">Thio et al. (2008)</xref></td></tr><tr><td align="left">Iranian</td><td align="left">57 individuals with occult HBV infection; 100 non-infected individuals</td><td align="left">The CCR5&#x00394;32 heterozygous genotype was found in 3 controls and no individuals with occult HBV infection carried the allele (small sample size study); No association between the CCR5&#x00394;32 and occult HBV infection</td><td align="left"><xref rid="bib0075" ref-type="bibr">Arababadi et al. (2010)</xref></td></tr><tr><td align="left">Chinese</td><td align="left">185 individuals who underwent liver transplantation due to HBV-related disease</td><td align="left">The CCR5&#x00394;32 allele was not found in any studied individual</td><td align="left"><xref rid="bib0870" ref-type="bibr">Li et al. (2011)</xref></td></tr><tr><td align="left">Iranian</td><td align="left">60 chronic HBV-infected individuals; 60 non-infected individuals</td><td align="left">The CCR5&#x00394;32 heterozygous genotype was found in 3 controls and no infected individual carried the allele (small sample size study); No association between the CCR5&#x00394;32 and HBV infection</td><td align="left"><xref rid="bib0740" ref-type="bibr">Khorramdelazad et al. (2013)</xref></td></tr><tr><td align="left">Iranian</td><td align="left">357 HBV-infected individuals; 455 non-infected individuals</td><td align="left">The CCR5&#x00394;32 was associated with protection against HBV infection</td><td align="left"><xref rid="bib0005" ref-type="bibr">Abdolmohammadi et al. (2016)</xref></td></tr><tr><td align="left">Iranian</td><td align="left">60 chronic HBV-infected individuals; 120 individuals with infection recover</td><td align="left">The CCR5&#x00394;32 heterozygous genotype was found in 1 individual with infection recover and no HBV-infected individual carried the allele (small sample size study); No association between the CCR5&#x00394;32 and HBV infection</td><td align="left"><xref rid="bib1250" ref-type="bibr">Safari et al. (2017)</xref></td></tr><tr><td align="left">Chinese</td><td align="left">263 HBV-infected individuals; 141 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and HBV infection</td><td align="left"><xref rid="bib1675" ref-type="bibr">Zhang et al. (2018)</xref></td></tr><tr><td align="left">Iranian</td><td align="left">100 chronic HBV-infected individuals; 40 individuals with infection recover; 100 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 (as an individual factor) and HBV infection; The WtAGCC haplotype (from CCR5&#x00394;32, CCR5&#x02212;2459A/G, MCP-1&#x02212;2518A/G, VDR-APa1A/C and VDR-Taq1T/C polymorphisms, respectively) was associated with HBV infection</td><td align="left"><xref rid="bib1040" ref-type="bibr">Moudi et al. (2019)</xref></td></tr><tr><td align="left">Brazilian</td><td align="left">335 HBV mono-infected individuals; 144 HBV/HIV co-infected individuals; 300 HIV mono-infected individuals; 334 non-infected individuals</td><td align="left">The CCR5&#x00394;32 was a protective factor against HBV/HIV co-infection, but the CCR5&#x00394;32 did not affect susceptibility or resistance to HBV mono-infection</td><td align="left"><xref rid="bib0430" ref-type="bibr">Ellwanger et al. (2020b)</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0040"><label>3.5</label><title>Hepatitis C virus</title><p id="par0170">The Hepatitis C virus (HCV) was formally described in 1989 (<xref rid="bib0250" ref-type="bibr">Choo et al., 1989</xref>) and, currently, HCV infection is one of the most important infectious diseases in terms of global public health burden. HCV is an enveloped single-stranded positive-sense RNA virus, has seven genotypes, and belongs to the <italic>Flaviviridae</italic> family, <italic>Hepacivirus</italic> genus (<xref rid="bib1155" ref-type="bibr">Pietschmann and Brown, 2019</xref>). It is estimated that 71 million individuals are chronically infected by HCV worldwide (<xref rid="bib1575" ref-type="bibr">Vigan&#x000f2; et al., 2019</xref>).</p><p id="par0175">Similar to the HBV infection, HCV-infected individuals can eliminate the virus naturally or develop chronic infection, which occurs in 55&#x02013;85 % of the cases. Chronic infection can cause liver inflammation, cirrhosis, and hepatocarcinoma (<xref rid="bib0920" ref-type="bibr">Lingala and Ghany, 2015</xref>). In addition to liver damage, HCV causes a series of immune-mediated extrahepatic manifestations, including rheumatologic, dermatologic, ophthalmologic, renal, pulmonary, neuropsychiatric, cardiovascular, and hematologic manifestations, especially mixed cryoglobulinemia (<xref rid="bib1215" ref-type="bibr">Romano et al., 2018</xref>). HCV therapy using direct-acting antivirals (DAAs) shows cure rates over 95 % (<xref rid="bib1155" ref-type="bibr">Pietschmann and Brown, 2019</xref>). Early treatment of infected patients decreases death rates from HCV-associated liver disease, reduces disease transmission, and alleviates extrahepatic health problems. Focusing the efforts on HCV treatment is extremely important because there is no effective HCV vaccine (<xref rid="bib1575" ref-type="bibr">Vigan&#x000f2; et al., 2019</xref>).</p><p id="par0180">HCV seropositivity is an important risk factor for HIV infection (<xref rid="bib1710" ref-type="bibr">Zwoli&#x00144;ska et al., 2013</xref>). Like HIV, HCV is primarily transmitted through blood transfusion and sexual intercourse, and HCV/HIV co-infection is a major problem worldwide. Depression of the immune system due to uncontrolled HIV infection may contribute to HCV progression (<xref rid="bib1315" ref-type="bibr">Schlabe and Rockstroh, 2018</xref>). Both susceptibility to HCV infection and disease progression are affected by viral and environmental factors and physio-metabolic, immune, and genetic components of the host (<xref rid="bib0405" ref-type="bibr">Ellwanger et al., 2018a</xref>).</p><p id="par0185">Infiltration of inflammatory cells in the hepatic tissue is a classic observation in HCV infection. Chemokines and chemokine receptors participate in the recruitment and activity of inflammatory cells in the liver, acting on anti&#x02212;HCV immune responses and ultimately modifying the rate of inflammation and other histological manifestations observed during infection. Based on this rationale, the CCR5 molecule was postulated as having an impact on HCV-induced liver injury, susceptibility to HCV infection, and modulation of the possibilities of viral clearance. The downregulation of CCR5 due to CCR5&#x00394;32 may interfere in these processes (<xref rid="bib0020" ref-type="bibr">Ahlenstiel et al., 2004</xref>; <xref rid="bib0270" ref-type="bibr">Coenen and Nattermann, 2010</xref>). In agreement, several polymorphisms in other immune system genes [especially human leukocyte antigen (HLA), mannose-binding lectin (MBL), toll-like receptor (TLR), interleukins (IL), and interferon (IFN) gene families] indeed modify both susceptibility to HCV infection and disease progression (<xref rid="bib0405" ref-type="bibr">Ellwanger et al., 2018a</xref>). Especially the focus of this review, clinical response to HCV therapy is influenced by <italic>CCR5</italic> gene polymorphisms (<xref rid="bib0780" ref-type="bibr">Konishi et al., 2004</xref>; <xref rid="bib1100" ref-type="bibr">Omran et al., 2013</xref>). Also, there is evidence showing that <italic>CCR5</italic> haplotypes can affect susceptibility to HCV infection (<xref rid="bib0665" ref-type="bibr">Huik et al., 2013</xref>).</p><p id="par0190">A recent <italic>in vitro</italic> study suggested that CCR5 blockage could have a beneficial effect on the treatment of HCV infection since CCR5 antagonists (maraviroc and cenicriviroc) inhibit HCV replication (<xref rid="bib0135" ref-type="bibr">Blackard et al., 2019</xref>). The use of CCR5 antagonists in humans is safe (<xref rid="bib0465" ref-type="bibr">F&#x000e4;tkenheuer et al., 2010</xref>; <xref rid="bib0585" ref-type="bibr">Gulick et al., 2014</xref>; <xref rid="bib0505" ref-type="bibr">Giaquinto et al., 2018</xref>) and these drugs have the potential to treat a number of diseases in which CCR5 is involved, including HCV-associated liver disease. Although the use of CCR5 antagonists on HCV mono-infection is not yet approved, it can be useful specifically for co-infected HIV/HCV patients, where CCR5 blocking (maraviroc) is already recommended (<xref rid="bib0610" ref-type="bibr">Ha&#x000ef;m-Boukobza et al., 2013</xref>; <xref rid="bib0135" ref-type="bibr">Blackard et al., 2019</xref>). However, the detailed patterns of CCR5 expression in different tissues and at various points in the clinical course of HCV infection are still poorly understood. According to a recent study, the expression of CCR5 in CD8&#x0202f;<sup>+</sup>&#x0202f;T cells is increased in the liver of chronic HCV-infected patients (<xref rid="bib1165" ref-type="bibr">Pirozyan et al., 2019</xref>), but other studies have found mixed results regarding CCR5 expression on T cells in the context of HCV infection (<xref rid="bib0890" ref-type="bibr">Lichterfeld et al., 2002</xref>; <xref rid="bib1580" ref-type="bibr">Vincent et al., 2005</xref>; <xref rid="bib0830" ref-type="bibr">Larrubia et al., 2007</xref>; <xref rid="bib1665" ref-type="bibr">Zahran et al., 2020</xref>). Therefore, considering that the role of CCR5 in HCV infection is still uncertain, the potential use of CCR5 blockers to treat HCV mono-infection should be cautious.</p><p id="par0195">The influence of the CCR5&#x00394;32 variant on HCV infection susceptibility was investigated by several studies. <xref rid="bib1615" ref-type="bibr">Woitas et al. (2002)</xref> found a significantly higher frequency of the CCR5&#x00394;32 homozygous genotype in HCV-infected individuals compared to controls, HIV-infected and HCV/HIV co-infected individuals, suggesting the CCR5&#x00394;32 as a risk factor for HCV infection. In agreement, the &#x00394;32 allele was a significant risk factor for infection when the authors compared the HCV-infected group to both controls and HIV-infected individuals. Moreover, the CCR5&#x00394;32 homozygous genotype was associated with increased HCV loads. In their study, it was observed an important deviation from the Hardy-Weinberg equilibrium in data from HCV-infected individuals; and a high portion of the individuals included in the study was hemophiliac (<xref rid="bib1615" ref-type="bibr">Woitas et al., 2002</xref>). Hemophiliac individuals were at high risk of exposure to HCV and HIV until the mid-1980s (<xref rid="bib1175" ref-type="bibr">Promrat et al., 2003</xref>; <xref rid="bib1670" ref-type="bibr">Zhang et al., 2003</xref>). Considering that the CCR5&#x00394;32 homozygous genotype provides protection against HIV infection, a high frequency of this genotype in an HCV-infected group may be due to HIV resistance, but not to HCV, among individuals highly exposed to both viruses. Due to those and other reasons, the results of <xref rid="bib1615" ref-type="bibr">Woitas et al. (2002)</xref> were criticized by different authors (<xref rid="bib0755" ref-type="bibr">Klein, 2003</xref>; <xref rid="bib0970" ref-type="bibr">Mangia et al., 2003</xref>; <xref rid="bib1170" ref-type="bibr">Poljak et al., 2003</xref>; <xref rid="bib1175" ref-type="bibr">Promrat et al., 2003</xref>; <xref rid="bib1670" ref-type="bibr">Zhang et al., 2003</xref>). In this sense, no influence of CCR5&#x00394;32 on susceptibility to HCV infection were reported in studies performed with various populations (<xref rid="bib0510" ref-type="bibr">Glas et al., 2003</xref>; <xref rid="bib0970" ref-type="bibr">Mangia et al., 2003</xref>; <xref rid="bib1170" ref-type="bibr">Poljak et al., 2003</xref>; <xref rid="bib1175" ref-type="bibr">Promrat et al., 2003</xref>; <xref rid="bib1670" ref-type="bibr">Zhang et al., 2003</xref>; <xref rid="bib1240" ref-type="bibr">Ruiz-Ferrer et al., 2004</xref>; <xref rid="bib1590" ref-type="bibr">Wald et al., 2004</xref>; <xref rid="bib1600" ref-type="bibr">Wasmuth et al., 2004</xref>; <xref rid="bib1490" ref-type="bibr">Thoelen et al., 2005</xref>; <xref rid="bib0555" ref-type="bibr">Goyal et al., 2006</xref>). Reinforcing the observations of those different studies, our group found no association between the CCR5&#x00394;32 and susceptibility to HCV infection or HCV/HIV co-infection in a study that evaluated a large number of Brazilian individuals (<xref rid="bib0410" ref-type="bibr">Ellwanger et al., 2018b</xref>). <xref rid="bib0130" ref-type="bibr">Bineshian et al. (2018)</xref> did not detect the CCR5&#x00394;32 allele in any Iranian HCV-infected individual and controls included in their study, preventing any conclusion in terms of susceptibility in that population. Finally, it is important to mention that in addition to the study by <xref rid="bib1615" ref-type="bibr">Woitas et al. (2002)</xref>, a study performed in 2013 also found an association between the CCR5&#x00394;32 homozygous genotype with chronic HCV infection in Europeans, but the authors of the study mentioned that specific factors regarding selection bias (<italic>e.g.</italic>, co-exposure to HIV) may have influenced their results (<xref rid="bib1435" ref-type="bibr">Suppiah et al., 2013</xref>). Taken together, the above-mentioned results called attention for the importance of performing genetic variant studies in different populations, exposed to different social and environmental factors and presenting distinct ethnic backgrounds.</p><p id="par0200">Considering multiple clinical and histological parameters, two main different results were obtained when the CCR5&#x00394;32 genetic variant was evaluated in the context of HCV-related diseases: reduced liver inflammation in &#x00394;32 allele carriers (<xref rid="bib0625" ref-type="bibr">Hellier et al., 2003</xref>; <xref rid="bib1590" ref-type="bibr">Wald et al., 2004</xref>; <xref rid="bib0545" ref-type="bibr">Goulding et al., 2005</xref>); and no association between the CCR5&#x00394;32 and clinical variables (<xref rid="bib0510" ref-type="bibr">Glas et al., 2003</xref>; <xref rid="bib0970" ref-type="bibr">Mangia et al., 2003</xref>; <xref rid="bib1175" ref-type="bibr">Promrat et al., 2003</xref>; <xref rid="bib0555" ref-type="bibr">Goyal et al., 2006</xref>; <xref rid="bib0995" ref-type="bibr">Mascheretti et al., 2004</xref>; <xref rid="bib1240" ref-type="bibr">Ruiz-Ferrer et al., 2004</xref>; <xref rid="bib1030" ref-type="bibr">Morard et al., 2014</xref>; <xref rid="bib0410" ref-type="bibr">Ellwanger et al., 2018b</xref>).</p><p id="par0205">In the context of persistence/resolution of HCV infection and viral control, in the one hand, studies described association of the CCR5&#x00394;32 allele with reduced rates of spontaneous viral clearance (<xref rid="bib1075" ref-type="bibr">Nattermann et al., 2011</xref>; <xref rid="bib1030" ref-type="bibr">Morard et al., 2014</xref>), higher viral load (<xref rid="bib1650" ref-type="bibr">Yilmaz et al., 2014</xref>), and reduced anti&#x02212;HCV immune response (<xref rid="bib0025" ref-type="bibr">Ahlenstiel et al., 2009</xref>). On the other hand, studies have reported association between the CCR5&#x00394;32 variant and increased rates of spontaneous viral clearance (<xref rid="bib0545" ref-type="bibr">Goulding et al., 2005</xref>; <xref rid="bib0435" ref-type="bibr">El-Moamly et al., 2013</xref>). No significant effect of the CCR5&#x00394;32 on viral clearance was reported by other authors (<xref rid="bib0995" ref-type="bibr">Mascheretti et al., 2004</xref>).</p><p id="par0210">The potential impact of the CCR5&#x00394;32 polymorphism on response to HCV therapy was also evaluated by some authors. <xref rid="bib0015" ref-type="bibr">Ahlenstiel et al. (2003)</xref> found an association between the CCR5&#x00394;32 allele and reduced response rates to interferon-&#x003b1; monotherapy, but the polymorphism did not affect the response to the combined interferon/ribavirin therapy. This finding shows that the use of more robust therapeutic regimens compensates the undesirable effects of CCR5&#x00394;32 on HCV therapy with interferon-&#x003b1; monotherapy. Of note, the effect of CCR5&#x00394;32 may be negligible in the context of modern HCV therapies (<xref rid="bib0015" ref-type="bibr">Ahlenstiel et al., 2003</xref>). Other studies did not report significant effects of the polymorphism on response to HCV therapy (<xref rid="bib0510" ref-type="bibr">Glas et al., 2003</xref>; <xref rid="bib1175" ref-type="bibr">Promrat et al., 2003</xref>; <xref rid="bib0555" ref-type="bibr">Goyal et al., 2006</xref>; <xref rid="bib0995" ref-type="bibr">Mascheretti et al., 2004</xref>; <xref rid="bib1435" ref-type="bibr">Suppiah et al., 2013</xref>; <xref rid="bib1030" ref-type="bibr">Morard et al., 2014</xref>). Again, it is important to mention that the ethnic distribution of the CCR5&#x00394;32 allele could interfere with study results. <xref rid="bib0780" ref-type="bibr">Konishi et al. (2004)</xref>, for example, did not detect the CCR5&#x00394;32 allele in any Japanese individual included in their study focused on host genetic factors involved in the response to interferon therapy. Lastly, the polymorphism also does not appear to be associated with any specific HCV genotype (<xref rid="bib0510" ref-type="bibr">Glas et al., 2003</xref>; <xref rid="bib1600" ref-type="bibr">Wasmuth et al., 2004</xref>; <xref rid="bib0555" ref-type="bibr">Goyal et al., 2006</xref>).</p><p id="par0215">Already in 2004, <xref rid="bib0020" ref-type="bibr">Ahlenstiel et al. (2004)</xref> highlighted that the impact of CCR5 on HCV infection was controversial. In 2020, many controversies remain, although some points are better defined. <xref rid="tbl0025" ref-type="table">Table 5</xref>
summarizes the main findings of the studies that evaluated CCR5&#x00394;32 on HCV infection. Although some studies indicate an influence of the polymorphism on susceptibility to infection, most studies indicate that the &#x00394;32 allele has little (or no) influence on HCV susceptibility. The impact of the CCR5&#x00394;32 on HCV-related liver disease is quite variable and context-dependent. Finally, available data suggest some benefit of CCR5 antagonists for the treatment of HCV mono-infection. However, these data are still limited and further studies evaluating this topic are needed.<table-wrap position="float" id="tbl0025"><label>Table 5</label><caption><p>Impacts of CCR5&#x00394;32 on HCV infection.</p></caption><alt-text id="at0105">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Population</th><th align="left">Sample</th><th align="left">Main findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">German</td><td align="left">153 HCV-infected individuals; 102 HIV-infected individuals; 130 HCV/HIV co-infected individuals; 102 non-infected individuals</td><td align="left">The CCR5&#x00394;32 polymorphism (&#x00394;32 allele and homozygous genotype) was associated with increased susceptibility to HCV infection; The CCR5&#x00394;32 homozygous genotype was associated with increased HCV loads</td><td align="left"><xref rid="bib1615" ref-type="bibr">Woitas et al. (2002)</xref></td></tr><tr><td align="left">German</td><td align="left">156 chronic HCV-infected individuals</td><td align="left">The CCR5&#x00394;32 allele was associated with reduced response rates to interferon-&#x003b1; monotherapy</td><td align="left"><xref rid="bib0015" ref-type="bibr">Ahlenstiel et al. (2003)</xref></td></tr><tr><td align="left">Caucasian</td><td align="left">62 chronic HCV-infected individuals; 119 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection, HCV-related liver disease or therapy response</td><td align="left"><xref rid="bib0510" ref-type="bibr">Glas et al. (2003)</xref></td></tr><tr><td align="left">European</td><td align="left">544 HCV-infected individuals with persistent infection; 128 individuals who cleared the virus (547 individuals were genotyped for CCR5&#x00394;32)</td><td align="left">The CCR5&#x00394;32 polymorphism was associated with reduced portal inflammation and increased liver fibrosis</td><td align="left"><xref rid="bib0625" ref-type="bibr">Hellier et al. (2003)</xref></td></tr><tr><td align="left">Information not available</td><td align="left">235 chronic HCV-infected individuals; 96 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection or HCV-related disease progression</td><td align="left"><xref rid="bib0970" ref-type="bibr">Mangia et al. (2003)</xref></td></tr><tr><td align="left">Slovenian</td><td align="left">150 HCV-infected individuals; 101 HIV-infected individuals; 385 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection</td><td align="left"><xref rid="bib1170" ref-type="bibr">Poljak et al. (2003)</xref></td></tr><tr><td align="left">American</td><td align="left">417 individuals with liver disease (including 339 HCV-infected individuals); 2380 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection, HCV-related liver disease or therapy response</td><td align="left"><xref rid="bib1175" ref-type="bibr">Promrat et al. (2003)</xref></td></tr><tr><td align="left">Caucasian (American; European)</td><td align="left">1419 hemophiliacs (stratified in the analyzes according to serological status for HCV and HIV)</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection; This study indicated that the results of <xref rid="bib1615" ref-type="bibr">Woitas et al. (2002)</xref> was affected by the inclusion of hemophiliacs in the HCV-infected group</td><td align="left"><xref rid="bib1670" ref-type="bibr">Zhang et al. (2003)</xref></td></tr><tr><td align="left">Japanese</td><td align="left">105 chronic HCV-infected individuals; 53 non-infected individuals</td><td align="left">The CCR5&#x00394;32 allele was not detected in any individuals included in the study</td><td align="left"><xref rid="bib0780" ref-type="bibr">Konishi et al. (2004)</xref></td></tr><tr><td align="left">German</td><td align="left">257 chronic HCV-infected individuals; 250 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection, HCV-related liver disease or therapy response</td><td align="left"><xref rid="bib0995" ref-type="bibr">Mascheretti et al. (2004)</xref></td></tr><tr><td align="left">Spanish</td><td align="left">139 HCV-infected individuals; 100 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection or liver injury</td><td align="left"><xref rid="bib1240" ref-type="bibr">Ruiz-Ferrer et al. (2004)</xref></td></tr><tr><td align="left">Israeli</td><td align="left">127 chronic HCV-infected individuals; 48 HCV-infected individual who had undergone liver transplantation due to liver cirrhosis; 75 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection; The CCR5&#x00394;32 allele was associated with reduced liver inflammation</td><td align="left"><xref rid="bib1590" ref-type="bibr">Wald et al. (2004)</xref></td></tr><tr><td align="left">German</td><td align="left">333 HCV-infected individuals; 125 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection; No major association between the CCR5&#x00394;32 and HCV-related liver disease or therapy response</td><td align="left"><xref rid="bib1600" ref-type="bibr">Wasmuth et al. (2004)</xref></td></tr><tr><td align="left">Irish</td><td align="left">196 chronic HCV-infected individuals; 88 individuals who cleared the virus; 120 non-infected individuals</td><td align="left">The CCR5&#x00394;32 polymorphism was associated with HCV clearance and less severe hepatic inflammatory scores</td><td align="left"><xref rid="bib0545" ref-type="bibr">Goulding et al. (2005)</xref></td></tr><tr><td align="left">Belgian</td><td align="left">163 HCV-infected individuals; 310 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection</td><td align="left"><xref rid="bib1490" ref-type="bibr">Thoelen et al. (2005)</xref></td></tr><tr><td align="left">Information not available</td><td align="left">252 chronic HCV-infected individuals; 408 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection, HCV-related liver disease or therapy response</td><td align="left"><xref rid="bib0555" ref-type="bibr">Goyal et al. (2006)</xref></td></tr><tr><td align="left">Information not available</td><td align="left">21 HCV-infected hemophiliacs</td><td align="left">The CCR5&#x00394;32 allele was associated with reduced anti-viral (mediated by interferon-&#x003b3;) response</td><td align="left"><xref rid="bib0025" ref-type="bibr">Ahlenstiel et al. (2009)</xref></td></tr><tr><td align="left">German</td><td align="left">277 chronic HCV-infected individuals; 119 individuals who cleared the virus; 105 non-infected individuals</td><td align="left">The CCR5&#x00394;32 wild-type genotype was associated with spontaneous viral clearance. Therefore, CCR5&#x00394;32 allele can be considered a risk factor for persistent infection</td><td align="left"><xref rid="bib1075" ref-type="bibr">Nattermann et al. (2011)</xref></td></tr><tr><td align="left">Egyptian</td><td align="left">190 <italic>Schistosoma mansoni</italic>/HCV co-infected individuals; 220 <italic>S. mansoni</italic>-infected individuals</td><td align="left">The CCR5&#x00394;32 allele was associated with spontaneous viral clearance in co-infected individuals</td><td align="left"><xref rid="bib0435" ref-type="bibr">El-Moamly et al. (2013)</xref></td></tr><tr><td align="left">Australian; European</td><td align="left">813 chronic HCV-infected individuals; 836 non-infected individuals</td><td align="left">The CCR5&#x00394;32 homozygous genotype was associated with chronic HCV infection (especially in Europeans); No association between the CCR5&#x00394;32 and therapy response</td><td align="left"><xref rid="bib1435" ref-type="bibr">Suppiah et al. (2013)</xref></td></tr><tr><td align="left">Swiss; Italian</td><td align="left">1290 chronic HCV-infected individuals; 160 individuals who cleared the virus</td><td align="left">The CCR5&#x00394;32 allele was associated with decreased rates of spontaneous viral clearance; No association between the CCR5&#x00394;32 and HCV-related liver disease or therapy response</td><td align="left"><xref rid="bib1030" ref-type="bibr">Morard et al. (2014)</xref></td></tr><tr><td align="left">Turkish</td><td align="left">58 chronic HCV-infected individuals; 58 non-infected individuals</td><td align="left">The CCR5&#x00394;32 allele was associated with higher HCV load and reduced histology activity index in liver samples</td><td align="left"><xref rid="bib1650" ref-type="bibr">Yilmaz et al. (2014)</xref></td></tr><tr><td align="left">Iranian</td><td align="left">100 HCV-infected individuals; 100 non-infected individuals</td><td align="left">The CCR5&#x00394;32 was not detected in any individuals included in the study</td><td align="left"><xref rid="bib0130" ref-type="bibr">Bineshian et al. (2018)</xref></td></tr><tr><td align="left">Brazilian</td><td align="left">674 HCV-infected individuals; 104 HCV/HIV co-infected individuals; 300 HIV-infected individuals; 274 non-infected individuals</td><td align="left">No association between the CCR5&#x00394;32 and susceptibility to HCV infection or HCV/HIV co-infection; No association between the CCR5&#x00394;32 and HCV-related fibrosis, cirrhosis or hepatocarcinoma</td><td align="left"><xref rid="bib0410" ref-type="bibr">Ellwanger et al. (2018b)</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0045"><label>3.6</label><title>Poliovirus</title><p id="par0220">Poliovirus (PV) is a single-stranded RNA enterovirus of the family <italic>Picornaviridae</italic>. There are three types of PV: wild PV type 1 (WPV1), type 2 (WPV2), and type 3 (WPV3). The PV replicates in the tonsils and intestinal tract. In few infection cases (&#x0223c;1%), the virus invades the CNS and can cause poliomyelitis resulting in paralysis. Poliomyelitis is a condition characterized by inflammation of the gray matter of the spinal cord and muscle paralysis unleashed by PV replication in motor neurons (<xref rid="bib1190" ref-type="bibr">Racaniello, 2006</xref>; <xref rid="bib0720" ref-type="bibr">Kew and Pallansch, 2018</xref>; <xref rid="bib0715" ref-type="bibr">Keohane et al., 2020</xref>). Polioencephalitis can also occur and is characterized by the inflammation of the gray matter of the brain (<xref rid="bib0715" ref-type="bibr">Keohane et al., 2020</xref>). PV infection is preventable through vaccination. The global PV vaccination program (Global Polio Eradication Initiative) has virtually eliminated cases of PV-derived paralysis, which currently occur to a limited extent in some countries, such as Pakistan and Afghanistan, and are caused by WPV1, while WPV2 and WPV3 have not circulated in human populations since 1999 and 2012, respectively (<xref rid="bib0720" ref-type="bibr">Kew and Pallansch, 2018</xref>).</p><p id="par0225">Host genetics and profile of immune responses affect the course of PV infection, determining if a particular individual will have neurological impairment (<xref rid="bib0065" ref-type="bibr">Andersen et al., 2019</xref>). Considering that CCR5 affects the course of other neuroinvasive viral infections such as TBEV and WNV, it was hypothesized that CCR5&#x00394;32 could influence the development of neurological impairment associated with PV infection, as this only occurs in a portion of infected individuals (<xref rid="bib1225" ref-type="bibr">Rosenberg et al., 2013</xref>). In this context, <xref rid="bib1225" ref-type="bibr">Rosenberg et al. (2013)</xref> evaluated the effect of the CCR5&#x00394;32 on severe cases of PV infection through a retrospective study performed in Finland, including rare samples of individuals with neurological symptoms from the 1984&#x02013;1985&#x0202f;PV outbreak occurred in that country (<xref rid="tbl0030" ref-type="table">Table 6</xref>
). The authors found no statistically significant effect of the CCR5&#x00394;32 on PV infection; only a trend of association between the &#x00394;32 allele and increased risk of PV infection was observed (<xref rid="bib1225" ref-type="bibr">Rosenberg et al., 2013</xref>). However, this study had a very small sample size (only seven cases of severe PV infection were evaluated) and therefore the results were not conclusive. In addition, due to the declining number of PV infection cases in the world, the effect of CCR5&#x00394;32 will be increasingly difficult to be assessed in population-based studies.<table-wrap position="float" id="tbl0030"><label>Table 6</label><caption><p>Impacts of CCR5&#x00394;32 on various viral infections.</p></caption><alt-text id="at0110">Table 6</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Pathogen/Disease</th><th align="left">Population</th><th align="left">Sample</th><th align="left">Main findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Poliovirus (PV) infection</td><td align="left">Finnish</td><td align="left">7 PV-infected individuals with neurological symptoms;79 non-infected individuals or asymptomatic infected individuals</td><td align="left">No association between CCR5&#x00394;32 and severe PV-associated neurologic disease (small sample size study)</td><td align="left"><xref rid="bib1225" ref-type="bibr">Rosenberg et al. (2013)</xref></td></tr><tr><td align="left" valign="middle" rowspan="3">Dengue virus (DENV) infection</td><td align="left">Brazilian</td><td align="left">87 DENV-infected children (severe cases); 326 controls</td><td align="left">No statistical association between CCR5&#x00394;32 and DENV infection</td><td align="left"><xref rid="bib1635" ref-type="bibr">Xavier-Carvalho et al. (2013)</xref></td></tr><tr><td align="left">Australian</td><td align="left">56 DENV-infected individuals; 91 non-infected individuals</td><td align="left">No statistical association between CCR5&#x00394;32 and DENV infection</td><td align="left"><xref rid="bib0175" ref-type="bibr">Brestovac et al. (2014)</xref></td></tr><tr><td align="left">Indian</td><td align="left">42 DENV-infected individuals (33 mild cases and 9 severe cases); 90 non-infected individuals</td><td align="left">The CCR5&#x00394;32 allele was not detected in any individuals included in the study</td><td align="left"><xref rid="bib0680" ref-type="bibr">Islam et al. (2019)</xref></td></tr><tr><td align="left" valign="middle" rowspan="2">Human cytomegalovirus (CMV) infection</td><td align="left">European-American; African-American</td><td align="left">203 European-American and 117 African-American individuals with AIDS and CMV retinitis</td><td align="left">No statistical association between CCR5&#x00394;32 (as an individual factor) and mortality, retinitis progression or retinal detachment</td><td align="left"><xref rid="bib1330" ref-type="bibr">Sezgin et al. (2011)</xref></td></tr><tr><td align="left">Polish</td><td align="left">72 children with intrauterine CMV infection; 398 non-infected children</td><td align="left">No statistical association between CCR5&#x00394;32 and CMV infection</td><td align="left"><xref rid="bib0710" ref-type="bibr">Kasztelewicz et al. (2017)</xref></td></tr><tr><td align="left" valign="middle" rowspan="2">Crimean-Congo hemorrhagic fever virus (CCHFV) infection</td><td align="left">Turkish</td><td align="left">3 CCHFV fatal cases; 12 CCHFV non-fatal cases</td><td align="left">All individuals had the wild-type genotype</td><td align="left"><xref rid="bib0440" ref-type="bibr">Engin et al. (2009)</xref></td></tr><tr><td align="left">Turkish</td><td align="left">133 CCHFV-infected individuals; 97 non-infected individuals</td><td align="left">The CCR5&#x00394;32 heterozygous genotype and the &#x00394;32 allele were associated with protection against CCHFV infection (both factors found in increased frequency in control group)</td><td align="left"><xref rid="bib1245" ref-type="bibr">Rustemoglu et al. (2017)</xref></td></tr><tr><td align="left">Enterovirus (EV) infection</td><td align="left">German</td><td align="left">97 individuals with enteroviral cardiomyopathy (23 individuals with persistent EV infection; 42 individuals who spontaneously cleared the virus; 32 individuals with persistent EV infection who received interferon-&#x003b2; therapy to clear the virus)</td><td align="left">CCR5&#x00394;32 was associated with spontaneous viral clearance and better clinical outcome (all &#x00394;32 allele carriers showed viral clearance and none of them died during the study period)</td><td align="left"><xref rid="bib0835" ref-type="bibr">Lassner et al. (2018)</xref></td></tr><tr><td align="left">Japanese encephalitis virus (JEV) infection</td><td align="left">Indian</td><td align="left">183 JEV-infected individuals; 361 non-infected individuals</td><td align="left">No statistical association between the CCR5&#x00394;32 and Japanese encephalitis considering the CCR5&#x00394;32 as an individual factor</td><td align="left"><xref rid="bib0340" ref-type="bibr">Deval et al. (2019)</xref></td></tr><tr><td align="left">Nephropathia epidemica (linked to hantavirus infection)</td><td align="left">Russian (Republic of Tatarstan)</td><td align="left">98 nephropathia epidemica cases; 592 controls</td><td align="left">CCR5&#x00394;32 did not affect susceptibility to hantavirus infection. However, the wild-type homozygous genotype was associated with more severe disease</td><td align="left"><xref rid="bib0760" ref-type="bibr">Kletenkov et al. (2019)</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0050"><label>3.7</label><title>Dengue virus</title><p id="par0230">Dengue virus (DENV) is a single-stranded RNA virus that belongs to the <italic>Flaviviridae</italic> family, <italic>Flavivirus</italic> genus. There are four DENV serotypes, being all transmitted to humans by <italic>Aedes</italic> mosquitoes (<italic>Aedes aegypti</italic> and <italic>Aedes albopictus</italic>) (<xref rid="bib0605" ref-type="bibr">Guzman et al., 2016</xref>). DENV infection is a global health problem with huge impacts on public health systems, especially in tropical countries (<xref rid="bib0120" ref-type="bibr">Bhatt et al., 2013</xref>), being considered the most common arbovirosis in the world (<xref rid="bib1415" ref-type="bibr">Stanaway et al., 2016</xref>). Globally, the incidence of symptomatic DENV infection is within the range of 50&#x02013;100 million cases per year, resulting in &#x0223c;10,000 deaths each year (<xref rid="bib1415" ref-type="bibr">Stanaway et al., 2016</xref>).</p><p id="par0235">Clinically, dengue illness is divided into three basic phases: acute febrile phase, critical phase, and recovery (convalescent) phase. Dengue disease occurs with/without warning signs or severe dengue. Warning signs (suggestive signs or symptoms of important fluid loss, capillary leakage, and shock, such as severe abdominal pain and mucosal bleeding; observed at the end of the febrile phase) allow the rapid identification of patients who need more clinical attention and supportive therapy, in an attempt to avoid severe dengue. When severe disease occurs, this condition can lead to serious organ involvement, shock, and hemorrhage, among other signals and symptoms (<xref rid="bib0605" ref-type="bibr">Guzman et al., 2016</xref>). Infection with a DENV serotype triggers long-term immunity to that specific serotype (homotypic DENV). Immunity to heterotypic DENV also occurs, but it is transitory. Therefore, an individual can have dengue disease more than once. Severe dengue occurs more frequently in recurrent infection with a different viral serotype (<xref rid="bib1065" ref-type="bibr">Murphy and Whitehead, 2011</xref>; <xref rid="bib1410" ref-type="bibr">St John and Rathore, 2019</xref>).</p><p id="par0240">The immune response mediates DENV clearance and the resolution of dengue diseases, but it is also involved in the disease pathogenesis (<xref rid="bib1065" ref-type="bibr">Murphy and Whitehead, 2011</xref>). Some evidence suggests the participation of CCL5/CCR5 axis in the protection against DENV (<xref rid="bib1365" ref-type="bibr">Sierra et al., 2014</xref>), as well as in the pathogenesis of Dengue disease (<xref rid="bib0680" ref-type="bibr">Islam et al., 2019</xref>). Indeed, DENV infection is associated with increased frequency of human CCR5&#x0202f;<sup>+</sup>&#x0202f;T cells (<xref rid="bib0335" ref-type="bibr">de-Oliveira-Pinto et al., 2012</xref>; <xref rid="bib0085" ref-type="bibr">Badolato-Corr&#x000ea;a et al., 2018</xref>). In a study performed by <xref rid="bib0985" ref-type="bibr">Marques et al. (2015)</xref>, lower viral replication was found in macrophages treated with CCR5 blockers. In the same study, CCR5-/- mice were protected from DENV infection. These findings suggest that CCR5&#x00394;32 could be a protective factor against DENV infection. However, <xref rid="bib1635" ref-type="bibr">Xavier-Carvalho et al. (2013)</xref> found no statistical difference in the frequency of CCR5&#x00394;32 polymorphism between Brazilian children with severe DENV infection and healthy controls. In the same direction, no effect of CCR5&#x00394;32 on susceptibility to DENV infection was found in a small sample-size study performed with individuals from Western Australia (<xref rid="bib0175" ref-type="bibr">Brestovac et al., 2014</xref>) and recent data suggested no important involvement of <italic>CCR5</italic> gene or <italic>CCR5</italic> polymorphisms in DENV infection (<xref rid="bib0185" ref-type="bibr">Cahill et al., 2018</xref>; <xref rid="bib1105" ref-type="bibr">Ornelas et al., 2019</xref>). Finally, the CCR5&#x00394;32 allele was not identified in a small group of Indian DENV-infected individuals (<xref rid="bib0680" ref-type="bibr">Islam et al., 2019</xref>). <xref rid="tbl0030" ref-type="table">Table 6</xref> shows some details of the studies involving CCR5&#x00394;32 and DENV infection.</p><p id="par0245">Taking together, the data mentioned above indicate that the effects of CCR5 on DENV infection are very different between humans and rodents. However, it should be noted that the approach of each mentioned study is quite particular, and we cannot exclude some potential effects of CCR5 and CCR5&#x00394;32 on DENV infection in humans.</p></sec><sec id="sec0055"><label>3.8</label><title>Human cytomegalovirus</title><p id="par0250">Human cytomegalovirus (CMV) is an enveloped double-stranded DNA virus belonging to the <italic>Herpesviridae</italic> family (<xref rid="bib0300" ref-type="bibr">Crough and Khanna, 2009</xref>; <xref rid="bib0630" ref-type="bibr">Herbein, 2018</xref>). The infection in immunocompetent adults is usually asymptomatic. However, in some cases, it can cause mononucleosis syndrome or other rare complications, including meningitis and myocarditis. CMV is an opportunistic pathogen and, therefore, symptomatic infection occurs more frequently in immunocompromised individuals (HIV infected or transplanted patients on immunosuppressive drugs). Congenital CMV infection is associated with morbidity and mortality in newborns, being associated with neurodevelopmental problems (<xref rid="bib0300" ref-type="bibr">Crough and Khanna, 2009</xref>). CMV is also linked to cancer development, once several CMV proteins (<italic>e.g.</italic>, pUL122, pUL123, pUS28, pUL83, pUL111A) activate pro-oncogenic pathways, including angiogenesis, escape of immune control and tumor suppressors, tumoral inflammation, invasion and metastasis, genome instability, and increased cell survival and proliferation (<xref rid="bib0630" ref-type="bibr">Herbein, 2018</xref>). Poor socioeconomic condition favors CMV infection. Antibodies indicating past CMV infection are found in &#x0223c;60 % of adults from high-income countries. In low-income countries, the rate of past infections can reach 100 % (<xref rid="bib0575" ref-type="bibr">Griffiths et al., 2015</xref>).</p><p id="par0255">CMV can manipulate the immune system producing virokines (virus-encoded cytokine/chemokine homologs) and viroceptors (virus-encoded cytokine/chemokine receptor homologs), molecules that enable the virus to evade host immune defenses. Such molecules can also facilitate viral replication (<xref rid="bib0950" ref-type="bibr">Lucas et al., 2001</xref>; <xref rid="bib0475" ref-type="bibr">Froberg, 2004</xref>; <xref rid="bib1585" ref-type="bibr">Vomaske et al., 2012</xref>). Importantly, CMV-encoded proteins can interact with CCR5, modulating its function and cell migration (<xref rid="bib1450" ref-type="bibr">Tadagaki et al., 2012</xref>; <xref rid="bib1585" ref-type="bibr">Vomaske et al., 2012</xref>), potentially affecting the pathogenesis of diseases in which CCR5 have an involvement, especially HIV infection. CMV infection in immunocompromised HIV/AIDS patients can cause different problems, including retinitis, esophagitis, gastritis, pneumonitis, and hepatitis (<xref rid="bib0300" ref-type="bibr">Crough and Khanna, 2009</xref>). CMV proteins can have an inhibitory effect on HIV&#x02212;CCR5 interaction, hampering cell infection by HIV (<xref rid="bib1450" ref-type="bibr">Tadagaki et al., 2012</xref>). In the opposite direction, <xref rid="bib0690" ref-type="bibr">Johnson et al. (2018)</xref> have shown that CMV upregulates CCR5 expression <italic>in vitro</italic>, suggesting a potential contribution to HIV susceptibility <italic>in vivo</italic>. In accordance, a previous study has indicated that CMV infection upregulates CCR5 expression (<xref rid="bib0685" ref-type="bibr">Johnson et al., 2015</xref>). However, mixed results were reported regarding the effect of CMV on CCR5 expression since there is evidence indicating that CMV infection may reduce CCR5 expression in various cell types (<xref rid="bib0860" ref-type="bibr">Lecointe et al., 2002</xref>; <xref rid="bib1540" ref-type="bibr">Varani et al., 2005</xref>). Interestingly, these mixed results may not be contradictory. CMV-infected cells may indeed exhibit decreased CCR5 expression, limiting HIV infection in these cells. However, CMV-infected cells release CMV-associated soluble factors that increase CCR5 expression in non-infected bystander cells, then facilitating HIV replication in such cells and, consequently, contributing to HIV pathogenesis (<xref rid="bib0750" ref-type="bibr">King et al., 2006</xref>).</p><p id="par0260">There is evidence showing that variants in the <italic>CCR5</italic> gene can influence multiple aspects of CMV infection (<xref rid="bib0945" ref-type="bibr">Loeffler et al., 2006</xref>; <xref rid="bib1330" ref-type="bibr">Sezgin et al., 2011</xref>). For example, the <italic>CCR5</italic> promoter polymorphism rs1800023 affects CMV replication (<xref rid="bib0165" ref-type="bibr">Bravo et al., 2014</xref>; <xref rid="bib0295" ref-type="bibr">Corrales et al., 2015</xref>). In a study evaluating children, <xref rid="bib0710" ref-type="bibr">Kasztelewicz et al. (2017)</xref> found no influence of CCR5&#x00394;32 on susceptibility to congenital CMV infection, severity of congenital CMV disease, or CMV-related sensorineural hearing loss at birth. As an individual genetic factor, CCR5&#x00394;32 was not statistically associated with the progression of CMV retinitis, a condition that CMV can cause in immunocompromised individuals (<xref rid="bib1330" ref-type="bibr">Sezgin et al., 2011</xref>) (<xref rid="tbl0030" ref-type="table">Table 6</xref>).</p></sec><sec id="sec0060"><label>3.9</label><title>Crimean-Congo hemorrhagic fever virus</title><p id="par0265">Crimean-Congo hemorrhagic fever virus (CCHFV) belongs to the genus <italic>Nairovirus</italic>, family <italic>Bunyaviridae</italic>. CCHFV circulates in Africa, Europe, Middle East, and Asia countries, and can infect a variety of domestic animals and wild species, but without causing symptomatic illness. Humans are accidental hosts of CCHFV, for which the virus is transmitted mainly by tick-bites (especially ticks of the genus <italic>Hyalomma</italic>), although other routes of transmission also exist, such as exposure to blood of infected animals. Most CCHFV-infected individuals have no symptoms or have mild nonspecific febrile syndrome. However, in some individuals, the infection can cause the Crimean-Congo hemorrhagic fever, a severe disease characterized by fever, myalgia, hemorrhage, among other manifestations. Neurological complications can also occur, being the spectrum and intensity of the disease quite variable (<xref rid="bib0445" ref-type="bibr">Erg&#x000f6;n&#x000fc;l, 2006</xref>; <xref rid="bib0115" ref-type="bibr">Bente et al., 2013</xref>; <xref rid="bib0500" ref-type="bibr">Garrison et al., 2019</xref>).</p><p id="par0270">Deregulation of several cytokines and chemokines is involved in the pathogenesis of Crimean-Congo hemorrhagic fever (<xref rid="bib0445" ref-type="bibr">Erg&#x000f6;n&#x000fc;l, 2006</xref>; <xref rid="bib1260" ref-type="bibr">Saksida et al., 2010</xref>; <xref rid="bib0115" ref-type="bibr">Bente et al., 2013</xref>; <xref rid="bib0500" ref-type="bibr">Garrison et al., 2019</xref>). In a study performed by <xref rid="bib0080" ref-type="bibr">Arasli et al. (2015)</xref>, expression of the CCR5 ligands CCL2, CCL3, and CCL4 was increased in CCHFV-infected adults compared to controls. Considering these same chemokines in CCHFV-infected children, only CCL4 was significantly increased compared to pediatric controls (<xref rid="bib0080" ref-type="bibr">Arasli et al., 2015</xref>).</p><p id="par0275">
<xref rid="bib0440" ref-type="bibr">Engin et al. (2009)</xref> evaluated the CCR5&#x00394;32 in 15 Turkish CCHFV-infected individuals and observed the wild-type homozygous genotype in all cases. In a subsequent study evaluating the Turkish population, <xref rid="bib1245" ref-type="bibr">Rustemoglu et al. (2017)</xref> found a protective effect of CCR5&#x00394;32 heterozygous genotype and &#x00394;32 allele on CCHFV infection, since the genotype and allele frequencies were higher in controls than in CCHFV-infected individuals. Conversely, the wild-type genotype (normal CCR5 expression) was prevalent among infected individuals. These findings suggest that CCR5 contributes to susceptibility to CCHFV infection and that CCR5 down-regulation due to CCR5&#x00394;32 results in some protection against the infection. However, further studies are needed to explain the mechanisms by which CCR5 participates in CCHFV infection. In the same study, the CCR5&#x00394;32 was not significantly associated with disease severity, clinical parameters, or mortality rate (<xref rid="bib1245" ref-type="bibr">Rustemoglu et al., 2017</xref>). Together, these findings (<xref rid="tbl0030" ref-type="table">Table 6</xref>) indicate that the effect of CCR5&#x00394;32 is given specifically on resistance against CCHFV infection, without affecting the pathogenesis/outcome of Crimean-Congo hemorrhagic fever.</p></sec><sec id="sec0065"><label>3.10</label><title>Enterovirus</title><p id="par0280">The genus <italic>Enterovirus</italic> is composed of non-enveloped, positive-stranded RNA viruses, belonging to the <italic>Picornaviridae</italic> family. Enteroviruses (EV) can infect the gastrointestinal tract, CNS, and other organs, including heart (<xref rid="bib1465" ref-type="bibr">Tapparel et al., 2013</xref>). Cardiomyopathy is a common consequence of EV infection in the heart. EV infection is associated with myocardial inflammation (myocarditis) and other damages to heart tissues (<xref rid="bib0090" ref-type="bibr">Badorff et al., 2000</xref>; <xref rid="bib0290" ref-type="bibr">Cooper, 2009</xref>; <xref rid="bib1255" ref-type="bibr">Sagar et al., 2012</xref>; <xref rid="bib1465" ref-type="bibr">Tapparel et al., 2013</xref>; <xref rid="bib1605" ref-type="bibr">Weintraub et al., 2017</xref>). A portion of EV-infected individuals clears the virus, while others develop persistent infection that can damage heart tissues. Viral persistence in individuals with enteroviral cardiomyopathy is associated with an increased mortality rates (<xref rid="bib0795" ref-type="bibr">K&#x000fc;hl et al., 2005</xref>; <xref rid="bib0835" ref-type="bibr">Lassner et al., 2018</xref>).</p><p id="par0285">Some studies suggest that CCR5 influences different aspects of the pathogenesis of viruses belonging to the <italic>Picornaviridae</italic> family, including Encephalomyocarditis virus (<xref rid="bib0260" ref-type="bibr">Christmann et al., 2011</xref>; <xref rid="bib1335" ref-type="bibr">Shaheen et al., 2015</xref>), Coxsackievirus B3 (<xref rid="bib1525" ref-type="bibr">Valaperti et al., 2013</xref>), and Rhinovirus (<xref rid="bib1045" ref-type="bibr">Muehling et al., 2018</xref>), once CCR5 participates in the regulation of the host immune response during infection by these viruses. Considering the effects of the genetic variant CCR5&#x00394;32 on CCR5 expression and CCR5-related immune responses, it is possible that CCR5&#x00394;32 also shows some impact on EV-related diseases.</p><p id="par0290">In a German study that evaluated patients with enteroviral (chronic/inflammatory) cardiomyopathy (<xref rid="bib0835" ref-type="bibr">Lassner et al., 2018</xref>), the CCR5&#x00394;32 was strongly associated with spontaneous viral clearance and better clinical outcome (reduced mortality rate) (<xref rid="tbl0030" ref-type="table">Table 6</xref>). These findings indicate a critical involvement of the CCR5 molecule in the pathogenesis of EV cardiomyopathy. It was suggested that the CCR5&#x00394;32 genotyping could be used to assist in the prediction of the clinical progression of enteroviral cardiomyopathy: the &#x00394;32 allele as a predictor of a better prognosis, without the need of antiviral interferon-&#x003b2; (IFN-&#x003b2;) therapy; and the wild-type genotype as a predictor of a worse prognosis and immediate need of antiviral IFN-&#x003b2; therapy (<xref rid="bib0835" ref-type="bibr">Lassner et al., 2018</xref>). The clinical use of IFN-&#x003b2; is effective to eliminate the virus, avoid irreversible cardiac injury, and reduce mortality rates, but it is also associated to numerous adverse effects (<xref rid="bib0800" ref-type="bibr">K&#x000fc;hl et al., 2012</xref>; <xref rid="bib0835" ref-type="bibr">Lassner et al., 2018</xref>). Considering the prognostic value of the CCR5&#x00394;32 on the clinical course of enteroviral cardiomyopathy, it is necessary to evaluate the relationship between the CCR5&#x00394;32 and the disease in different human populations, mainly through genetic association studies. If this association is confirmed in other populations, the CCR5&#x00394;32 genotyping will be a broad-spectrum clinical tool, enhancing and driving the treatment of enteroviral cardiomyopathy.</p></sec><sec id="sec0070"><label>3.11</label><title>Japanese encephalitis virus</title><p id="par0295">Japanese encephalitis virus (JEV) contains a single-stranded positive-sense RNA genome and belongs to the family <italic>Flaviviridae</italic>, genus <italic>Flavivirus</italic>. Birds and pigs are the JEV amplifying hosts. JEV is transmitted by <italic>Culex</italic> mosquitoes and occur especially in Australia and Asian countries. Humans and horses are dead-end JEV hosts. The human infection causes a broad range of clinical manifestations, varying from asymptomatic infection (most cases) to mild febrile syndrome and even lethal meningomyeloencephalitis. JEV is the etiological agent of most cases of viral encephalitis in many countries, reaching &#x0223c;30 % mortality rate (<xref rid="bib1530" ref-type="bibr">van den Hurk et al., 2009</xref>; <xref rid="bib1495" ref-type="bibr">Tiwari et al., 2012</xref>; <xref rid="bib0850" ref-type="bibr">Le Flohic et al., 2013</xref>).</p><p id="par0300">Some evidence obtained in laboratory conditions (<italic>in vitro</italic> analysis and murine models) showed that JEV infection induces the up-regulation of <italic>CCR5</italic> gene (<xref rid="bib0590" ref-type="bibr">Gupta and Rao, 2011</xref>; <xref rid="bib1115" ref-type="bibr">Pareek et al., 2014</xref>; <xref rid="bib1680" ref-type="bibr">Zhang et al., 2019</xref>). Also, increased infiltration of CCR5<sup>+</sup> CD8<sup>+</sup> T cells was observed in the brains of JEV-infected mice (<xref rid="bib1680" ref-type="bibr">Zhang et al., 2019</xref>). In this context, using a mouse model of Japanese encephalitis, <xref rid="bib0825" ref-type="bibr">Larena et al. (2012)</xref> showed that CCR5 protects the host against JEV infection in the CNS, being essential for disease recovery. CCR5-deficient mice showed higher viral loads in the brain and spinal cord as well as increased mortality rate, as compared to control mice (<xref rid="bib0825" ref-type="bibr">Larena et al., 2012</xref>). Also using a mouse model of Japanese encephalitis, <xref rid="bib0745" ref-type="bibr">Kim et al. (2016)</xref> demonstrated that CCR5 controls the infiltration of CD4<sup>+</sup>Foxp3<sup>+</sup> T regulatory (Treg) cells in the CNS, contributing to protection against Japanese encephalitis. The infiltration and action of inflammatory cells in the brain are important to limit neuroinvasive infections, processes that are regulated by multiple factors, especially cytokines, chemokines and their receptors, including CCR5. However, the uncontrolled action of inflammatory cells can cause damage to the CNS. Of note, CD4<sup>+</sup>Foxp3<sup>+</sup> Treg cells regulate the immune responses, avoiding undesirable or excessive action of inflammatory cells (<xref rid="bib0100" ref-type="bibr">Bardina and Lim, 2012</xref>; <xref rid="bib1545" ref-type="bibr">Veiga-Parga et al., 2013</xref>; <xref rid="bib1385" ref-type="bibr">Simonetta and Bourgeois, 2013</xref>; <xref rid="bib0190" ref-type="bibr">Campbell, 2015</xref>; <xref rid="bib0745" ref-type="bibr">Kim et al., 2016</xref>). According to these pieces of evidence, CCR5-mediated action of Treg cells is critical for the control of Japanese encephalitis. However, the role of CCR5 in JEV infection may be more complex than it appears at first. <xref rid="bib0935" ref-type="bibr">Liu et al. (2018)</xref> demonstrated that the use of the CCR5 antagonist maraviroc reduces the JEV-induced inflammation in mice brain, increasing survival rate. This result suggests that potential deleterious effects of CCR5-mediated inflammation in the brain may override the effects of CCR5-mediated action of Treg cells and, therefore, the use of CCR5 antagonists to treat Japanese encephalitis may be beneficial. Based on these complex and contradictory results, it can be concluded that CCR5 indeed has an important influence on Japanese encephalitis, but it is not yet possible to state its specific roles, once they are varied and appear to be context-dependent. Also, the results obtained in animal models may not fully represent the disease course in humans.</p><p id="par0305">Indeed, some evidences suggest the involvement of CCR5 in the pathogenesis of Japanese encephalitis in humans. In Indian individuals with mild cases of Japanese encephalitis, a significant dowregulation of the <italic>CCR5</italic> gene was observed as compared to healthy controls (<xref rid="bib0255" ref-type="bibr">Chowdhury and Khan, 2019</xref>). However, the CCR5&#x00394;32 does not have a relevant influence on the disease. <xref rid="bib0340" ref-type="bibr">Deval et al. (2019)</xref> investigated the effect of various genetic variants, including CCR5&#x00394;32, on the development of Japanese encephalitis in individuals from North India (<xref rid="tbl0030" ref-type="table">Table 6</xref>). No statistically significant difference was found when the CCR5&#x00394;32 (as an individual factor) was compared between cases and controls (<xref rid="bib0340" ref-type="bibr">Deval et al., 2019</xref>). Considering that both studies mentioned above were performed in the Indian population, studies evaluating the potential effects of CCR5 and CCR5&#x00394;32 on Japanese encephalitis in other populations are necessary.</p></sec><sec id="sec0075"><label>3.12</label><title>Hantavirus infection</title><p id="par0310">Puumala virus (PUV) infection is a zoonosis endemic in Europe. PUV is an enveloped single-stranded RNA virus, belonging to the <italic>Bunyaviridae</italic> family, genus <italic>Hantaviridae</italic>. Most PUV infections are mild or subclinical. In some infected individuals, PUV is responsible for the development of nephropathia epidemica, a milder form of hemorrhagic fever with renal syndrome, a condition typically caused by other Hantaviruses (<xref rid="bib1325" ref-type="bibr">Settergren, 2000</xref>; <xref rid="bib1070" ref-type="bibr">Mustonen et al., 2013</xref>; <xref rid="bib0855" ref-type="bibr">Lebecque and Dupont, 2019</xref>). An <italic>in vitro</italic> study found increased <italic>CCR5</italic> gene expression in primary monocytes infected by hantaviruses (Hantaan virus, Sin Nombre virus and Andes virus) (<xref rid="bib0980" ref-type="bibr">Markoti&#x00107; et al., 2007</xref>). In this sense, host genetic factors and the immune responses affect different aspects of PUV infection and progression of nephropathia epidemica (<xref rid="bib1070" ref-type="bibr">Mustonen et al., 2013</xref>), although the role of CCR5 in this disease is little known.</p><p id="par0315">
<xref rid="bib0760" ref-type="bibr">Kletenkov et al. (2019)</xref> evaluated the potential influence of the CCR5&#x00394;32 on nephropathia epidemica in individuals from Republic of Tatarstan, Russia (<xref rid="tbl0030" ref-type="table">Table 6</xref>). Of note, in their study, the authors stated hantavirus infection as the cause of Nephropathia epidemica, not specifying the PUV detection. No statistical difference was observed in CCR5&#x00394;32 genotype frequencies between cases and controls, indicating that CCR5&#x00394;32 does not influenced the susceptibility to hantavirus infection in the studied population. Considering only nephropathia epidemica cases, the study revealed an association between the wild-type homozygous genotype (functional CCR5) and increased severity of the disease. Conversely, the heterozygous genotype was considered a protective factor against increased disease severity (<xref rid="bib0760" ref-type="bibr">Kletenkov et al., 2019</xref>). To the best of our knowledge, there are no other studies that have evaluated CCR5&#x00394;32 in nephropathia epidemica. However, the results presented by <xref rid="bib0760" ref-type="bibr">Kletenkov et al. (2019)</xref> suggest that further studies evaluating the roles of CCR5 and CCR5&#x00394;32 on hantavirus infection are important.</p></sec></sec><sec id="sec0080"><label>4</label><title><italic>CCR5</italic> gene editing and CCR5 modulation: what would be the effects of CCR5 absence on everyday life<bold>?</bold></title><p id="par0320">In 2019, the multiple roles of CCR5 in physiological and pathological conditions gained the attention of the scientific community and lay public due to <italic>CCR5</italic> gene editing in human embryos, the &#x0201c;CRISPR babies&#x0201d;, performed by a Chinese biophysicist. The researcher claimed to have used CRISPR gene editing technology to edit the <italic>CCR5</italic> of germline cells to mimic the effects of CCR5&#x00394;32, aiming to generate babies resistant to HIV infection. The ethical, safety, and legal aspects related to this procedure have caused an intense and broad discussion in the media and scientific literature (<xref rid="bib0275" ref-type="bibr">Cohen, 2019</xref>; <xref rid="bib0310" ref-type="bibr">Daley et al., 2019</xref>; <xref rid="bib0565" ref-type="bibr">Greely, 2019</xref>; <xref rid="bib1220" ref-type="bibr">Rosenbaum, 2019</xref>), and this case culminated in a three years prison sentence for the biophysicist responsible for the procedure (<xref rid="bib0305" ref-type="bibr">Cyranoski, 2020</xref>). Also, the consequences of the CCR5 absence have brought many concerns to light, once the CCR5 protein participates in tissue development processes, control of immune responses, and several other physiological processes. Considering these concerns, our group and others described some undesirable effects associated to natural CCR5 absence (due to the CCR5&#x00394;32 homozygous genotype) and <italic>CCR5</italic> editing (<xref rid="bib0420" ref-type="bibr">Ellwanger et al., 2019</xref>; <xref rid="bib1595" ref-type="bibr">Wang and Yang, 2019</xref>; <xref rid="bib1640" ref-type="bibr">Xie et al., 2019</xref>).</p><p id="par0325">Besides gene editing techniques, the expression of CCR5 can be artificially modulated through the use of pharmacological antagonists (<italic>e.g.</italic> maraviroc), chemokine ligands, and monoclonal antibodies (<xref rid="bib0460" ref-type="bibr">Fantuzzi et al., 2019</xref>). The use of CCR5 antagonists is well established for the treatment of HIV infection and is currently being tested for the treatment of many other diseases, such as cancer (<xref rid="bib1135" ref-type="bibr">Pervaiz et al., 2019</xref>; <xref rid="bib0655" ref-type="bibr">Huang et al., 2020a</xref>), stroke (<xref rid="bib0695" ref-type="bibr">Joy et al., 2019</xref>), and cocaine addiction-related disorders (<xref rid="bib0615" ref-type="bibr">Hall et al., 2020</xref>; <xref rid="bib1085" ref-type="bibr">Nayak et al., 2020</xref>).</p><p id="par0330">Taking together, it is increasingly clear that the specific inhibition of CCR5 expression through different techniques is gaining pace in different clinical contexts. The pharmacological CCR5 blockade has many benefits in different clinical situations, particularly in the treatment of HIV infection. Also, the potential of gene editing (especially in somatic cells) for the treatment of genetic diseases is very promising. However, considering viral infections, two aspects must be considered, as follows:</p><p id="par0335">I) The non-redundant characteristics of the CCR5 should be taken into consideration when studying the CCR5 protein and the effects of CCR5&#x00394;32 on viral infections: The traditional concepts of redundancy and robustness of the chemokine system consider that the absence of a specific chemokine or chemokine receptor is adequately compensated by other molecules. Although these concepts are generally correct for some chemokines/receptors and for some physiological conditions, the lack of CCR5 expression may affect the host protection against some specific infectious diseases once the CCR5 absence is not perfectly compensated for by other receptors (<xref rid="bib0425" ref-type="bibr">Ellwanger et al., 2020a</xref>). The nonredundancy of CCR5 is relevant especially for infections by neuroinvasive flaviviruses (<xref rid="bib0100" ref-type="bibr">Bardina and Lim, 2012</xref>). For example, the absence of CCR5 due to CCR5&#x00394;32 is considered deleterious in WNV infection (<xref rid="bib0540" ref-type="bibr">Glass et al., 2006</xref>; <xref rid="bib0905" ref-type="bibr">Lim et al., 2008</xref>) and in some aspects of TBEV infection (<xref rid="bib0380" ref-type="bibr">Ellwanger and Chies, 2019a</xref>). The non-redundant role of CCR5 is also likely in JEV infection (<xref rid="bib0825" ref-type="bibr">Larena et al., 2012</xref>).</p><p id="par0340">II) Studies evaluating the actual impact of CCR5 antagonists on neuroinvasive infections are needed: It is possible that those individuals using CCR5 antagonists (<italic>e.g.</italic>, for the treatment of HIV infection) and living in areas endemic for neuroinvasive viruses, especially WNV and TBEV, may be at increased risk of developing viral encephalitis-related problems. However, it is still necessary that studies consistently evaluate this assumption, since the available evidence does not support risks for the use of CCR5 antagonists in endemic areas of flaviviruses (<xref rid="bib0990" ref-type="bibr">Martin-Blondel et al., 2016</xref>). As mentioned in the topic addressing WNV in this review, it is prudent to recommend to individuals using CCR5 antagonists to adopt measures to minimize the risk of neuroinvasive infections, such as the use of mosquito repellents and mosquito nets (considering the risk of WNV infection), and to limit their exposure to tick-infested areas (considering the risk of TBEV infection). Concerns regarding the use of CCR5 antagonists in areas of JEV circulation have also been raised by other authors (<xref rid="bib0745" ref-type="bibr">Kim et al., 2016</xref>; <xref rid="bib0825" ref-type="bibr">Larena et al., 2012</xref>). If the connection between the use of CCR5 antagonists and increased risk of neuroinvasive infections is confirmed in methodologically well-controlled studies, these recommendations should be considered of essential importance for users of CCR5 antagonists.</p></sec><sec id="sec0085"><label>5</label><title>The triad &#x0201c;extracellular vesicles, viruses, and CCR5&#x0201d;</title><p id="par0345">&#x0201c;Extracellular vesicles&#x0201d; (EVs) is a general term used to designate different membranous vesicles released by various cell types. EVs include microparticles, microvesicles, nanovesicles, nanoparticles, ectosomes, exosomes, exovesicles, exosome-like vesicles, oncosomes, among other vesicle types. EVs act in the transport of different molecules (<italic>e.g.</italic> microRNAs, mRNAs, proteins) between cells and tissues in a regulated and precise manner. EVs promote the maintenance of physiological processes, also participating in the pathogenesis of various diseases, such as cancer and inflammatory diseases (<xref rid="bib0285" ref-type="bibr">Colombo et al., 2014</xref>; <xref rid="bib1475" ref-type="bibr">Th&#x000e9;ry et al., 2018</xref>). Besides, the regulation of multiple aspects of the immune system is strongly influenced by EVs (<xref rid="bib1095" ref-type="bibr">O&#x02019;Neill and Quah, 2008</xref>; <xref rid="bib0285" ref-type="bibr">Colombo et al., 2014</xref>; <xref rid="bib0390" ref-type="bibr">Ellwanger et al., 2016</xref>).</p><p id="par0350">The multiple roles of EVs in viral infections began to be studied more intensively in recent years, representing an emerging topic in the field of infectious diseases. Currently, the relationship between EVs and viral infections has already been explored (to a greater or lesser extent) in the context of the following viruses: Bunyaviruses, Cytomegalovirus, Dengue virus (DENV), Ebola virus, Epstein-Barr virus, Hepatitis A virus, Hepatitis C virus (HCV), Human papillomavirus, Herpes simplex virus, Human T cell lymphotropic virus, Kaposi&#x02019;s sarcoma-associated herpesvirus, Zika virus (ZIKV), TBEV, HIV (<xref rid="bib0705" ref-type="bibr">Kaminski et al., 2019b</xref>), and Influenza virus (<xref rid="bib1695" ref-type="bibr">Zheng et al., 2020</xref>).</p><p id="par0355">EVs participate in immune evasion processes, ultimately allowing viruses to bypass host defenses (<xref rid="bib0705" ref-type="bibr">Kaminski et al., 2019b</xref>). For example, HIV is likely to usurp the exosome biogenesis pathway in such a way that enhances its infectivity, while increasing its evading strategies from the host immune defenses (<xref rid="bib0395" ref-type="bibr">Ellwanger et al., 2017a</xref>). Regarding TBEV, exosomes were indicated as important participants in both viral infection and pathogenesis; in this case, tick-derived exosomes facilitate TBEV transmission to the host. Also, exosomes derived from TBEV-infected host neurons can facilitate the spread of the virus in the CNS (<xref rid="bib1700" ref-type="bibr">Zhou et al., 2018</xref>). Exosomes have shown multi-dimensional roles in DENV life cycle. They can modulate negatively or positively DENV pathogenesis, where they are suggested as instrumental for Dengue Hemorrhagic Fever development in reason of the transportation of specific microRNAs (<xref rid="bib1025" ref-type="bibr">Mishra et al., 2019</xref>). Since HCV can be found inside exosomes (<xref rid="bib0925" ref-type="bibr">Liu et al., 2014</xref>), it is not suprising that blood-derived exosomes from HCV-infected patients can transmit the virus to other cells (<xref rid="bib0180" ref-type="bibr">Bukong et al., 2014</xref>). These findings suggest that exosomes and other EVs assist in the transport of HCV particles/components between cells, ultimately facilitating viral infection. Of note, EVs can transport multiple viral components or molecules from virus-infected cells that end up facilitating the spread of the virus in the host. On the other hand, EVs can act in favor of the host, transporting molecules that assist host defenses in the elimination or control of infections (<xref rid="bib0705" ref-type="bibr">Kaminski et al., 2019b</xref>).</p><p id="par0360">EVs can transport a range of cytokines and chemokines, such as IL-1, IL-2, IFN-&#x003b1;, IFN-&#x003b2;, CCL2, CCL3, CCL4, and CXCL10 (<xref rid="bib0225" ref-type="bibr">Chen et al., 2011</xref>; <xref rid="bib0775" ref-type="bibr">Konadu et al., 2015</xref>; <xref rid="bib0645" ref-type="bibr">Hosseinkhani et al., 2018</xref>; <xref rid="bib0765" ref-type="bibr">Kodidela et al., 2018</xref>; <xref rid="bib0490" ref-type="bibr">Gao et al., 2019a</xref>, <xref rid="bib0495" ref-type="bibr">b</xref>; <xref rid="bib0040" ref-type="bibr">Aiello et al., 2020</xref>; <xref rid="bib0240" ref-type="bibr">Chiantore et al., 2020</xref>). Besides, EVs and microparticles also transport chemokine receptors (<xref rid="bib1350" ref-type="bibr">Shen et al., 2016</xref>; <xref rid="bib0875" ref-type="bibr">Li et al., 2018</xref>; <xref rid="bib0885" ref-type="bibr">Liang et al., 2018</xref>), including CCR5 (<xref rid="bib0955" ref-type="bibr">Mack et al., 2000</xref>; <xref rid="bib1500" ref-type="bibr">Tokarz et al., 2019</xref>). Interestingly, EVs from CCR5 wild type cells can deliver CCR5 molecules to CCR5 &#x00394;32/&#x00394;32 cells, making them susceptible to HIV infection (<xref rid="bib0955" ref-type="bibr">Mack et al., 2000</xref>). A similar phenomenon has been reported involving microparticles, HIV, and CXCR4 (<xref rid="bib1230" ref-type="bibr">Rozmyslowicz et al., 2003</xref>). CCR5 expression is also influenced by the release of EVs, specifically microparticles (<xref rid="bib1205" ref-type="bibr">Renovato-Martins et al., 2017</xref>). Therefore, EVs have the potential to attribute greater complexity to CCR5 roles in viral infections. It is possible that the presence of CCR5 in cells is not only dependent on mechanisms of membrane expression and internalization of the receptor. It can also be dependent on CCR5 delivery mediated by EVs. However, the actual impact of EVs on CCR5-mediated immune response in infections remains to be determined and deserves further investigation.</p><p id="par0365">Finally, a truncated CCR5 soluble form (<xref rid="bib1510" ref-type="bibr">Tsimanis et al., 2005</xref>), as well as soluble CXCR4, have also been reported in the plasma of humans (<xref rid="bib0965" ref-type="bibr">Malvoisin et al., 2011</xref>). Of note, the truncated CCR5 soluble form has &#x0223c;22&#x0202f;kDa (half the size of the CCR5 found on cell membranes) and is truncated at the end of the second extracellular loop (the third extracellular loop and the subsequent three transmembrane regions are absent) (<xref rid="bib1510" ref-type="bibr">Tsimanis et al., 2005</xref>). However, the existence of cell-free soluble CCR5 is still controversial and does not represent a consensus in the scientific community. Such doubts occur mainly in consideration of the structure of the receptor, which is highly characteristic of a cell membrane-associated molecule. We believe that EVs-containing CCR5 can explain potential (misleading) detections of soluble CCR5. The importance of circulating EVs-containing CCR5 on viral infections represents an additional and interesting open question to be investigated.</p></sec><sec id="sec0090"><label>6</label><title>Neglected and emerging topics in CCR5 research: Rocio virus, Zika virus, Epstein-Barr virus, and rhinovirus</title><p id="par0370">
<xref rid="bib0210" ref-type="bibr">Ch&#x000e1;vez et al. (2013)</xref> demonstrated an involvement of the CCR5 protein in the infection by Rocio virus (ROCV), a mosquito-borne flavivirus that caused a major human encephalitis outbreak between 1975 and 1980, in the region of Ribeira Valley, S&#x000e3;o Paulo State, Brazil (<xref rid="bib0400" ref-type="bibr">Ellwanger et al., 2017b</xref>). Specifically, using a mouse model of ROCV-associated encephalitis, CCR5-deficient mice showed increased survival rate and reduced levels of brain inflammation compared to mice expressing CCR5, indicating the participation of CCR5 in ROCV-associated encephalitis (<xref rid="bib0210" ref-type="bibr">Ch&#x000e1;vez et al., 2013</xref>). Although other studies discussed in this review have shown an important involvement of CCR5 in infection by flaviviruses [especially as an important molecule for the resolution of neuroinfection, in opposition to results of <xref rid="bib0210" ref-type="bibr">Ch&#x000e1;vez et al. (2013)</xref>], the role of the CCR5 in ROCV infection represents a neglected topic. This knowledge gap should be addressed in further studies since the reemergence of ROCV in Brazil is a concern in terms of public health (<xref rid="bib0470" ref-type="bibr">Figueiredo, 2007</xref>; <xref rid="bib0400" ref-type="bibr">Ellwanger et al., 2017b</xref>). Although no other ROCV outbreaks have been reported in Brazil after the 1980s, there is evidence of ROCV circulation in animals (<xref rid="bib0200" ref-type="bibr">Casseb et al., 2014</xref>; <xref rid="bib1125" ref-type="bibr">Pauvolid-Corr&#x000ea;a et al., 2014</xref>; <xref rid="bib1375" ref-type="bibr">Silva et al., 2014</xref>).</p><p id="par0375">
<xref rid="bib0085" ref-type="bibr">Badolato-Corr&#x000ea;a et al. (2018)</xref> reported that Zika virus (ZIKV) infection induces an upregulation of CCR5 expression on T cells. Of note, ZIKV is another mosquito-borne flavivirus that recently reemerged in many countries, affecting Brazil in particular. ZIKV infection is associated with microcephaly and other human development problems (<xref rid="bib0110" ref-type="bibr">Baud et al., 2017</xref>). <xref rid="bib1660" ref-type="bibr">Zachova et al. (2019)</xref> showed that Epstein-Barr virus (EBV)-infected B cells have increased CCR5 expression compared to EBV-non-infected cells. Also, recent evidence points to a pivotal role of the CCR5 in the attenuation of rhinovirus-associated inflammation, by controlling the activity of CD4<sup>+</sup>Foxp3<sup>+</sup> Treg cells (<xref rid="bib0640" ref-type="bibr">Hossain et al., 2020</xref>). Altered levels of cytokines and chemokines are associated with several aspects of ZIKV (<xref rid="bib0105" ref-type="bibr">Barros et al., 2018</xref>; <xref rid="bib1080" ref-type="bibr">Naveca et al., 2018</xref>; <xref rid="bib0730" ref-type="bibr">Khaiboullina et al., 2019</xref>; <xref rid="bib0915" ref-type="bibr">Lima et al., 2019</xref>), EBV (<xref rid="bib1160" ref-type="bibr">Piovan et al., 2005</xref>; <xref rid="bib0375" ref-type="bibr">Ehlin-Henriksson et al., 2009</xref>; <xref rid="bib0280" ref-type="bibr">Cohen et al., 2017</xref>), and rhinovirus infections (<xref rid="bib1195" ref-type="bibr">Rajan et al., 2014</xref>; <xref rid="bib1345" ref-type="bibr">Shelfoon et al., 2016</xref>; <xref rid="bib0620" ref-type="bibr">Hansel et al., 2017</xref>). However, the potential role of the chemokine receptor CCR5 in the pathogenesis of ZIKV, EBV, and rhinovirus represents open questions in the field of CCR5 research.</p></sec><sec id="sec0095"><label>7</label><title>CCR5 and coronaviruses: is there a connection?</title><p id="par0380">Coronaviruses are positive-sense RNA viruses that belong to the <italic>Coronaviridae</italic> family (<xref rid="bib0880" ref-type="bibr">Li et al., 2020</xref>). Coronaviruses infect a wide range of species, including humans. Until 2019, humans have faced two major outbreaks of high pathogenic coronaviruses, the severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak and the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak (<xref rid="bib0480" ref-type="bibr">Fung and Liu, 2019</xref>). In 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan (Hubei province, China) (<xref rid="bib1625" ref-type="bibr">Wu et al., 2020</xref>) and rapidly spread to more than 180 countries/regions (Interactive dashboard of global COVID-19 cases - Johns Hopkins University: <ext-link ext-link-type="uri" xlink:href="https://arcg.is/0fHmTX" id="intr0040">https://arcg.is/0fHmTX</ext-link>; <xref rid="bib0355" ref-type="bibr">Dong et al., 2020</xref>). Of note, SARS-CoV-2 infection causes the &#x0201c;coronavirus disease 2019&#x0201d; and therefore is also called &#x0201c;COVID-19&#x0201d;. Considering the ongoing SARS-CoV-2 pandemic and the clinical variability observed in the affected individuals, ranging from mild to severe respiratory disease (<xref rid="bib0235" ref-type="bibr">Chen et al., 2020</xref>; <xref rid="bib0660" ref-type="bibr">Huang et al., 2020b</xref>), the following question arose: does CCR5 have any clinically relevant influence on SARS-CoV-2 or other coronaviruses infections?</p><p id="par0385">Recent data indicated that SARS-CoV-2 binds to the ACE2 receptor (<xref rid="bib0070" ref-type="bibr">Andersen et al., 2020</xref>), using this receptor for entry into human cells. Therefore, it is unlikely that CCR5 or CCR5&#x00394;32 have some significant effect on the susceptibility or resistance to SARS-CoV-2 infection. However, CCR5 may have some impact on the clinical course of SARS-CoV-2 infection.</p><p id="par0390">The pattern and intensity of the human immune responses regulate the clinical progression and even the outcome of infections by coronaviruses (<xref rid="bib0880" ref-type="bibr">Li et al., 2020</xref>), including SARS-CoV-2 (<xref rid="bib1185" ref-type="bibr">Qin et al., 2020</xref>; <xref rid="bib1355" ref-type="bibr">Shi et al., 2020</xref>). SARS-CoV-infected mice showed increased expression of CCR5 mRNA in lungs along with the production of CCL2, CCL3 and CCL5 chemokines, the major CCR5 natural agonists (<xref rid="bib0220" ref-type="bibr">Chen et al., 2010</xref>). Intracranial infection of mice with Mouse Hepatitis Virus (MHV, a murine coronavirus) induces an increased CCR5 expression, which contributed to MHV-induced demyelination through CCR5-mediated macrophage recruitment to the CNS (<xref rid="bib0525" ref-type="bibr">Glass et al., 2001</xref>). Subsequent studies using MHV-infected mice showed that CCR5 participates in the regulation of CD4<sup>+</sup> and CD8<sup>+</sup> T cell activities against the virus in the CNS (<xref rid="bib0515" ref-type="bibr">Glass and Lane, 2003a</xref>, <xref rid="bib0520" ref-type="bibr">b</xref>). Also, SARS-CoV-infected human monocyte-derived dendritic cells showed increased CCR5 expression <italic>in vitro</italic> (<xref rid="bib0845" ref-type="bibr">Law et al., 2009</xref>).</p><p id="par0395">Taking together, the findings mentioned above suggest that CCR5 could have some influence on the clinical course of SARS-CoV-2 infection. However, future studies addressing humans are needed to clarify this suggestion. In this sense, we emphasize that so far, there is no evidence showing a clear involvement of CCR5 in SARS-CoV-2 human infection.</p></sec><sec id="sec0100"><label>8</label><title>Final considerations regarding the phenotypic effects of the CCR5</title><p id="par0400">The CCR5&#x00394;32 is a highly penetrating polymorphism, and exerts a robust phenotypic effect on CCR5. However, the expression of CCR5 is regulated by other polymorphisms in addition to CCR5&#x00394;32 (<xref rid="bib1010" ref-type="bibr">Mehlotra, 2019</xref>). Also, the CCR5 expression is influenced by non-coding genetic elements. The effect of the genetic backround of the host can also be exacerbated or diminished depending on the environmental conditions to which the individual is exposed (<xref rid="bib0415" ref-type="bibr">Ellwanger et al., 2018c</xref>; <xref rid="bib0805" ref-type="bibr">Kulkarni et al., 2019</xref>). Taking together, these factors help to explain why many of the effects exerted by CCR5 on a given disease are specific to a certain population, ethnic group, or individual.</p></sec><sec id="sec0105"><label>9</label><title>Conclusions</title><p id="par0405">Research involving CCR5 and HIV began in the mid-1990s. Since then, many achievements in the field of CCR5/HIV research have been made, such as the identification of CCR5&#x00394;32 as a strong protective factor against HIV infection and the development of CCR5 antagonists for the treatment of HIV infection. Currently, these drugs are being tested for the treatment of other inflammatory and infectious diseases. In this context, the use of CCR5 antagonists has raised some concerns, since the blockade of CCR5 can affect or even weaken the host defenses against certain infections, especially neuroinvasive infections by flaviviruses. However, to date, there is no strong evidence indicating that the use of CCR5 antagonists has increased the susceptibility of individuals to problematic flaviviruses infections.</p><p id="par0410">The frequency of CCR5&#x00394;32 is quite varied among human populations, and therefore the effects of the allele in a particular population may not apply to another population. Moreover, the effects of CCR5 and CCR5&#x00394;32 are disease-specific. For instance, the CCR5&#x00394;32 does not significantly affect susceptibility to WNV infection. However, the effect of the CCR5 and CCR5&#x00394;32 on WNV disease progression is very robust. Some animal-derived findings suggest the involvement of the CCR5 in the pathogenesis of DENV infection. However, the effects of CCR5 on DENV infection are very different between humans and rodents. Of note, CCR5&#x00394;32 does not significantly affect susceptibility to DENV infection or disease progression. Moreover, the effect of CCR5&#x00394;32 on HBV-related disease is population-specific. Interestingly, CMV release virokines, which are molecules that can manipulate the host immune response and affect the CCR5 function. The examples cited above highlight the varied impacts of CCR5 and CCR5&#x00394;32 on viral infections.</p><p id="par0415">The few studies involving CCHFV, EV, and Hantavirus infection have indicated important effects of CCR5&#x00394;32 on these conditions. Based on these findings, further studies should investigate the role of CCR5&#x00394;32 and CCR5 protein in such infections, considering populations with distinct genetic backgrounds. Some evidence suggested the participation of CCR5 in infections by ZIKV, EBV, and rhinovirus. Also, a mouse model of ROCV-associated encephalitis suggested an important role for CCR5 in host immune responses against the virus. However, the roles of CCR5 and CCR5&#x00394;32 in infections by ZIKV, EBV, rhinovirus, and ROCV are still poorly understood and need to be investigated in future studies. The role of EVs in the transport of CCR5 between cells indicates that the expression of CCR5 on the cell surface may also depend on the release of EVs containing CCR5. Also, the transport of host molecules and viruses through EVs adds complexity to the topics covered in this review and should be taken into account in future studies that investigate the role of CCR5 in viral infections. Gene editing technologies have the potential to be used to treat different diseases, mainly when applied to somatic cells. However, <italic>CCR5</italic> gene editing in human embryos presents a number of ethical problems. Besides, the absence of CCR5 can have deleterious effects in certain conditions, such as increased susceptibility to symptomatic WNV infection. Finally, this article showed that the participation of CCR5 in different viral infections is complex and varied and, therefore, cannot be generalized. This article also pointed out neglected gaps in knowledge involving CCR5 that should be addressed in future studies.</p></sec><sec id="sec00005"><title>CRediT authorship contribution statement</title><p id="par00005">
<bold>Joel Henrique Ellwanger:</bold> Conceptualization, Investigation, Writing - original draft, Writing - review &#x00026; editing, Visualization, Project administration. <bold>Bruna Kulmann-Leal:</bold> Investigation, Validation, Writing - review &#x00026; editing. <bold>Val&#x000e9;ria de Lima Kaminski:</bold> Investigation, Writing - review &#x00026; editing. <bold>Andressa Gon&#x000e7;alves Rodrigues:</bold> Investigation, Writing - review &#x00026; editing. <bold>Marcelo Alves de Souza Bragatte:</bold> Visualization, Writing - review &#x00026; editing. <bold>Jos&#x000e9; Artur Bogo Chies:</bold> Investigation, Resources, Writing - review &#x00026; editing, Supervision, Funding acquisition.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="par0420">The authors declare no conflicts of interest.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Abdolmohammadi</surname><given-names>R.</given-names></name><name><surname>Shahbazi Azar</surname><given-names>S.</given-names></name><name><surname>Khosravi</surname><given-names>A.</given-names></name><name><surname>Shahbazi</surname><given-names>M.</given-names></name></person-group><article-title>CCR5 polymorphism as a protective factor for hepatocellular carcinoma in hepatitis B virus-infected Iranian patients</article-title><source>Asian Pac. J. Cancer Prev.</source><volume>17</volume><year>2016</year><fpage>4643</fpage><lpage>4646</lpage><pub-id pub-id-type="doi">10.22034/apjcp.2016.17.10.4643</pub-id><pub-id pub-id-type="pmid">27892677</pub-id></element-citation></ref><ref id="bib0010"><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Achour</surname><given-names>L.</given-names></name><name><surname>Scott</surname><given-names>M.G.</given-names></name><name><surname>Shirvani</surname><given-names>H.</given-names></name><name><surname>Thuret</surname><given-names>A.</given-names></name><name><surname>Bismuth</surname><given-names>G.</given-names></name><name><surname>Labb&#x000e9;-Julli&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Marullo</surname><given-names>S.</given-names></name></person-group><article-title>CD4-CCR5 interaction in intracellular compartments contributes to receptor expression at the cell surface</article-title><source>Blood</source><volume>113</volume><year>2009</year><fpage>1938</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-02-141275</pub-id><pub-id pub-id-type="pmid">19064722</pub-id></element-citation></ref><ref id="bib0015"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Ahlenstiel</surname><given-names>G.</given-names></name><name><surname>Berg</surname><given-names>T.</given-names></name><name><surname>Woitas</surname><given-names>R.P.</given-names></name><name><surname>Gr&#x000fc;nhage</surname><given-names>F.</given-names></name><name><surname>Iwan</surname><given-names>A.</given-names></name><name><surname>Hess</surname><given-names>L.</given-names></name><name><surname>Brackmann</surname><given-names>H.H.</given-names></name><name><surname>Kupfer</surname><given-names>B.</given-names></name><name><surname>Schernick</surname><given-names>A.</given-names></name><name><surname>Sauerbruch</surname><given-names>T.</given-names></name><name><surname>Spengler</surname><given-names>U.</given-names></name></person-group><article-title>Effects of the CCR5-&#x00394;32 mutation on antiviral treatment in chronic hepatitis C</article-title><source>J. Hepatol.</source><volume>39</volume><year>2003</year><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/s0168-8278(03)00193-4</pub-id><pub-id pub-id-type="pmid">12873822</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Ahlenstiel</surname><given-names>G.</given-names></name><name><surname>Woitas</surname><given-names>R.P.</given-names></name><name><surname>Rockstroh</surname><given-names>J.</given-names></name><name><surname>Spengler</surname><given-names>U.</given-names></name></person-group><article-title>CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response?</article-title><source>J. Antimicrob. Chemother.</source><volume>53</volume><year>2004</year><fpage>895</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh239</pub-id><pub-id pub-id-type="pmid">15128728</pub-id></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Ahlenstiel</surname><given-names>G.</given-names></name><name><surname>Woitas</surname><given-names>R.P.</given-names></name><name><surname>Iwan</surname><given-names>A.</given-names></name><name><surname>Nattermann</surname><given-names>J.</given-names></name><name><surname>Feldmann</surname><given-names>G.</given-names></name><name><surname>Rockstroh</surname><given-names>J.K.</given-names></name><name><surname>Oldenburg</surname><given-names>J.</given-names></name><name><surname>Kupfer</surname><given-names>B.</given-names></name><name><surname>Sauerbruch</surname><given-names>T.</given-names></name><name><surname>Spengler</surname><given-names>U.</given-names></name></person-group><article-title>Effects of the CCR5- &#x00394;32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia</article-title><source>Immunol. Invest.</source><volume>38</volume><year>2009</year><fpage>284</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1080/08820130802307294</pub-id><pub-id pub-id-type="pmid">19811439</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Ahmadabadi</surname><given-names>B.N.</given-names></name><name><surname>Hassanshahi</surname><given-names>G.</given-names></name><name><surname>Khoramdelazad</surname><given-names>H.</given-names></name><name><surname>Mirzaei</surname><given-names>V.</given-names></name><name><surname>Sajadi</surname><given-names>S.M.A.</given-names></name><name><surname>Hajghani</surname><given-names>M.</given-names></name><name><surname>Khodadadi</surname><given-names>H.</given-names></name><name><surname>Pourali</surname><given-names>R.</given-names></name><name><surname>Arababadi</surname><given-names>M.K.</given-names></name><name><surname>Kennedy</surname><given-names>D.</given-names></name></person-group><article-title>Downregulation of CCR5 expression on the peripheral blood CD8<sup>+</sup> T cells of southeastern Iranian patients with chronic hepatitis B infection</article-title><source>Inflammation</source><volume>36</volume><year>2013</year><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1007/s10753-012-9528-4</pub-id><pub-id pub-id-type="pmid">22918850</pub-id></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>S.H.</given-names></name><name><surname>Kim</surname><given-names>D.Y.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name><name><surname>Hong</surname><given-names>S.P.</given-names></name><name><surname>Shin</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>D.Y.S.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>J.K.</given-names></name><name><surname>Paik</surname><given-names>Y.H.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name><name><surname>Chon</surname><given-names>C.Y.</given-names></name><name><surname>Moon</surname><given-names>Y.M.</given-names></name><name><surname>Han</surname><given-names>K.H.</given-names></name></person-group><article-title>Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea</article-title><source>J. Med. Virol.</source><volume>78</volume><year>2006</year><fpage>1564</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1002/jmv.20739</pub-id><pub-id pub-id-type="pmid">17063508</pub-id></element-citation></ref><ref id="bib0040"><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>A.</given-names></name><name><surname>Giannessi</surname><given-names>F.</given-names></name><name><surname>Percario</surname><given-names>Z.A.</given-names></name><name><surname>Affabris</surname><given-names>E.</given-names></name></person-group><article-title>An emerging interplay between extracellular vesicles and cytokines</article-title><source>Cytokine Growth Factor Rev.</source><volume>51</volume><year>2020</year><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2019.12.003</pub-id><pub-id pub-id-type="pmid">31874738</pub-id></element-citation></ref><ref id="bib0045"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Ajuebor</surname><given-names>M.N.</given-names></name><name><surname>Aspinall</surname><given-names>A.I.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Le</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Urbanski</surname><given-names>S.J.</given-names></name><name><surname>Sidobre</surname><given-names>S.</given-names></name><name><surname>Kronenberg</surname><given-names>M.</given-names></name><name><surname>Hogaboam</surname><given-names>C.M.</given-names></name><name><surname>Swain</surname><given-names>M.G.</given-names></name></person-group><article-title>Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells</article-title><source>J. Immunol.</source><volume>174</volume><year>2005</year><fpage>8027</fpage><lpage>8037</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.12.8027</pub-id><pub-id pub-id-type="pmid">15944310</pub-id></element-citation></ref><ref id="bib0050"><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Ajuebor</surname><given-names>M.N.</given-names></name><name><surname>Carey</surname><given-names>J.A.</given-names></name><name><surname>Swain</surname><given-names>M.G.</given-names></name></person-group><article-title>CCR5 in T cell-mediated liver diseases: what&#x02019;s going on?</article-title><source>J. Immunol.</source><volume>177</volume><year>2006</year><fpage>2039</fpage><lpage>2045</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.4.2039</pub-id><pub-id pub-id-type="pmid">16887960</pub-id></element-citation></ref><ref id="bib0055"><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Alkhatib</surname><given-names>G.</given-names></name></person-group><article-title>The biology of CCR5 and CXCR4</article-title><source>Curr. Opin. HIV AIDS</source><volume>4</volume><year>2009</year><fpage>96</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1097/COH.0b013e328324bbec</pub-id><pub-id pub-id-type="pmid">19339947</pub-id></element-citation></ref><ref id="bib0060"><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>A.G.</given-names></name><name><surname>Chung</surname><given-names>C.H.</given-names></name><name><surname>Atkins</surname><given-names>A.</given-names></name><name><surname>Dampier</surname><given-names>W.</given-names></name><name><surname>Khalili</surname><given-names>K.</given-names></name><name><surname>Nonnemacher</surname><given-names>M.R.</given-names></name><name><surname>Wigdahl</surname><given-names>B.</given-names></name></person-group><article-title>Gene editing of HIV-1 co-receptors to prevent and/or cure virus infection</article-title><source>Front. Microbiol.</source><volume>9</volume><year>2018</year><fpage>2940</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02940</pub-id><pub-id pub-id-type="pmid">30619107</pub-id></element-citation></ref><ref id="bib0065"><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>N.B.</given-names></name><name><surname>Larsen</surname><given-names>S.M.</given-names></name><name><surname>Nissen</surname><given-names>S.K.</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>S.E.</given-names></name><name><surname>Mardahl</surname><given-names>M.</given-names></name><name><surname>Christiansen</surname><given-names>M.</given-names></name><name><surname>Kay</surname><given-names>L.</given-names></name><name><surname>Mogensen</surname><given-names>T.H.</given-names></name></person-group><article-title>Host genetics, innate immune responses, and cellular death pathways in poliomyelitis patients</article-title><source>Front. Microbiol.</source><volume>10</volume><year>2019</year><fpage>1495</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.01495</pub-id><pub-id pub-id-type="pmid">31354645</pub-id></element-citation></ref><ref id="bib0070"><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>K.G.</given-names></name><name><surname>Rambaut</surname><given-names>A.</given-names></name><name><surname>Lipkin</surname><given-names>W.I.</given-names></name><name><surname>Holmes</surname><given-names>E.C.</given-names></name><name><surname>Garry</surname><given-names>R.F.</given-names></name></person-group><article-title>The proximal origin of SARS-CoV-2</article-title><source>Nat. Med.</source><volume>26</volume><year>2020</year><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmid">32284615</pub-id></element-citation></ref><ref id="bib0075"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Arababadi</surname><given-names>M.K.</given-names></name><name><surname>Pourfathollah</surname><given-names>A.A.</given-names></name><name><surname>Jafarzadeh</surname><given-names>A.</given-names></name><name><surname>Hassanshahi</surname><given-names>G.</given-names></name><name><surname>Mohit</surname><given-names>M.</given-names></name><name><surname>Hajghani</surname><given-names>M.</given-names></name><name><surname>Shamsizadeh</surname><given-names>A.</given-names></name></person-group><article-title>Peripheral blood CD8<sup>+</sup> T cells CCR5 expression and its &#x00394;32 mutation in Iranian patients with occult hepatitis B infections</article-title><source>Lab. Med.</source><volume>41</volume><year>2010</year><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1309/LMVUKWROX0EBQR01</pub-id></element-citation></ref><ref id="bib0080"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Arasli</surname><given-names>M.</given-names></name><name><surname>Ozsurekci</surname><given-names>Y.</given-names></name><name><surname>Elaldi</surname><given-names>N.</given-names></name><name><surname>McAuley</surname><given-names>A.J.</given-names></name><name><surname>Karadag Oncel</surname><given-names>E.</given-names></name><name><surname>Tekin</surname><given-names>I.O.</given-names></name><name><surname>Gozel</surname><given-names>M.G.</given-names></name><name><surname>Kaya</surname><given-names>A.</given-names></name><name><surname>Icagasioglu</surname><given-names>F.D.</given-names></name><name><surname>Caglayik</surname><given-names>D.Y.</given-names></name><name><surname>Korukluoglu</surname><given-names>G.</given-names></name><name><surname>Kokturk</surname><given-names>F.</given-names></name><name><surname>Bakir</surname><given-names>M.</given-names></name><name><surname>Bente</surname><given-names>D.A.</given-names></name><name><surname>Ceyhan</surname><given-names>M.</given-names></name></person-group><article-title>Elevated chemokine levels during adult but not pediatric Crimean-Congo hemorrhagic fever</article-title><source>J. Clin. Virol.</source><volume>66</volume><year>2015</year><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2015.03.010</pub-id><pub-id pub-id-type="pmid">25866343</pub-id></element-citation></ref><ref id="bib0085"><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Badolato-Corr&#x000ea;a</surname><given-names>J.</given-names></name><name><surname>S&#x000e1;nchez-Arcila</surname><given-names>J.C.</given-names></name><name><surname>Alves de Souza</surname><given-names>T.M.</given-names></name><name><surname>Santos Barbosa</surname><given-names>L.</given-names></name><name><surname>Conrado Guerra Nunes</surname><given-names>P.</given-names></name><name><surname>da Rocha Queiroz Lima</surname><given-names>M.</given-names></name><name><surname>Gandini</surname><given-names>M.</given-names></name><name><surname>de Filippis AM</surname><given-names>Bispo</given-names></name><name><surname>Ven&#x000e2;ncio da Cunha</surname><given-names>R.</given-names></name><name><surname>Leal de Azeredo</surname><given-names>E.</given-names></name><name><surname>de-Oliveira-Pinto</surname><given-names>L.M.</given-names></name></person-group><article-title>Human T cell responses to Dengue and Zika virus infection compared to Dengue/Zika coinfection</article-title><source>Immun. Inflamm. Dis.</source><volume>6</volume><year>2018</year><fpage>194</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1002/iid3.203</pub-id><pub-id pub-id-type="pmid">29282904</pub-id></element-citation></ref><ref id="bib0090"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Badorff</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>G.H.</given-names></name><name><surname>Knowlton</surname><given-names>K.U.</given-names></name></person-group><article-title>Enteroviral cardiomyopathy: bad news for the dystrophin-glycoprotein complex</article-title><source>Herz</source><volume>25</volume><year>2000</year><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1007/s000590050011</pub-id><pub-id pub-id-type="pmid">10904843</pub-id></element-citation></ref><ref id="bib0095"><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Balistreri</surname><given-names>C.R.</given-names></name><name><surname>Carruba</surname><given-names>G.</given-names></name><name><surname>Calabr&#x000f2;</surname><given-names>M.</given-names></name><name><surname>Campisi</surname><given-names>I.</given-names></name><name><surname>Di Carlo</surname><given-names>D.</given-names></name><name><surname>Lio</surname><given-names>D.</given-names></name><name><surname>Colonna-Romano</surname><given-names>G.</given-names></name><name><surname>Candore</surname><given-names>G.</given-names></name><name><surname>Caruso</surname><given-names>C.</given-names></name></person-group><article-title>CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily</article-title><source>Ann. N. Y. Acad. Sci.</source><volume>1155</volume><year>2009</year><fpage>289</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2008.03691.x</pub-id><pub-id pub-id-type="pmid">19250219</pub-id></element-citation></ref><ref id="bib0100"><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Bardina</surname><given-names>S.V.</given-names></name><name><surname>Lim</surname><given-names>J.K.</given-names></name></person-group><article-title>The role of chemokines in the pathogenesis of neurotropic flaviviruses</article-title><source>Immunol. Res.</source><volume>54</volume><year>2012</year><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/s12026-012-8333-3</pub-id><pub-id pub-id-type="pmid">22547394</pub-id></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Barros</surname><given-names>J.B.S.</given-names></name><name><surname>da Silva</surname><given-names>P.A.N.</given-names></name><name><surname>Koga</surname><given-names>R.C.R.</given-names></name><name><surname>Gonzalez-Dias</surname><given-names>P.</given-names></name><name><surname>Carmo Filho</surname><given-names>J.R.</given-names></name><name><surname>Nagib</surname><given-names>P.R.A.</given-names></name><name><surname>Coelho</surname><given-names>V.</given-names></name><name><surname>Nakaya</surname><given-names>H.I.</given-names></name><name><surname>Fonseca</surname><given-names>S.G.</given-names></name><name><surname>Pfrimer</surname><given-names>I.A.H.</given-names></name></person-group><article-title>Acute Zika virus infection in an endemic area shows modest proinflammatory systemic immunoactivation and cytokine-symptom associations</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>821</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00821</pub-id><pub-id pub-id-type="pmid">29774022</pub-id></element-citation></ref><ref id="bib0110"><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Baud</surname><given-names>D.</given-names></name><name><surname>Gubler</surname><given-names>D.J.</given-names></name><name><surname>Schaub</surname><given-names>B.</given-names></name><name><surname>Lanteri</surname><given-names>M.C.</given-names></name><name><surname>Musso</surname><given-names>D.</given-names></name></person-group><article-title>An update on Zika virus infection</article-title><source>Lancet</source><volume>390</volume><year>2017</year><fpage>2099</fpage><lpage>2109</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31450-2</pub-id><pub-id pub-id-type="pmid">28647173</pub-id></element-citation></ref><ref id="bib0115"><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Bente</surname><given-names>D.A.</given-names></name><name><surname>Forrester</surname><given-names>N.L.</given-names></name><name><surname>Watts</surname><given-names>D.M.</given-names></name><name><surname>McAuley</surname><given-names>A.J.</given-names></name><name><surname>Whitehouse</surname><given-names>C.A.</given-names></name><name><surname>Bray</surname><given-names>M.</given-names></name></person-group><article-title>Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity</article-title><source>Antiviral Res.</source><volume>100</volume><year>2013</year><fpage>159</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.07.006</pub-id><pub-id pub-id-type="pmid">23906741</pub-id></element-citation></ref><ref id="bib0120"><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>S.</given-names></name><name><surname>Gething</surname><given-names>P.W.</given-names></name><name><surname>Brady</surname><given-names>O.J.</given-names></name><name><surname>Messina</surname><given-names>J.P.</given-names></name><name><surname>Farlow</surname><given-names>A.W.</given-names></name><name><surname>Moyes</surname><given-names>C.L.</given-names></name><name><surname>Drake</surname><given-names>J.M.</given-names></name><name><surname>Brownstein</surname><given-names>J.S.</given-names></name><name><surname>Hoen</surname><given-names>A.G.</given-names></name><name><surname>Sankoh</surname><given-names>O.</given-names></name><name><surname>Myers</surname><given-names>M.F.</given-names></name><name><surname>George</surname><given-names>D.B.</given-names></name><name><surname>Jaenisch</surname><given-names>T.</given-names></name><name><surname>Wint</surname><given-names>G.R.W.</given-names></name><name><surname>Simmons</surname><given-names>C.P.</given-names></name><name><surname>Scott</surname><given-names>T.W.</given-names></name><name><surname>Farrar</surname><given-names>J.J.</given-names></name><name><surname>Hay</surname><given-names>S.I.</given-names></name></person-group><article-title>The global distribution and burden of dengue</article-title><source>Nature</source><volume>496</volume><year>2013</year><fpage>504</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/nature12060</pub-id><pub-id pub-id-type="pmid">23563266</pub-id></element-citation></ref><ref id="bib0125"><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Bigham</surname><given-names>A.W.</given-names></name><name><surname>Buckingham</surname><given-names>K.J.</given-names></name><name><surname>Husain</surname><given-names>S.</given-names></name><name><surname>Emond</surname><given-names>M.J.</given-names></name><name><surname>Bofferding</surname><given-names>K.M.</given-names></name><name><surname>Gildersleeve</surname><given-names>H.</given-names></name><name><surname>Rutherford</surname><given-names>A.</given-names></name><name><surname>Astakhova</surname><given-names>N.M.</given-names></name><name><surname>Perelygin</surname><given-names>A.A.</given-names></name><name><surname>Busch</surname><given-names>M.P.</given-names></name><name><surname>Murray</surname><given-names>K.O.</given-names></name><name><surname>Sejvar</surname><given-names>J.J.</given-names></name><name><surname>Green</surname><given-names>S.</given-names></name><name><surname>Kriesel</surname><given-names>J.</given-names></name><name><surname>Brinton</surname><given-names>M.A.</given-names></name><name><surname>Bamshad</surname><given-names>M.</given-names></name></person-group><article-title>Host genetic risk factors for West Nile virus infection and disease progression</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><object-id pub-id-type="publisher-id">e24745</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024745</pub-id></element-citation></ref><ref id="bib0130"><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Bineshian</surname><given-names>F.</given-names></name><name><surname>Hosseini</surname><given-names>A.</given-names></name><name><surname>Sharifi</surname><given-names>Z.</given-names></name><name><surname>Aghaie</surname><given-names>A.</given-names></name></person-group><article-title>A Study on the association between <italic>CCR&#x00394;32</italic> mutation and HCV Infection in Iranian patients</article-title><source>Avicenna J. Med. Biotechnol.</source><volume>10</volume><year>2018</year><fpage>261</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">30555661</pub-id></element-citation></ref><ref id="bib0135"><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Blackard</surname><given-names>J.T.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Rouster</surname><given-names>S.D.</given-names></name><name><surname>Karns</surname><given-names>R.</given-names></name><name><surname>Horn</surname><given-names>P.S.</given-names></name><name><surname>Kottilil</surname><given-names>S.</given-names></name><name><surname>Shata</surname><given-names>M.T.</given-names></name><name><surname>Sherman</surname><given-names>K.E.</given-names></name></person-group><article-title>CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication <italic>in vitro</italic></article-title><source>PLoS One</source><volume>14</volume><year>2019</year><object-id pub-id-type="publisher-id">e0224523</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0224523</pub-id></element-citation></ref><ref id="bib0140"><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Blanpain</surname><given-names>C.</given-names></name><name><surname>Migeotte</surname><given-names>I.</given-names></name><name><surname>Lee</surname><given-names>B.</given-names></name><name><surname>Vakili</surname><given-names>J.</given-names></name><name><surname>Doranz</surname><given-names>B.J.</given-names></name><name><surname>Govaerts</surname><given-names>C.</given-names></name><name><surname>Vassart</surname><given-names>G.</given-names></name><name><surname>Doms</surname><given-names>R.W.</given-names></name><name><surname>Parmentier</surname><given-names>M.</given-names></name></person-group><article-title>CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist</article-title><source>Blood</source><volume>94</volume><year>1999</year><fpage>1899</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1182/blood.V94.6.1899</pub-id><pub-id pub-id-type="pmid">10477718</pub-id></element-citation></ref><ref id="bib0145"><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Blanpain</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>B.</given-names></name><name><surname>Tackoen</surname><given-names>M.</given-names></name><name><surname>Puffer</surname><given-names>B.</given-names></name><name><surname>Boom</surname><given-names>A.</given-names></name><name><surname>Libert</surname><given-names>F.</given-names></name><name><surname>Sharron</surname><given-names>M.</given-names></name><name><surname>Wittamer</surname><given-names>V.</given-names></name><name><surname>Vassart</surname><given-names>G.</given-names></name><name><surname>Doms</surname><given-names>R.W.</given-names></name><name><surname>Parmentier</surname><given-names>M.</given-names></name></person-group><article-title>Multiple nonfunctional alleles of CCR5 are frequent in various human populations</article-title><source>Blood</source><volume>96</volume><year>2000</year><fpage>1638</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1182/blood.V96.5.1638.h8001638_1638_1645</pub-id><pub-id pub-id-type="pmid">10961858</pub-id></element-citation></ref><ref id="bib0150"><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Boldt</surname><given-names>A.B.W.</given-names></name><name><surname>Culpi</surname><given-names>L.</given-names></name><name><surname>Tsuneto</surname><given-names>L.T.</given-names></name><name><surname>Souza</surname><given-names>I.R.</given-names></name><name><surname>Kun</surname><given-names>J.F.J.</given-names></name><name><surname>Petzl-Erler</surname><given-names>L.M.</given-names></name></person-group><article-title>Analysis of the <italic>CCR5</italic> gene coding region diversity in five South American populations reveals two new non-synonymous alleles in Amerindians and high <italic>CCR5*D32</italic> frequency in Euro-Brazilians</article-title><source>Genet. Mol. Biol.</source><volume>32</volume><year>2009</year><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1590/S1415-47572009005000011</pub-id><pub-id pub-id-type="pmid">21637640</pub-id></element-citation></ref><ref id="bib0155"><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Boncompain</surname><given-names>G.</given-names></name><name><surname>Herit</surname><given-names>F.</given-names></name><name><surname>Tessier</surname><given-names>S.</given-names></name><name><surname>Lescure</surname><given-names>A.</given-names></name><name><surname>Del Nery</surname><given-names>E.</given-names></name><name><surname>Gestraud</surname><given-names>P.</given-names></name><name><surname>Staropoli</surname><given-names>I.</given-names></name><name><surname>Fukata</surname><given-names>Y.</given-names></name><name><surname>Fukata</surname><given-names>M.</given-names></name><name><surname>Brelot</surname><given-names>A.</given-names></name><name><surname>Niedergang</surname><given-names>F.</given-names></name><name><surname>Perez</surname><given-names>F.</given-names></name></person-group><article-title>Targeting CCR5 trafficking to inhibit HIV-1 infection</article-title><source>Sci. Adv.</source><volume>5</volume><year>2019</year><object-id pub-id-type="publisher-id">eaax0821</object-id><pub-id pub-id-type="doi">10.1126/sciadv.aax0821</pub-id></element-citation></ref><ref id="bib0160"><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Braunersreuther</surname><given-names>V.</given-names></name><name><surname>Zernecke</surname><given-names>A.</given-names></name><name><surname>Arnaud</surname><given-names>C.</given-names></name><name><surname>Liehn</surname><given-names>E.A.</given-names></name><name><surname>Steffens</surname><given-names>S.</given-names></name><name><surname>Shagdarsuren</surname><given-names>E.</given-names></name><name><surname>Bidzhekov</surname><given-names>K.</given-names></name><name><surname>Burger</surname><given-names>F.</given-names></name><name><surname>Pelli</surname><given-names>G.</given-names></name><name><surname>Luckow</surname><given-names>B.</given-names></name><name><surname>Mach</surname><given-names>F.</given-names></name><name><surname>Weber</surname><given-names>C.</given-names></name></person-group><article-title>Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><volume>27</volume><year>2007</year><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000253886.44609.ae</pub-id><pub-id pub-id-type="pmid">17138939</pub-id></element-citation></ref><ref id="bib0165"><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Bravo</surname><given-names>D.</given-names></name><name><surname>Clari</surname><given-names>M.A.</given-names></name><name><surname>Aguilar</surname><given-names>G.</given-names></name><name><surname>Belda</surname><given-names>J.</given-names></name><name><surname>Gim&#x000e9;nez</surname><given-names>E.</given-names></name><name><surname>Carbonell</surname><given-names>J.A.</given-names></name><name><surname>Henao</surname><given-names>L.</given-names></name><name><surname>Navarro</surname><given-names>D.</given-names></name></person-group><article-title>Looking for biological factors to predict the risk of active cytomegalovirus infection in non-immunosuppressed critically ill patients</article-title><source>J. Med. Virol.</source><volume>86</volume><year>2014</year><fpage>827</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1002/jmv.23838</pub-id><pub-id pub-id-type="pmid">24431153</pub-id></element-citation></ref><ref id="bib0170"><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Brelot</surname><given-names>A.</given-names></name><name><surname>Chakrabarti</surname><given-names>L.A.</given-names></name></person-group><article-title>CCR5 revisited: how mechanisms of HIV entry govern AIDS pathogenesis</article-title><source>J. Mol. Biol.</source><volume>430</volume><year>2018</year><fpage>2557</fpage><lpage>2589</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2018.06.027</pub-id><pub-id pub-id-type="pmid">29932942</pub-id></element-citation></ref><ref id="bib0175"><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Brestovac</surname><given-names>B.</given-names></name><name><surname>Halicki</surname><given-names>L.A.</given-names></name><name><surname>Harris</surname><given-names>R.P.</given-names></name><name><surname>Sampson</surname><given-names>I.</given-names></name><name><surname>Speers</surname><given-names>D.J.</given-names></name><name><surname>Mamotte</surname><given-names>C.</given-names></name><name><surname>Williams</surname><given-names>D.</given-names></name></person-group><article-title>Primary acute dengue and the deletion in chemokine receptor 5 (CCR5&#x00394;32)</article-title><source>Microbes Infect.</source><volume>16</volume><year>2014</year><fpage>518</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2014.02.007</pub-id><pub-id pub-id-type="pmid">24607451</pub-id></element-citation></ref><ref id="bib0180"><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Bukong</surname><given-names>T.N.</given-names></name><name><surname>Momen-Heravi</surname><given-names>F.</given-names></name><name><surname>Kodys</surname><given-names>K.</given-names></name><name><surname>Bala</surname><given-names>S.</given-names></name><name><surname>Szabo</surname><given-names>G.</given-names></name></person-group><article-title>Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90</article-title><source>PLoS Pathog.</source><volume>10</volume><year>2014</year><object-id pub-id-type="publisher-id">e1004424</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004424</pub-id></element-citation></ref><ref id="bib0185"><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Cahill</surname><given-names>M.E.</given-names></name><name><surname>Conley</surname><given-names>S.</given-names></name><name><surname>DeWan</surname><given-names>A.T.</given-names></name><name><surname>Montgomery</surname><given-names>R.R.</given-names></name></person-group><article-title>Identification of genetic variants associated with dengue or West Nile virus disease: a systematic review and meta-analysis</article-title><source>BMC Infect. Dis.</source><volume>18</volume><year>2018</year><fpage>282</fpage><pub-id pub-id-type="doi">10.1186/s12879-018-3186-6</pub-id><pub-id pub-id-type="pmid">29929468</pub-id></element-citation></ref><ref id="bib0190"><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>D.J.</given-names></name></person-group><article-title>Control of regulatory T cell migration, function, and homeostasis</article-title><source>J. Immunol.</source><volume>195</volume><year>2015</year><fpage>2507</fpage><lpage>2513</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500801</pub-id><pub-id pub-id-type="pmid">26342103</pub-id></element-citation></ref><ref id="bib0195"><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Carlin</surname><given-names>L.E.</given-names></name><name><surname>Hemann</surname><given-names>E.A.</given-names></name><name><surname>Zacharias</surname><given-names>Z.R.</given-names></name><name><surname>Heusel</surname><given-names>J.W.</given-names></name><name><surname>Legge</surname><given-names>K.L.</given-names></name></person-group><article-title>Natural killer cell recruitment to the lung during Influenza A virus infection is dependent on CXCR3, CCR5, and virus exposure dose</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>781</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00781</pub-id><pub-id pub-id-type="pmid">29719539</pub-id></element-citation></ref><ref id="bib0200"><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Casseb</surname><given-names>A.R.</given-names></name><name><surname>Cruz</surname><given-names>A.V.</given-names></name><name><surname>Jesus</surname><given-names>I.S.</given-names></name><name><surname>Chiang</surname><given-names>J.O.</given-names></name><name><surname>Martins</surname><given-names>L.C.</given-names></name><name><surname>Silva</surname><given-names>S.P.</given-names></name><name><surname>Henriques</surname><given-names>D.F.</given-names></name><name><surname>Casseb</surname><given-names>L.M.N.</given-names></name><name><surname>Vasconcelos</surname><given-names>P.F.C.</given-names></name></person-group><article-title>Seroprevalence of flaviviruses antibodies in water buffaloes (<italic>Bubalus bubalis</italic>) in Brazilian Amazon</article-title><source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source><volume>20</volume><year>2014</year><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/1678-9199-20-9</pub-id><pub-id pub-id-type="pmid">24666635</pub-id></element-citation></ref><ref id="bib0205"><element-citation publication-type="book" id="sbref0205"><person-group person-group-type="author"><name><surname>CDC - Centers for Disease Control and Prevention</surname></name><name><surname>National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)</surname></name><name><surname>Division of Vector-Borne Diseases (DVBD)</surname></name></person-group><chapter-title>West Nile virus. Transmission</chapter-title><comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/westnile/transmission/index.html" id="intr0045">https://www.cdc.gov/westnile/transmission/index.html</ext-link> Acessed on: January 27, 2020</comment><year>2018</year></element-citation></ref><ref id="bib0210"><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Ch&#x000e1;vez</surname><given-names>J.H.</given-names></name><name><surname>Fran&#x000e7;a</surname><given-names>R.F.O.</given-names></name><name><surname>Oliveira</surname><given-names>C.J.F.</given-names></name><name><surname>de Aquino</surname><given-names>M.T.P.</given-names></name><name><surname>Farias</surname><given-names>K.J.S.</given-names></name><name><surname>Machado</surname><given-names>P.R.L.</given-names></name><name><surname>de Oliveira</surname><given-names>T.F.M.</given-names></name><name><surname>Yokosawa</surname><given-names>J.</given-names></name><name><surname>Soares</surname><given-names>E.G.</given-names></name><name><surname>da Silva</surname><given-names>J.S.</given-names></name><name><surname>da Fonseca</surname><given-names>B.A.L.</given-names></name><name><surname>Figueiredo</surname><given-names>L.T.M.</given-names></name></person-group><article-title>Influence of the CCR-5/MIP-1 &#x003b1; axis in the pathogenesis of Rocio virus encephalitis in a mouse model</article-title><source>Am. J. Trop. Med. Hyg.</source><volume>89</volume><year>2013</year><fpage>1013</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.12-0591</pub-id><pub-id pub-id-type="pmid">24080631</pub-id></element-citation></ref><ref id="bib0215"><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Che</surname><given-names>L.F.</given-names></name><name><surname>Shao</surname><given-names>S.F.</given-names></name><name><surname>Wang</surname><given-names>L.X.</given-names></name></person-group><article-title>Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107</article-title><source>Exp. Ther. Med.</source><volume>11</volume><year>2016</year><fpage>503</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.3892/etm.2015.2911</pub-id><pub-id pub-id-type="pmid">26893637</pub-id></element-citation></ref><ref id="bib0220"><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Lau</surname><given-names>Y.F.</given-names></name><name><surname>Lamirande</surname><given-names>E.W.</given-names></name><name><surname>Paddock</surname><given-names>C.D.</given-names></name><name><surname>Bartlett</surname><given-names>J.H.</given-names></name><name><surname>Zaki</surname><given-names>S.R.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4<sup>+</sup> T cells are important in control of SARS-CoV infection</article-title><source>J. Virol.</source><volume>84</volume><year>2010</year><fpage>1289</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.1128/JVI.01281-09</pub-id><pub-id pub-id-type="pmid">19906920</pub-id></element-citation></ref><ref id="bib0225"><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name></person-group><article-title>Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine</article-title><source>J. Immunol.</source><volume>186</volume><year>2011</year><fpage>2219</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002991</pub-id><pub-id pub-id-type="pmid">21242526</pub-id></element-citation></ref><ref id="bib0230"><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>A.</given-names></name><name><surname>Ni</surname><given-names>K.</given-names></name><name><surname>Xiang</surname><given-names>Z.</given-names></name><name><surname>Wen</surname><given-names>K.</given-names></name><name><surname>Tu</surname><given-names>W.</given-names></name></person-group><article-title>Influenza virus infection exacerbates experimental autoimmune encephalomyelitis disease by promoting type I T cells infiltration into central nervous system</article-title><source>J. Autoimmun.</source><volume>77</volume><year>2017</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2016.10.006</pub-id><pub-id pub-id-type="pmid">28341037</pub-id></element-citation></ref><ref id="bib0235"><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="bib0240"><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Chiantore</surname><given-names>M.V.</given-names></name><name><surname>Mangino</surname><given-names>G.</given-names></name><name><surname>Iuliano</surname><given-names>M.</given-names></name><name><surname>Capriotti</surname><given-names>L.</given-names></name><name><surname>Di Bonito</surname><given-names>P.</given-names></name><name><surname>Fiorucci</surname><given-names>G.</given-names></name><name><surname>Romeo</surname><given-names>G.</given-names></name></person-group><article-title>Human Papillomavirus and carcinogenesis: novel mechanisms of cell communication involving extracellular vesicles</article-title><source>Cytokine Growth Factor Rev.</source><volume>51</volume><year>2020</year><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2019.12.009</pub-id><pub-id pub-id-type="pmid">31973992</pub-id></element-citation></ref><ref id="bib0245"><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Chies</surname><given-names>J.A.B.</given-names></name><name><surname>Nardi</surname><given-names>N.B.</given-names></name></person-group><article-title>Sickle cell disease: a chronic inflammatory condition</article-title><source>Med. Hypotheses</source><volume>57</volume><year>2001</year><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1054/mehy.2000.1310</pub-id><pub-id pub-id-type="pmid">11421623</pub-id></element-citation></ref><ref id="bib0250"><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name><surname>Choo</surname><given-names>Q.L.</given-names></name><name><surname>Kuo</surname><given-names>G.</given-names></name><name><surname>Weiner</surname><given-names>A.J.</given-names></name><name><surname>Overby</surname><given-names>L.R.</given-names></name><name><surname>Bradley</surname><given-names>D.W.</given-names></name><name><surname>Houghton</surname><given-names>M.</given-names></name></person-group><article-title>Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</article-title><source>Science</source><volume>244</volume><year>1989</year><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1126/science.2523562</pub-id><pub-id pub-id-type="pmid">2523562</pub-id></element-citation></ref><ref id="bib0255"><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>P.</given-names></name><name><surname>Khan</surname><given-names>S.A.</given-names></name></person-group><article-title>Differential expression levels of inflammatory chemokines and <italic>TLR</italic>s in patients suffering from mild and severe Japanese encephalitis</article-title><source>Viral Immunol.</source><volume>32</volume><year>2019</year><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1089/vim.2018.0103</pub-id><pub-id pub-id-type="pmid">30585774</pub-id></element-citation></ref><ref id="bib0260"><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name><surname>Christmann</surname><given-names>B.S.</given-names></name><name><surname>Moran</surname><given-names>J.M.</given-names></name><name><surname>McGraw</surname><given-names>J.A.</given-names></name><name><surname>Buller</surname><given-names>R.M.</given-names></name><name><surname>Corbett</surname><given-names>J.A.</given-names></name></person-group><article-title>Ccr5 regulates inflammatory gene expression in response to encephalomyocarditis virus infection</article-title><source>Am. J. Pathol.</source><volume>179</volume><year>2011</year><fpage>2941</fpage><lpage>2951</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.08.012</pub-id><pub-id pub-id-type="pmid">22001348</pub-id></element-citation></ref><ref id="bib0265"><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Ciota</surname><given-names>A.T.</given-names></name></person-group><article-title>West Nile virus and its vectors</article-title><source>Curr. Opin. Insect Sci.</source><volume>28-36</volume><year>2017</year><pub-id pub-id-type="doi">10.1016/j.cois.2017.05.002</pub-id></element-citation></ref><ref id="bib0270"><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Coenen</surname><given-names>M.</given-names></name><name><surname>Nattermann</surname><given-names>J.</given-names></name></person-group><article-title>The role of CCR5 in HCV infection</article-title><source>Eur. J. Med. Res.</source><volume>15</volume><year>2010</year><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1186/2047-783x-15-3-97</pub-id><pub-id pub-id-type="pmid">20452893</pub-id></element-citation></ref><ref id="bib0275"><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J.</given-names></name></person-group><article-title>The untold story of the &#x02018;circle of trust&#x02019; behind the world&#x02019;s first gene-edited babies</article-title><source>Science.</source><year>2019</year><pub-id pub-id-type="doi">10.1126/science.aay9400</pub-id></element-citation></ref><ref id="bib0280"><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>M.</given-names></name><name><surname>Vistarop</surname><given-names>A.G.</given-names></name><name><surname>Huaman</surname><given-names>F.</given-names></name><name><surname>Narbaitz</surname><given-names>M.</given-names></name><name><surname>Metrebian</surname><given-names>F.</given-names></name><name><surname>De Matteo</surname><given-names>E.</given-names></name><name><surname>Preciado</surname><given-names>M.V.</given-names></name><name><surname>Chabay</surname><given-names>P.A.</given-names></name></person-group><article-title>Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><fpage>10813</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-11052-z</pub-id><pub-id pub-id-type="pmid">28883511</pub-id></element-citation></ref><ref id="bib0285"><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>M.</given-names></name><name><surname>Raposo</surname><given-names>G.</given-names></name><name><surname>Th&#x000e9;ry</surname><given-names>C.</given-names></name></person-group><article-title>Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles</article-title><source>Annu. Rev. Cell Dev. Biol.</source><volume>30</volume><year>2014</year><fpage>255</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-101512-122326</pub-id><pub-id pub-id-type="pmid">25288114</pub-id></element-citation></ref><ref id="bib0290"><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>L.T.Jr.</given-names></name></person-group><source>Myocarditis. N Engl J Med</source><volume>360</volume><year>2009</year><fpage>1526</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0800028</pub-id><pub-id pub-id-type="pmid">19357408</pub-id></element-citation></ref><ref id="bib0295"><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name><surname>Corrales</surname><given-names>I.</given-names></name><name><surname>Gim&#x000e9;nez</surname><given-names>E.</given-names></name><name><surname>Solano</surname><given-names>C.</given-names></name><name><surname>Amat</surname><given-names>P.</given-names></name><name><surname>de la C&#x000e1;mara</surname><given-names>R.</given-names></name><name><surname>Nieto</surname><given-names>J.</given-names></name><name><surname>Garcia-Noblejas</surname><given-names>A.</given-names></name><name><surname>Navarro</surname><given-names>D.</given-names></name></person-group><article-title>Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes</article-title><source>J. Med. Virol.</source><volume>87</volume><year>2015</year><fpage>248</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1002/jmv.24050</pub-id><pub-id pub-id-type="pmid">25132583</pub-id></element-citation></ref><ref id="bib0300"><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name><surname>Crough</surname><given-names>T.</given-names></name><name><surname>Khanna</surname><given-names>R.</given-names></name></person-group><article-title>Immunobiology of human cytomegalovirus: from bench to bedside</article-title><source>Clin. Microbiol. Rev.</source><volume>22</volume><year>2009</year><fpage>76</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1128/CMR.00034-08</pub-id><pub-id pub-id-type="pmid">19136435</pub-id></element-citation></ref><ref id="bib0305"><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D.</given-names></name></person-group><article-title>What CRISPR-baby prison sentences mean for research</article-title><source>Nature</source><volume>577</volume><year>2020</year><fpage>154</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-00001-y</pub-id><pub-id pub-id-type="pmid">31911693</pub-id></element-citation></ref><ref id="bib0310"><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name><surname>Daley</surname><given-names>G.Q.</given-names></name><name><surname>Lovell-Badge</surname><given-names>R.</given-names></name><name><surname>Steffann</surname><given-names>J.</given-names></name></person-group><article-title>After the storm - A responsible path for genome editing</article-title><source>N. Engl. J. Med.</source><volume>380</volume><year>2019</year><fpage>897</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1900504</pub-id><pub-id pub-id-type="pmid">30649993</pub-id></element-citation></ref><ref id="bib0315"><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name><surname>Danial-Farran</surname><given-names>N.</given-names></name><name><surname>Eghbaria</surname><given-names>S.</given-names></name><name><surname>Schwartz</surname><given-names>N.</given-names></name><name><surname>Kra-Oz</surname><given-names>Z.</given-names></name><name><surname>Bisharat</surname><given-names>N.</given-names></name></person-group><article-title>Genetic variants associated with susceptibility of Ashkenazi Jews to West Nile virus infection</article-title><source>Epidemiol. Infect.</source><volume>143</volume><year>2015</year><fpage>857</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1017/S0950268814001290</pub-id><pub-id pub-id-type="pmid">24865988</pub-id></element-citation></ref><ref id="bib0320"><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>A.S.W.</given-names></name><name><surname>Roozen</surname><given-names>H.N.</given-names></name><name><surname>Dufort</surname><given-names>M.J.</given-names></name><name><surname>DeBerg</surname><given-names>H.A.</given-names></name><name><surname>Delaney</surname><given-names>M.A.</given-names></name><name><surname>Mair</surname><given-names>F.</given-names></name><name><surname>Erickson</surname><given-names>J.R.</given-names></name><name><surname>Slichter</surname><given-names>C.K.</given-names></name><name><surname>Berkson</surname><given-names>J.D.</given-names></name><name><surname>Klock</surname><given-names>A.M.</given-names></name><name><surname>Mack</surname><given-names>M.</given-names></name><name><surname>Lwo</surname><given-names>Y.</given-names></name><name><surname>Ko</surname><given-names>A.</given-names></name><name><surname>Brand</surname><given-names>R.M.</given-names></name><name><surname>McGowan</surname><given-names>I.</given-names></name><name><surname>Linsley</surname><given-names>P.S.</given-names></name><name><surname>Dixon</surname><given-names>D.R.</given-names></name><name><surname>Prlic</surname><given-names>M.</given-names></name></person-group><article-title>The human tissue-resident CCR5<sup>+</sup> T cell compartment maintains protective and functional properties during inflammation</article-title><source>Sci. Transl. Med.</source><volume>11</volume><year>2019</year><object-id pub-id-type="publisher-id">eaaw8718</object-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw8718</pub-id></element-citation></ref><ref id="bib0325"><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>T.C.</given-names></name><name><surname>Beck</surname><given-names>M.A.</given-names></name><name><surname>Kuziel</surname><given-names>W.A.</given-names></name><name><surname>Henderson</surname><given-names>F.</given-names></name><name><surname>Maeda</surname><given-names>N.</given-names></name></person-group><article-title>Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus</article-title><source>Am. J. Pathol.</source><volume>156</volume><year>2000</year><fpage>1951</fpage><lpage>1959</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65068-7</pub-id><pub-id pub-id-type="pmid">10854218</pub-id></element-citation></ref><ref id="bib0330"><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Ellmeier</surname><given-names>W.</given-names></name><name><surname>Choe</surname><given-names>S.</given-names></name><name><surname>Unutmaz</surname><given-names>D.</given-names></name><name><surname>Burkhart</surname><given-names>M.</given-names></name><name><surname>Di Marzio</surname><given-names>P.</given-names></name><name><surname>Marmon</surname><given-names>S.</given-names></name><name><surname>Sutton</surname><given-names>R.E.</given-names></name><name><surname>Hill</surname><given-names>C.M.</given-names></name><name><surname>Davis</surname><given-names>C.B.</given-names></name><name><surname>Peiper</surname><given-names>S.C.</given-names></name><name><surname>Schall</surname><given-names>T.J.</given-names></name><name><surname>Littman</surname><given-names>D.R.</given-names></name><name><surname>Landau</surname><given-names>N.R.</given-names></name></person-group><article-title>Identification of a major co-receptor for primary isolates of HIV-1</article-title><source>Nature</source><volume>381</volume><year>1996</year><fpage>661</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1038/381661a0</pub-id><pub-id pub-id-type="pmid">8649511</pub-id></element-citation></ref><ref id="bib0335"><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name><surname>de-Oliveira-Pinto</surname><given-names>L.M.</given-names></name><name><surname>Marinho</surname><given-names>C.F.</given-names></name><name><surname>Povoa</surname><given-names>T.F.</given-names></name><name><surname>de Azeredo</surname><given-names>E.L.</given-names></name><name><surname>de Souza</surname><given-names>L.A.</given-names></name><name><surname>Barbosa</surname><given-names>L.D.R.</given-names></name><name><surname>Motta-Castro</surname><given-names>A.R.</given-names></name><name><surname>Alves</surname><given-names>A.M.B.</given-names></name><name><surname>&#x000c1;vila</surname><given-names>C.A.L.</given-names></name><name><surname>de Souza</surname><given-names>L.A.J.</given-names></name><name><surname>da Cunha</surname><given-names>R.V.</given-names></name><name><surname>Damasco</surname><given-names>P.V.</given-names></name><name><surname>Paes</surname><given-names>M.V.</given-names></name><name><surname>Kubelka</surname><given-names>C.F.</given-names></name></person-group><article-title>Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue fever</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e38527</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0038527</pub-id></element-citation></ref><ref id="bib0340"><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name><surname>Deval</surname><given-names>H.</given-names></name><name><surname>Alagarasu</surname><given-names>K.</given-names></name><name><surname>Mittal</surname><given-names>M.</given-names></name><name><surname>Srivastava</surname><given-names>N.</given-names></name><name><surname>Bachal</surname><given-names>R.</given-names></name><name><surname>Gondhalekar</surname><given-names>A.</given-names></name><name><surname>Chaudhary</surname><given-names>U.</given-names></name><name><surname>Chowdhary</surname><given-names>D.</given-names></name><name><surname>Bondre</surname><given-names>V.P.</given-names></name></person-group><article-title>Association of single nucleotide polymorphisms in <italic>TNFA</italic> and <italic>CCR5</italic> genes with Japanese Encephalitis: a study from an endemic region of North India</article-title><source>J. Neuroimmunol.</source><volume>336</volume><year>2019</year><object-id pub-id-type="publisher-id">577043</object-id><pub-id pub-id-type="doi">10.1016/j.jneuroim.2019.577043</pub-id></element-citation></ref><ref id="bib0345"><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>M.S.</given-names></name></person-group><article-title>Virus and host determinants of West Nile virus pathogenesis</article-title><source>PLoS Pathog.</source><volume>5</volume><year>2009</year><object-id pub-id-type="publisher-id">e1000452</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000452</pub-id></element-citation></ref><ref id="bib0350"><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name><surname>Dobaczewski</surname><given-names>M.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Bujak</surname><given-names>M.</given-names></name><name><surname>Gonzalez-Quesada</surname><given-names>C.</given-names></name><name><surname>Frangogiannis</surname><given-names>N.G.</given-names></name></person-group><article-title>CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells</article-title><source>Am. J. Pathol.</source><volume>176</volume><year>2010</year><fpage>2177</fpage><lpage>2187</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090759</pub-id><pub-id pub-id-type="pmid">20382703</pub-id></element-citation></ref><ref id="bib0355"><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>E.</given-names></name><name><surname>Du</surname><given-names>H.</given-names></name><name><surname>Gardner</surname><given-names>L.</given-names></name></person-group><article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><year>2020</year><fpage>533</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30120-1</pub-id><pub-id pub-id-type="pmid">32087114</pub-id></element-citation></ref><ref id="bib0360"><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name><surname>Doodes</surname><given-names>P.D.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Hamel</surname><given-names>K.M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Rodeghero</surname><given-names>R.L.</given-names></name><name><surname>Kobezda</surname><given-names>T.</given-names></name><name><surname>Finnegan</surname><given-names>A.</given-names></name></person-group><article-title>CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis</article-title><source>Arthritis Rheum.</source><volume>60</volume><year>2009</year><fpage>2945</fpage><lpage>2953</lpage><pub-id pub-id-type="doi">10.1002/art.24842</pub-id><pub-id pub-id-type="pmid">19790057</pub-id></element-citation></ref><ref id="bib0365"><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name><surname>Dragic</surname><given-names>T.</given-names></name><name><surname>Litwin</surname><given-names>V.</given-names></name><name><surname>Allaway</surname><given-names>G.P.</given-names></name><name><surname>Martin</surname><given-names>S.R.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Nagashima</surname><given-names>K.A.</given-names></name><name><surname>Cayanan</surname><given-names>C.</given-names></name><name><surname>Maddon</surname><given-names>P.J.</given-names></name><name><surname>Koup</surname><given-names>R.A.</given-names></name><name><surname>Moore</surname><given-names>J.P.</given-names></name><name><surname>Paxton</surname><given-names>W.A.</given-names></name></person-group><article-title>HIV-1 entry into CD4<sup>+</sup> cells is mediated by the chemokine receptor CC-CKR-5</article-title><source>Nature</source><volume>381</volume><year>1996</year><fpage>667</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/381667a0</pub-id><pub-id pub-id-type="pmid">8649512</pub-id></element-citation></ref><ref id="bib0370"><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name><surname>Durrant</surname><given-names>D.M.</given-names></name><name><surname>Daniels</surname><given-names>B.P.</given-names></name><name><surname>Pasieka</surname><given-names>T.</given-names></name><name><surname>Dorsey</surname><given-names>D.</given-names></name><name><surname>Klein</surname><given-names>R.S.</given-names></name></person-group><article-title>CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system</article-title><source>J. Neuroinflammation</source><volume>12</volume><year>2015</year><fpage>233</fpage><pub-id pub-id-type="doi">10.1186/s12974-015-0447-9</pub-id><pub-id pub-id-type="pmid">26667390</pub-id></element-citation></ref><ref id="bib0375"><element-citation publication-type="journal" id="sbref0375"><person-group person-group-type="author"><name><surname>Ehlin-Henriksson</surname><given-names>B.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Cagigi</surname><given-names>A.</given-names></name><name><surname>Mowafi</surname><given-names>F.</given-names></name><name><surname>Klein</surname><given-names>G.</given-names></name><name><surname>Nilsson</surname><given-names>A.</given-names></name></person-group><article-title>Changes in chemokines and chemokine receptor expression on tonsillar B cells upon Epstein-Barr virus infection</article-title><source>Immunology</source><volume>127</volume><year>2009</year><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.03029.x</pub-id><pub-id pub-id-type="pmid">19604305</pub-id></element-citation></ref><ref id="bib0380"><element-citation publication-type="journal" id="sbref0380"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Host immunogenetics in tick-borne encephalitis virus infection-The CCR5 crossroad</article-title><source>Ticks Tick. Dis.</source><volume>10</volume><year>2019</year><fpage>729</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1016/j.ttbdis.2019.03.005</pub-id></element-citation></ref><ref id="bib0385"><element-citation publication-type="journal" id="sbref0385"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Host genetic factors can impact vaccine immunogenicity and effectiveness</article-title><source>Lancet Infect. Dis.</source><volume>19</volume><year>2019</year><fpage>359</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30121-5</pub-id><pub-id pub-id-type="pmid">30938297</pub-id></element-citation></ref><ref id="bib0390"><element-citation publication-type="journal" id="sbref0390"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Crovella</surname><given-names>S.</given-names></name><name><surname>Dos Reis</surname><given-names>E.C.</given-names></name><name><surname>Pontillo</surname><given-names>A.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Exosomes are possibly used as a tool of immune regulation during the dendritic cell-based immune therapy against HIV-I</article-title><source>Med. Hypotheses</source><volume>95</volume><year>2016</year><fpage>67</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2016.09.005</pub-id><pub-id pub-id-type="pmid">27692171</pub-id></element-citation></ref><ref id="bib0395"><element-citation publication-type="journal" id="sbref0395"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Veit</surname><given-names>T.D.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Exosomes in HIV infection: a review and critical look</article-title><source>Infect. Genet. Evol.</source><volume>53</volume><year>2017</year><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.05.021</pub-id><pub-id pub-id-type="pmid">28546080</pub-id></element-citation></ref><ref id="bib0400"><element-citation publication-type="journal" id="sbref0400"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Kaminski</surname><given-names>V.L.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Rocio virus: an overview</article-title><source>RDGBM</source><volume>1</volume><year>2017</year><fpage>14</fpage><lpage>20</lpage></element-citation></ref><ref id="bib0405"><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Kaminski</surname><given-names>V.L.</given-names></name><name><surname>Valverde-Villegas</surname><given-names>J.M.</given-names></name><name><surname>Simon</surname><given-names>D.</given-names></name><name><surname>Lunge</surname><given-names>V.R.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming</article-title><source>Infect. Genet. Evol.</source><volume>66</volume><year>2018</year><fpage>376</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.08.011</pub-id><pub-id pub-id-type="pmid">28811194</pub-id></element-citation></ref><ref id="bib0410"><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Leal</surname><given-names>B.K.</given-names></name><name><surname>Valverde-Villegas</surname><given-names>J.M.</given-names></name><name><surname>Simon</surname><given-names>D.</given-names></name><name><surname>Marangon</surname><given-names>C.G.</given-names></name><name><surname>Mattevi</surname><given-names>V.S.</given-names></name><name><surname>Lazzaretti</surname><given-names>R.K.</given-names></name><name><surname>Sprinz</surname><given-names>E.</given-names></name><name><surname>Kuhmmer</surname><given-names>R.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>CCR5&#x00394;32 in HCV infection, HCV/HIV co-infection, and HCV-related diseases</article-title><source>Infect. Genet. Evol.</source><volume>59</volume><year>2018</year><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2018.02.002</pub-id><pub-id pub-id-type="pmid">29408489</pub-id></element-citation></ref><ref id="bib0415"><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Zambra</surname><given-names>F.M.B.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>R.L.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>MicroRNA-related polymorphisms in infectious diseases-Tiny changes with a huge impact on viral infections and potential clinical applications</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>1316</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01316</pub-id><pub-id pub-id-type="pmid">29963045</pub-id></element-citation></ref><ref id="bib0420"><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Kaminski</surname><given-names>V.L.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title><italic>CCR5</italic> gene editing - revisiting pros and cons of CCR5 absence</article-title><source>Infect. Genet. Evol.</source><volume>68</volume><year>2019</year><fpage>218</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2018.12.027</pub-id><pub-id pub-id-type="pmid">30590171</pub-id></element-citation></ref><ref id="bib0425"><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Kaminski</surname><given-names>V.L.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>What we say and what we mean when we say redundancy and robustness of the chemokine system - how CCR5 challenges these concepts</article-title><source>Immunol. Cell Biol.</source><volume>98</volume><year>2020</year><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/imcb.12291</pub-id><pub-id pub-id-type="pmid">31613403</pub-id></element-citation></ref><ref id="bib0430"><element-citation publication-type="journal" id="sbref0430"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Kulmann-Leal</surname><given-names>B.</given-names></name><name><surname>Wolf</surname><given-names>J.M.</given-names></name><name><surname>Michita</surname><given-names>R.T.</given-names></name><name><surname>Simon</surname><given-names>D.</given-names></name><name><surname>Lunge</surname><given-names>V.R.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Role of the genetic variant CCR5&#x00394;32 in HBV infection and HBV/HIV co-infection</article-title><source>Virus Res.</source><volume>277</volume><year>2020</year><object-id pub-id-type="publisher-id">197838</object-id><pub-id pub-id-type="doi">10.1016/j.virusres.2019.197838</pub-id></element-citation></ref><ref id="bib0435"><element-citation publication-type="journal" id="sbref0435"><person-group person-group-type="author"><name><surname>El-Moamly</surname><given-names>A.A.</given-names></name><name><surname>El-Sweify</surname><given-names>M.A.</given-names></name><name><surname>Rashad</surname><given-names>R.M.</given-names></name><name><surname>Abdalla</surname><given-names>E.M.</given-names></name><name><surname>Ragheb</surname><given-names>M.M.</given-names></name><name><surname>Awad</surname><given-names>M.M.</given-names></name></person-group><article-title>Role of CCR5&#x00394;32 mutation in protecting patients with <italic>Schistosoma mansoni</italic> infection against hepatitis C viral infection or progression</article-title><source>Parasitol. Res.</source><volume>112</volume><year>2013</year><fpage>2745</fpage><lpage>2752</lpage><pub-id pub-id-type="doi">10.1007/s00436-013-3380-9</pub-id><pub-id pub-id-type="pmid">23515570</pub-id></element-citation></ref><ref id="bib0440"><element-citation publication-type="journal" id="sbref0440"><person-group person-group-type="author"><name><surname>Engin</surname><given-names>A.</given-names></name><name><surname>K&#x000f6;ksal</surname><given-names>B.</given-names></name><name><surname>Do&#x0011f;an</surname><given-names>&#x000d6;T.</given-names></name><name><surname>Elaldi</surname><given-names>N.</given-names></name><name><surname>D&#x000f6;kmeta&#x0015f;</surname><given-names>&#x00130;</given-names></name><name><surname>Bakir</surname><given-names>M.</given-names></name><name><surname>&#x000d6;zdemir</surname><given-names>&#x000d6;.</given-names></name></person-group><article-title>Cytochrome P450 2D6 and MDR1 gene mutation in relation to mortality in patients with Crimean-Congo hemorrhagic fever: a preliminary study</article-title><source>Turkiye Klinikleri J Med Sci</source><volume>29</volume><year>2009</year><fpage>905</fpage><lpage>910</lpage></element-citation></ref><ref id="bib0445"><element-citation publication-type="journal" id="sbref0445"><person-group person-group-type="author"><name><surname>Erg&#x000f6;n&#x000fc;l</surname><given-names>O.</given-names></name></person-group><article-title>Crimean-Congo haemorrhagic fever</article-title><source>Lancet Infect. Dis.</source><volume>6</volume><year>2006</year><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(06)70435-2</pub-id><pub-id pub-id-type="pmid">16554245</pub-id></element-citation></ref><ref id="bib0450"><element-citation publication-type="journal" id="sbref0450"><person-group person-group-type="author"><name><surname>Fadel</surname><given-names>S.A.</given-names></name><name><surname>Bromley</surname><given-names>S.K.</given-names></name><name><surname>Medoff</surname><given-names>B.D.</given-names></name><name><surname>Luster</surname><given-names>A.D.</given-names></name></person-group><article-title>CXCR3-deficiency protects influenza-infected CCR5-deficient mice from mortality</article-title><source>Eur. J. Immunol.</source><volume>38</volume><year>2008</year><fpage>3376</fpage><lpage>3387</lpage><pub-id pub-id-type="doi">10.1002/eji.200838628</pub-id><pub-id pub-id-type="pmid">19039768</pub-id></element-citation></ref><ref id="bib0455"><element-citation publication-type="journal" id="sbref0455"><person-group person-group-type="author"><name><surname>Falcon</surname><given-names>A.</given-names></name><name><surname>Cuevas</surname><given-names>M.T.</given-names></name><name><surname>Rodriguez-Frandsen</surname><given-names>A.</given-names></name><name><surname>Reyes</surname><given-names>N.</given-names></name><name><surname>Pozo</surname><given-names>F.</given-names></name><name><surname>Moreno</surname><given-names>S.</given-names></name><name><surname>Ledesma</surname><given-names>J.</given-names></name><name><surname>Mart&#x000ed;nez-Alarc&#x000f3;n</surname><given-names>J.</given-names></name><name><surname>Nieto</surname><given-names>A.</given-names></name><name><surname>Casas</surname><given-names>I.</given-names></name></person-group><article-title>CCR5 deficiency predisposes to fatal outcome in influenza virus infection</article-title><source>J. Gen. Virol.</source><volume>96</volume><year>2015</year><fpage>2074</fpage><lpage>2078</lpage><pub-id pub-id-type="doi">10.1099/vir.0.000165</pub-id><pub-id pub-id-type="pmid">25918237</pub-id></element-citation></ref><ref id="bib0460"><element-citation publication-type="journal" id="sbref0460"><person-group person-group-type="author"><name><surname>Fantuzzi</surname><given-names>L.</given-names></name><name><surname>Tagliamonte</surname><given-names>M.</given-names></name><name><surname>Gauzzi</surname><given-names>M.C.</given-names></name><name><surname>Lopalco</surname><given-names>L.</given-names></name></person-group><article-title>Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders</article-title><source>Cell. Mol. Life Sci.</source><volume>76</volume><year>2019</year><fpage>4869</fpage><lpage>4886</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03255-6</pub-id><pub-id pub-id-type="pmid">31377844</pub-id></element-citation></ref><ref id="bib0465"><element-citation publication-type="journal" id="sbref0465"><person-group person-group-type="author"><name><surname>F&#x000e4;tkenheuer</surname><given-names>G.</given-names></name><name><surname>Hoffmann</surname><given-names>C.</given-names></name><name><surname>Slim</surname><given-names>J.</given-names></name><name><surname>Rouzier</surname><given-names>R.</given-names></name><name><surname>Keung</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Treitel</surname><given-names>M.</given-names></name><name><surname>Sansone-Parsons</surname><given-names>A.</given-names></name><name><surname>Kasserra</surname><given-names>C.</given-names></name><name><surname>O&#x02019;Mara</surname><given-names>E.</given-names></name><name><surname>Sch&#x000fc;rmann</surname><given-names>D.</given-names></name></person-group><article-title>Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable</article-title><source>J. Acquir. Immune Defic. Syndr.</source><volume>53</volume><year>2010</year><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181bb28dc</pub-id><pub-id pub-id-type="pmid">19838130</pub-id></element-citation></ref><ref id="bib0470"><element-citation publication-type="journal" id="sbref0470"><person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>L.T.</given-names></name></person-group><article-title>Emergent arboviruses in Brazil</article-title><source>Rev. Soc. Bras. Med. Trop.</source><volume>40</volume><year>2007</year><fpage>224</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1590/s0037-86822007000200016</pub-id><pub-id pub-id-type="pmid">17568894</pub-id></element-citation></ref><ref id="bib0475"><element-citation publication-type="journal" id="sbref0475"><person-group person-group-type="author"><name><surname>Froberg</surname><given-names>M.K.</given-names></name></person-group><article-title>Review: CMV escapes!</article-title><source>Ann. Clin. Lab. Sci.</source><volume>34</volume><year>2004</year><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">15228222</pub-id></element-citation></ref><ref id="bib0480"><element-citation publication-type="journal" id="sbref0480"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>T.S.</given-names></name><name><surname>Liu</surname><given-names>D.X.</given-names></name></person-group><article-title>Human coronavirus: host-pathogen interaction</article-title><source>Annu. Rev. Microbiol.</source><volume>73</volume><year>2019</year><fpage>529</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115759</pub-id><pub-id pub-id-type="pmid">31226023</pub-id></element-citation></ref><ref id="bib0485"><element-citation publication-type="journal" id="sbref0485"><person-group person-group-type="author"><name><surname>Ganczak</surname><given-names>M.</given-names></name><name><surname>Skonieczna-&#x0017b;ydecka</surname><given-names>K.</given-names></name><name><surname>Drozd-D&#x00105;browska</surname><given-names>M.</given-names></name><name><surname>Adler</surname><given-names>G.</given-names></name></person-group><article-title>Possible impact of 190G &#x00026; A CCR2 and &#x00394;32 CCR5 mutations on decrease of the HBV vaccine immunogenicity-A preliminary report</article-title><source>Int. J. Environ. Res. Public Health</source><volume>14</volume><year>2017</year><fpage>166</fpage><pub-id pub-id-type="doi">10.3390/ijerph14020166</pub-id></element-citation></ref><ref id="bib0490"><element-citation publication-type="journal" id="sbref0490"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>K.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name></person-group><article-title>Exosomes derived from septic mouse serum modulate immune responses via exosome-associated cytokines</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>1560</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01560</pub-id><pub-id pub-id-type="pmid">31354717</pub-id></element-citation></ref><ref id="bib0495"><element-citation publication-type="journal" id="sbref0495"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>K.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name></person-group><article-title>Association between cytokines and exosomes in synovial fluid of individuals with knee osteoarthritis</article-title><source>Mod. Rheumatol.</source><year>2019</year><pub-id pub-id-type="doi">10.1080/14397595.2019.1651445</pub-id><comment>in press</comment></element-citation></ref><ref id="bib0500"><element-citation publication-type="journal" id="sbref0500"><person-group person-group-type="author"><name><surname>Garrison</surname><given-names>A.R.</given-names></name><name><surname>Smith</surname><given-names>D.R.</given-names></name><name><surname>Golden</surname><given-names>J.W.</given-names></name></person-group><article-title>Animal models for Crimean-Congo hemorrhagic fever human disease</article-title><source>Viruses</source><volume>11</volume><year>2019</year><fpage>590</fpage><pub-id pub-id-type="doi">10.3390/v11070590</pub-id></element-citation></ref><ref id="bib0505"><element-citation publication-type="journal" id="sbref0505"><person-group person-group-type="author"><name><surname>Giaquinto</surname><given-names>C.</given-names></name><name><surname>Mawela</surname><given-names>M.P.</given-names></name><name><surname>Chokephaibulkit</surname><given-names>K.</given-names></name><name><surname>Negra</surname><given-names>M.D.</given-names></name><name><surname>Mitha</surname><given-names>I.H.</given-names></name><name><surname>Fourie</surname><given-names>J.</given-names></name><name><surname>Fang</surname><given-names>A.</given-names></name><name><surname>van der Ryst</surname><given-names>E.</given-names></name><name><surname>Valluri</surname><given-names>S.R.</given-names></name><name><surname>Vourvahis</surname><given-names>M.</given-names></name><name><surname>Zhang-Roper</surname><given-names>R.Y.</given-names></name><name><surname>Craig</surname><given-names>C.</given-names></name><name><surname>McFadyen</surname><given-names>L.</given-names></name><name><surname>Clark</surname><given-names>A.</given-names></name><name><surname>Heera</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacokinetics, safety and efficacy of maraviroc in treatment-experienced pediatric patients infected with CCR5-tropic HIV-1</article-title><source>Pediatr. Infect. Dis. J.</source><volume>37</volume><year>2018</year><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000001808</pub-id><pub-id pub-id-type="pmid">29023357</pub-id></element-citation></ref><ref id="bib0510"><element-citation publication-type="journal" id="sbref0510"><person-group person-group-type="author"><name><surname>Glas</surname><given-names>J.</given-names></name><name><surname>T&#x000f6;r&#x000f6;k</surname><given-names>H.P.</given-names></name><name><surname>Simperl</surname><given-names>C.</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>A.</given-names></name><name><surname>Martin</surname><given-names>K.</given-names></name><name><surname>Schmidt</surname><given-names>F.</given-names></name><name><surname>Schaefer</surname><given-names>M.</given-names></name><name><surname>Schiemann</surname><given-names>U.</given-names></name><name><surname>Folwaczny</surname><given-names>C.</given-names></name></person-group><article-title>The &#x00394;32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-&#x003b1; and ribavirin</article-title><source>Clin. Immunol.</source><volume>108</volume><year>2003</year><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S1521-6616(03)00059-7</pub-id><pub-id pub-id-type="pmid">12865070</pub-id></element-citation></ref><ref id="bib0515"><element-citation publication-type="journal" id="sbref0515"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>W.G.</given-names></name><name><surname>Lane</surname><given-names>T.E.</given-names></name></person-group><article-title>Functional expression of chemokine receptor CCR5 on CD4<sup>+</sup> T cells during virus-induced central nervous system disease</article-title><source>J. Virol.</source><volume>77</volume><year>2003</year><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1128/jvi.77.1.191-198.2003</pub-id><pub-id pub-id-type="pmid">12477824</pub-id></element-citation></ref><ref id="bib0520"><element-citation publication-type="journal" id="sbref0520"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>W.G.</given-names></name><name><surname>Lane</surname><given-names>T.E.</given-names></name></person-group><article-title>Functional analysis of the CC chemokine receptor 5 (CCR5) on virus-specific CD8<sup>+</sup> T cells following coronavirus infection of the central nervous system</article-title><source>Virology</source><volume>312</volume><year>2003</year><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/s0042-6822(03)00237-x</pub-id><pub-id pub-id-type="pmid">12919745</pub-id></element-citation></ref><ref id="bib0525"><element-citation publication-type="journal" id="sbref0525"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>W.G.</given-names></name><name><surname>Liu</surname><given-names>M.T.</given-names></name><name><surname>Kuziel</surname><given-names>W.A.</given-names></name><name><surname>Lane</surname><given-names>T.E.</given-names></name></person-group><article-title>Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus</article-title><source>Virology</source><volume>288</volume><year>2001</year><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.1050</pub-id><pub-id pub-id-type="pmid">11543653</pub-id></element-citation></ref><ref id="bib0530"><element-citation publication-type="journal" id="sbref0530"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>W.G.</given-names></name><name><surname>Rosenberg</surname><given-names>H.F.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>Chemokine regulation of inflammation during acute viral infection</article-title><source>Curr. Opin. Allergy Clin. Immunol.</source><volume>3</volume><year>2003</year><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1097/01.all.0000104448.09202.91</pub-id><pub-id pub-id-type="pmid">14612671</pub-id></element-citation></ref><ref id="bib0535"><element-citation publication-type="journal" id="sbref0535"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>W.G.</given-names></name><name><surname>Lim</surname><given-names>J.K.</given-names></name><name><surname>Cholera</surname><given-names>R.</given-names></name><name><surname>Pletnev</surname><given-names>A.G.</given-names></name><name><surname>Gao</surname><given-names>J.L.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection</article-title><source>J. Exp. Med.</source><volume>202</volume><year>2005</year><fpage>1087</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1084/jem.20042530</pub-id><pub-id pub-id-type="pmid">16230476</pub-id></element-citation></ref><ref id="bib0540"><element-citation publication-type="journal" id="sbref0540"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>W.G.</given-names></name><name><surname>McDermott</surname><given-names>D.H.</given-names></name><name><surname>Lim</surname><given-names>J.K.</given-names></name><name><surname>Lekhong</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>S.F.</given-names></name><name><surname>Frank</surname><given-names>W.A.</given-names></name><name><surname>Pape</surname><given-names>J.</given-names></name><name><surname>Cheshier</surname><given-names>R.C.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>CCR5 deficiency increases risk of symptomatic West Nile virus infection</article-title><source>J. Exp. Med.</source><volume>203</volume><year>2006</year><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1084/jem.20051970</pub-id><pub-id pub-id-type="pmid">16418398</pub-id></element-citation></ref><ref id="bib0545"><element-citation publication-type="journal" id="sbref0545"><person-group person-group-type="author"><name><surname>Goulding</surname><given-names>C.</given-names></name><name><surname>McManus</surname><given-names>R.</given-names></name><name><surname>Murphy</surname><given-names>A.</given-names></name><name><surname>MacDonald</surname><given-names>G.</given-names></name><name><surname>Barrett</surname><given-names>S.</given-names></name><name><surname>Crowe</surname><given-names>J.</given-names></name><name><surname>Hegarty</surname><given-names>J.</given-names></name><name><surname>McKiernan</surname><given-names>S.</given-names></name><name><surname>Kelleher</surname><given-names>D.</given-names></name></person-group><article-title>The CCR5-&#x00394;32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source</article-title><source>Gut</source><volume>54</volume><year>2005</year><fpage>1157</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1136/gut.2004.055699</pub-id><pub-id pub-id-type="pmid">15863470</pub-id></element-citation></ref><ref id="bib0550"><element-citation publication-type="journal" id="sbref0550"><person-group person-group-type="author"><name><surname>Govaerts</surname><given-names>C.</given-names></name><name><surname>Bondue</surname><given-names>A.</given-names></name><name><surname>Springael</surname><given-names>J.Y.</given-names></name><name><surname>Olivella</surname><given-names>M.</given-names></name><name><surname>Deupi</surname><given-names>X.</given-names></name><name><surname>Le Poul</surname><given-names>E.</given-names></name><name><surname>Wodak</surname><given-names>S.J.</given-names></name><name><surname>Parmentier</surname><given-names>M.</given-names></name><name><surname>Pardo</surname><given-names>L.</given-names></name><name><surname>Blanpain</surname><given-names>C.</given-names></name></person-group><article-title>Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3</article-title><source>J. Biol. Chem.</source><volume>278</volume><year>2003</year><fpage>1892</fpage><lpage>1903</lpage><pub-id pub-id-type="doi">10.1074/jbc.M205685200</pub-id><pub-id pub-id-type="pmid">12411445</pub-id></element-citation></ref><ref id="bib0555"><element-citation publication-type="journal" id="sbref0555"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>A.</given-names></name><name><surname>Suneetha</surname><given-names>P.V.</given-names></name><name><surname>Kumar</surname><given-names>G.T.</given-names></name><name><surname>Shukla</surname><given-names>D.K.</given-names></name><name><surname>Arora</surname><given-names>N.</given-names></name><name><surname>Sarin</surname><given-names>S.K.</given-names></name></person-group><article-title>CCR5&#x00394;32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C</article-title><source>World J. Gastroenterol.</source><volume>12</volume><year>2006</year><fpage>4721</fpage><lpage>4726</lpage><pub-id pub-id-type="doi">10.3748/wjg.v12.i29.4721</pub-id><pub-id pub-id-type="pmid">16937446</pub-id></element-citation></ref><ref id="bib0560"><element-citation publication-type="journal" id="sbref0560"><person-group person-group-type="author"><name><surname>Grayson</surname><given-names>M.H.</given-names></name><name><surname>Ramos</surname><given-names>M.S.</given-names></name><name><surname>Rohlfing</surname><given-names>M.M.</given-names></name><name><surname>Kitchens</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>H.D.</given-names></name><name><surname>Gould</surname><given-names>A.</given-names></name><name><surname>Agapov</surname><given-names>E.</given-names></name><name><surname>Holtzman</surname><given-names>M.J.</given-names></name></person-group><article-title>Controls for lung dendritic cell maturation and migration during respiratory viral infection</article-title><source>J. Immunol.</source><volume>179</volume><year>2007</year><fpage>1438</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.3.1438</pub-id><pub-id pub-id-type="pmid">17641009</pub-id></element-citation></ref><ref id="bib0565"><element-citation publication-type="journal" id="sbref0565"><person-group person-group-type="author"><name><surname>Greely</surname><given-names>H.T.</given-names></name></person-group><article-title>CRISPR&#x02019;d babies: human germline genome editing in the &#x02018;He Jiankui affair&#x02019;</article-title><source>J. Law Biosci.</source><volume>6</volume><year>2019</year><fpage>111</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1093/jlb/lsz010</pub-id><pub-id pub-id-type="pmid">31666967</pub-id></element-citation></ref><ref id="bib0570"><element-citation publication-type="journal" id="sbref0570"><person-group person-group-type="author"><name><surname>Gregianini</surname><given-names>T.S.</given-names></name><name><surname>Varella IRS</surname><given-names>Fisch P.</given-names></name><name><surname>Martins</surname><given-names>L.G.</given-names></name><name><surname>Veiga</surname><given-names>A.B.G.</given-names></name></person-group><article-title>Dual and triple infections with influenza A and B viruses: a case-control study in Southern Brazil</article-title><source>J. Infect. Dis.</source><volume>220</volume><year>2019</year><fpage>961</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz221</pub-id><pub-id pub-id-type="pmid">31125400</pub-id></element-citation></ref><ref id="bib0575"><element-citation publication-type="journal" id="sbref0575"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>P.</given-names></name><name><surname>Baraniak</surname><given-names>I.</given-names></name><name><surname>Reeves</surname><given-names>M.</given-names></name></person-group><article-title>The pathogenesis of human cytomegalovirus</article-title><source>J. Pathol.</source><volume>235</volume><year>2015</year><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1002/path.4437</pub-id><pub-id pub-id-type="pmid">25205255</pub-id></element-citation></ref><ref id="bib0580"><element-citation publication-type="journal" id="sbref0580"><person-group person-group-type="author"><name><surname>Guglielmi</surname><given-names>L.</given-names></name><name><surname>Gimenez</surname><given-names>S.</given-names></name><name><surname>Larroque</surname><given-names>M.</given-names></name><name><surname>Tong</surname><given-names>X.</given-names></name><name><surname>Portal&#x000e8;s</surname><given-names>P.</given-names></name><name><surname>Corbeau</surname><given-names>P.</given-names></name></person-group><article-title>Circulating human CD4<sup>+</sup> T cells have intracellular pools of CCR5 molecules</article-title><source>Blood</source><volume>118</volume><year>2011</year><fpage>1177</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-03-339754</pub-id><pub-id pub-id-type="pmid">21799101</pub-id></element-citation></ref><ref id="bib0585"><element-citation publication-type="journal" id="sbref0585"><person-group person-group-type="author"><name><surname>Gulick</surname><given-names>R.M.</given-names></name><name><surname>Fatkenheuer</surname><given-names>G.</given-names></name><name><surname>Burnside</surname><given-names>R.</given-names></name><name><surname>Hardy</surname><given-names>W.D.</given-names></name><name><surname>Nelson</surname><given-names>M.R.</given-names></name><name><surname>Goodrich</surname><given-names>J.</given-names></name><name><surname>Mukwaya</surname><given-names>G.</given-names></name><name><surname>Portsmouth</surname><given-names>S.</given-names></name><name><surname>Heera</surname><given-names>J.R.</given-names></name></person-group><article-title>Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients</article-title><source>J. Acquir. Immune Defic. Syndr.</source><volume>65</volume><year>2014</year><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3182a7a97a</pub-id><pub-id pub-id-type="pmid">24419064</pub-id></element-citation></ref><ref id="bib0590"><element-citation publication-type="journal" id="sbref0590"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N.</given-names></name><name><surname>Rao</surname><given-names>P.V.</given-names></name></person-group><article-title>Transcriptomic profile of host response in Japanese encephalitis virus infection</article-title><source>Virol. J.</source><volume>8</volume><year>2011</year><fpage>92</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-92</pub-id><pub-id pub-id-type="pmid">21371334</pub-id></element-citation></ref><ref id="bib0595"><element-citation publication-type="journal" id="sbref0595"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R.K.</given-names></name><name><surname>Abdul-Jawad</surname><given-names>S.</given-names></name><name><surname>McCoy</surname><given-names>L.E.</given-names></name><name><surname>Mok</surname><given-names>H.P.</given-names></name><name><surname>Peppa</surname><given-names>D.</given-names></name><name><surname>Salgado</surname><given-names>M.</given-names></name><name><surname>Martinez-Picado</surname><given-names>J.</given-names></name><name><surname>Nijhuis</surname><given-names>M.</given-names></name><name><surname>Wensing</surname><given-names>A.M.J.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Grant</surname><given-names>P.</given-names></name><name><surname>Nastouli</surname><given-names>E.</given-names></name><name><surname>Lambert</surname><given-names>J.</given-names></name><name><surname>Pace</surname><given-names>M.</given-names></name><name><surname>Salasc</surname><given-names>F.</given-names></name><name><surname>Monit</surname><given-names>C.</given-names></name><name><surname>Innes</surname><given-names>A.J.</given-names></name><name><surname>Muir</surname><given-names>L.</given-names></name><name><surname>Waters</surname><given-names>L.</given-names></name><name><surname>Frater</surname><given-names>J.</given-names></name><name><surname>Lever</surname><given-names>A.M.L.</given-names></name><name><surname>Edwards</surname><given-names>S.G.</given-names></name><name><surname>Gabriel</surname><given-names>I.H.</given-names></name><name><surname>Olavarria</surname><given-names>E.</given-names></name></person-group><article-title>HIV-1 remission following CCR5&#x00394;32/&#x00394;32 haematopoietic stem-cell transplantation</article-title><source>Nature</source><volume>568</volume><year>2019</year><fpage>244</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1027-4</pub-id><pub-id pub-id-type="pmid">30836379</pub-id></element-citation></ref><ref id="bib0600"><element-citation publication-type="journal" id="sbref0600"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R.K.</given-names></name><name><surname>Peppa</surname><given-names>D.</given-names></name><name><surname>Hill</surname><given-names>A.L.</given-names></name><name><surname>G&#x000e1;lvez</surname><given-names>C.</given-names></name><name><surname>Salgado</surname><given-names>M.</given-names></name><name><surname>Pace</surname><given-names>M.</given-names></name><name><surname>McCoy</surname><given-names>L.E.</given-names></name><name><surname>Griffith</surname><given-names>S.A.</given-names></name><name><surname>Thornhill</surname><given-names>J.</given-names></name><name><surname>Alrubayyi</surname><given-names>A.</given-names></name><name><surname>Huyveneers</surname><given-names>L.E.P.</given-names></name><name><surname>Nastouli</surname><given-names>E.</given-names></name><name><surname>Grant</surname><given-names>P.</given-names></name><name><surname>Edwards</surname><given-names>S.G.</given-names></name><name><surname>Innes</surname><given-names>A.J.</given-names></name><name><surname>Frater</surname><given-names>J.</given-names></name><name><surname>Nijhuis</surname><given-names>M.</given-names></name><name><surname>Wensing</surname><given-names>A.M.J.</given-names></name><name><surname>Martinez-Picado</surname><given-names>J.</given-names></name><name><surname>Olavarria</surname><given-names>E.</given-names></name></person-group><article-title>Evidence for HIV-1 cure after CCR5&#x00394;32/&#x00394;32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report</article-title><source>Lancet HIV</source><volume>7</volume><year>2020</year><fpage>e340</fpage><lpage>e347</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(20)30069-2</pub-id><pub-id pub-id-type="pmid">32169158</pub-id></element-citation></ref><ref id="bib0605"><element-citation publication-type="journal" id="sbref0605"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>M.G.</given-names></name><name><surname>Gubler</surname><given-names>D.J.</given-names></name><name><surname>Izquierdo</surname><given-names>A.</given-names></name><name><surname>Martinez</surname><given-names>E.</given-names></name><name><surname>Halstead</surname><given-names>S.B.</given-names></name></person-group><article-title>Dengue infection</article-title><source>Nat. Rev. Dis. Primers</source><volume>2</volume><year>2016</year><fpage>16055</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2016.55</pub-id><pub-id pub-id-type="pmid">27534439</pub-id></element-citation></ref><ref id="bib0610"><element-citation publication-type="journal" id="sbref0610"><person-group person-group-type="author"><name><surname>Ha&#x000ef;m-Boukobza</surname><given-names>S.</given-names></name><name><surname>Balabanian</surname><given-names>K.</given-names></name><name><surname>Teicher</surname><given-names>E.</given-names></name><name><surname>Bourgeade</surname><given-names>M.</given-names></name><name><surname>Perlemuter</surname><given-names>G.</given-names></name><name><surname>Roque-Afonso</surname><given-names>A.M.</given-names></name><name><surname>Duclos-Vallee</surname><given-names>J.C.</given-names></name></person-group><article-title>Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients</article-title><source>J. Hepatol.</source><volume>59</volume><year>2013</year><fpage>613</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2013.03.034</pub-id><pub-id pub-id-type="pmid">23583366</pub-id></element-citation></ref><ref id="bib0615"><element-citation publication-type="journal" id="sbref0615"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>F.S.</given-names></name><name><surname>Raman</surname><given-names>D.</given-names></name><name><surname>Tiwari</surname><given-names>A.K.</given-names></name></person-group><article-title>CCR5 and responses to cocaine: addiction is not just about the brain</article-title><source>Brain Behav. Immun.</source><volume>84</volume><year>2020</year><fpage>8</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2019.12.008</pub-id><pub-id pub-id-type="pmid">31843646</pub-id></element-citation></ref><ref id="bib0620"><element-citation publication-type="journal" id="sbref0620"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>T.T.</given-names></name><name><surname>Tunstall</surname><given-names>T.</given-names></name><name><surname>Trujillo-Torralbo</surname><given-names>M.B.</given-names></name><name><surname>Shamji</surname><given-names>B.</given-names></name><name><surname>Del-Rosario</surname><given-names>A.</given-names></name><name><surname>Dhariwal</surname><given-names>J.</given-names></name><name><surname>Kirk</surname><given-names>P.D.W.</given-names></name><name><surname>Stumpf</surname><given-names>M.P.H.</given-names></name><name><surname>Koopmann</surname><given-names>J.</given-names></name><name><surname>Telcian</surname><given-names>A.</given-names></name><name><surname>Aniscenko</surname><given-names>J.</given-names></name><name><surname>Gogsadze</surname><given-names>L.</given-names></name><name><surname>Bakhsoliani</surname><given-names>E.</given-names></name><name><surname>Stanciu</surname><given-names>L.</given-names></name><name><surname>Bartlett</surname><given-names>N.</given-names></name><name><surname>Edwards</surname><given-names>M.</given-names></name><name><surname>Walton</surname><given-names>R.</given-names></name><name><surname>Mallia</surname><given-names>P.</given-names></name><name><surname>Hunt</surname><given-names>T.M.</given-names></name><name><surname>Hunt</surname><given-names>T.M.L.</given-names></name><name><surname>Hunt</surname><given-names>D.G.</given-names></name><name><surname>Westwick</surname><given-names>J.</given-names></name><name><surname>Edwards</surname><given-names>M.</given-names></name><name><surname>Kon</surname><given-names>O.M.</given-names></name><name><surname>Jackson</surname><given-names>D.J.</given-names></name><name><surname>Johnston</surname><given-names>S.L.</given-names></name></person-group><article-title>A comprehensive evaluation of nasal and bronchial cytokines and chemokines following experimental rhinovirus infection in allergic asthma: increased interferons (IFN-&#x003b3; and IFN-&#x003bb;) and type 2 inflammation (IL-5 and IL-13)</article-title><source>EBioMedicine</source><volume>19</volume><year>2017</year><fpage>128</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2017.03.033</pub-id><pub-id pub-id-type="pmid">28373098</pub-id></element-citation></ref><ref id="bib0625"><element-citation publication-type="journal" id="sbref0625"><person-group person-group-type="author"><name><surname>Hellier</surname><given-names>S.</given-names></name><name><surname>Frodsham</surname><given-names>A.J.</given-names></name><name><surname>Hennig</surname><given-names>B.J.W.</given-names></name><name><surname>Klenerman</surname><given-names>P.</given-names></name><name><surname>Knapp</surname><given-names>S.</given-names></name><name><surname>Ramaley</surname><given-names>P.</given-names></name><name><surname>Satsangi</surname><given-names>J.</given-names></name><name><surname>Wright</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Thomas</surname><given-names>H.C.</given-names></name><name><surname>Thursz</surname><given-names>M.</given-names></name><name><surname>Hill</surname><given-names>A.V.S.</given-names></name></person-group><article-title>Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection</article-title><source>Hepatology</source><volume>38</volume><year>2003</year><fpage>1468</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1016/j.hep.2003.09.027</pub-id><pub-id pub-id-type="pmid">14647058</pub-id></element-citation></ref><ref id="bib0630"><element-citation publication-type="journal" id="sbref0630"><person-group person-group-type="author"><name><surname>Herbein</surname><given-names>G.</given-names></name></person-group><article-title>The human cytomegalovirus, from oncomodulation to oncogenesis</article-title><source>Viruses</source><volume>10</volume><year>2018</year><fpage>408</fpage><pub-id pub-id-type="doi">10.3390/v10080408</pub-id></element-citation></ref><ref id="bib0635"><element-citation publication-type="journal" id="sbref0635"><person-group person-group-type="author"><name><surname>Hoover</surname><given-names>K.C.</given-names></name></person-group><article-title>Intragenus (<italic>Homo</italic>) variation in a chemokine receptor gene (<italic>CCR5</italic>)</article-title><source>PLoS One</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0204989</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0204989</pub-id></element-citation></ref><ref id="bib0640"><element-citation publication-type="journal" id="sbref0640"><person-group person-group-type="author"><name><surname>Hossain</surname><given-names>F.M.A.</given-names></name><name><surname>Park</surname><given-names>S.O.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Eo</surname><given-names>J.C.</given-names></name><name><surname>Choi</surname><given-names>J.Y.</given-names></name><name><surname>Uyangaa</surname><given-names>E.</given-names></name><name><surname>Kim</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Eo</surname><given-names>S.K.</given-names></name></person-group><article-title>CCR5 attenuates neutrophilic airway inflammation exacerbated by infection with rhinovirus</article-title><source>Cell. Immunol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cellimm.2020.104066</pub-id><comment>in press</comment></element-citation></ref><ref id="bib0645"><element-citation publication-type="journal" id="sbref0645"><person-group person-group-type="author"><name><surname>Hosseinkhani</surname><given-names>B.</given-names></name><name><surname>Kuypers</surname><given-names>S.</given-names></name><name><surname>van den Akker</surname><given-names>N.M.S.</given-names></name><name><surname>Molin</surname><given-names>D.G.M.</given-names></name><name><surname>Michiels</surname><given-names>L.</given-names></name></person-group><article-title>Extracellular vesicles work as a functional inflammatory mediator between vascular endothelial cells and immune cells</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>1789</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01789</pub-id><pub-id pub-id-type="pmid">30131806</pub-id></element-citation></ref><ref id="bib0650"><element-citation publication-type="journal" id="sbref0650"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Paxton</surname><given-names>W.A.</given-names></name><name><surname>Wolinsky</surname><given-names>S.M.</given-names></name><name><surname>Neumann</surname><given-names>A.U.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name><name><surname>Kang</surname><given-names>S.</given-names></name><name><surname>Ceradini</surname><given-names>D.</given-names></name><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>K.</given-names></name><name><surname>Kunstman</surname><given-names>K.</given-names></name><name><surname>Erickson</surname><given-names>D.</given-names></name><name><surname>Dragon</surname><given-names>E.</given-names></name><name><surname>Landau</surname><given-names>N.R.</given-names></name><name><surname>Phair</surname><given-names>J.</given-names></name><name><surname>Ho</surname><given-names>D.D.</given-names></name><name><surname>Koup</surname><given-names>R.A.</given-names></name></person-group><article-title>The role of a mutant CCR5 allele in HIV-1 transmission and disease progression</article-title><source>Nat. Med.</source><volume>2</volume><year>1996</year><fpage>1240</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1038/nm1196-1240</pub-id><pub-id pub-id-type="pmid">8898752</pub-id></element-citation></ref><ref id="bib0655"><element-citation publication-type="journal" id="sbref0655"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Zepp</surname><given-names>M.</given-names></name><name><surname>Georges</surname><given-names>R.B.</given-names></name><name><surname>Jarahian</surname><given-names>M.</given-names></name><name><surname>Kazemi</surname><given-names>M.</given-names></name><name><surname>Eyol</surname><given-names>E.</given-names></name><name><surname>Berger</surname><given-names>M.R.</given-names></name></person-group><article-title>The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction</article-title><source>Cancer Lett.</source><volume>474</volume><year>2020</year><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.01.009</pub-id><pub-id pub-id-type="pmid">31954769</pub-id></element-citation></ref><ref id="bib0660"><element-citation publication-type="journal" id="sbref0660"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Jin</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib0665"><element-citation publication-type="journal" id="sbref0665"><person-group person-group-type="author"><name><surname>Huik</surname><given-names>K.</given-names></name><name><surname>Avi</surname><given-names>R.</given-names></name><name><surname>Carrillo</surname><given-names>A.</given-names></name><name><surname>Harper</surname><given-names>N.</given-names></name><name><surname>Pauskar</surname><given-names>M.</given-names></name><name><surname>Sadam</surname><given-names>M.</given-names></name><name><surname>Karki</surname><given-names>T.</given-names></name><name><surname>Krispin</surname><given-names>T.</given-names></name><name><surname>Kongo</surname><given-names>U.K.</given-names></name><name><surname>Jermilova</surname><given-names>T.</given-names></name><name><surname>R&#x000fc;&#x000fc;tel</surname><given-names>K.</given-names></name><name><surname>Talu</surname><given-names>A.</given-names></name><name><surname>Abel-Ollo</surname><given-names>K.</given-names></name><name><surname>Uusk&#x000fc;la</surname><given-names>A.</given-names></name><name><surname>Ahuja</surname><given-names>S.K.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Lutsar</surname><given-names>I.</given-names></name></person-group><article-title><italic>CCR5</italic> haplotypes influence HCV serostatus in Caucasian intravenous drug users</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e70561</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0070561</pub-id></element-citation></ref><ref id="bib0670"><element-citation publication-type="journal" id="sbref0670"><person-group person-group-type="author"><name><surname>H&#x000fc;tter</surname><given-names>G.</given-names></name><name><surname>Nowak</surname><given-names>D.</given-names></name><name><surname>Mossner</surname><given-names>M.</given-names></name><name><surname>Ganepola</surname><given-names>S.</given-names></name><name><surname>M&#x000fc;ssig</surname><given-names>A.</given-names></name><name><surname>Allers</surname><given-names>K.</given-names></name><name><surname>Schneider</surname><given-names>T.</given-names></name><name><surname>Hofmann</surname><given-names>J.</given-names></name><name><surname>K&#x000fc;cherer</surname><given-names>C.</given-names></name><name><surname>Blau</surname><given-names>O.</given-names></name><name><surname>Blau</surname><given-names>I.W.</given-names></name><name><surname>Hofmann</surname><given-names>W.K.</given-names></name><name><surname>Thiel</surname><given-names>E.</given-names></name></person-group><article-title>Long-term control of HIV by <italic>CCR5</italic> Delta32/Delta32 stem-cell transplantation</article-title><source>N. Engl. J. Med.</source><volume>360</volume><year>2009</year><fpage>692</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802905</pub-id><pub-id pub-id-type="pmid">19213682</pub-id></element-citation></ref><ref id="bib0675"><element-citation publication-type="journal" id="sbref0675"><person-group person-group-type="author"><name><surname>H&#x000fc;tter</surname><given-names>G.</given-names></name><name><surname>Neumann</surname><given-names>M.</given-names></name><name><surname>Nowak</surname><given-names>D.</given-names></name><name><surname>Klein</surname><given-names>S.</given-names></name><name><surname>Kl&#x000fc;ter</surname><given-names>H.</given-names></name><name><surname>Hofmann</surname><given-names>W.K.</given-names></name></person-group><article-title>The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation</article-title><source>J. Inflamm. Lond.</source><volume>8</volume><year>2011</year><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/1476-9255-8-29</pub-id><pub-id pub-id-type="pmid">22029606</pub-id></element-citation></ref><ref id="bib0680"><element-citation publication-type="journal" id="sbref0680"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>M.</given-names></name><name><surname>Kalita</surname><given-names>T.</given-names></name><name><surname>Saikia</surname><given-names>A.K.</given-names></name><name><surname>Begum</surname><given-names>A.</given-names></name><name><surname>Baruah</surname><given-names>V.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Borkotoky</surname><given-names>R.</given-names></name><name><surname>Bose</surname><given-names>S.</given-names></name></person-group><article-title>Significance of RANTES-CCR5 axis and linked downstream immunomodulation in Dengue pathogenesis: A study from Guwahati, India</article-title><source>J. Med. Virol.</source><volume>91</volume><year>2019</year><fpage>2066</fpage><lpage>2073</lpage><pub-id pub-id-type="doi">10.1002/jmv.25561</pub-id><pub-id pub-id-type="pmid">31368534</pub-id></element-citation></ref><ref id="bib0685"><element-citation publication-type="journal" id="sbref0685"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>E.L.</given-names></name><name><surname>Howard</surname><given-names>C.L.</given-names></name><name><surname>Thurman</surname><given-names>J.</given-names></name><name><surname>Pontiff</surname><given-names>K.</given-names></name><name><surname>Johnson</surname><given-names>E.L.S.</given-names></name><name><surname>Chakraborty</surname><given-names>R.</given-names></name></person-group><article-title>Cytomegalovirus upregulates expression of CCR5 in central memory cord blood mononuclear cells, which may facilitate in utero HIV type 1 transmission</article-title><source>J. Infect. Dis.</source><volume>211</volume><year>2015</year><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu424</pub-id><pub-id pub-id-type="pmid">25081935</pub-id></element-citation></ref><ref id="bib0690"><element-citation publication-type="journal" id="sbref0690"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>E.L.</given-names></name><name><surname>Boggavarapu</surname><given-names>S.</given-names></name><name><surname>Johnson</surname><given-names>E.L.S.</given-names></name><name><surname>Lal</surname><given-names>A.A.</given-names></name><name><surname>Agrawal</surname><given-names>P.</given-names></name><name><surname>Bhaumik</surname><given-names>S.K.</given-names></name><name><surname>Murali-Krishna</surname><given-names>K.</given-names></name><name><surname>Chakraborty</surname><given-names>R.</given-names></name></person-group><article-title>Human cytomegalovirus enhances placental susceptibility and replication of Human Immunodeficiency Virus type 1 (HIV-1), which may facilitate in utero HIV-1 transmission</article-title><source>J. Infect. Dis.</source><volume>218</volume><year>2018</year><fpage>1464</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy327</pub-id><pub-id pub-id-type="pmid">29860306</pub-id></element-citation></ref><ref id="bib0695"><element-citation publication-type="journal" id="sbref0695"><person-group person-group-type="author"><name><surname>Joy</surname><given-names>M.T.</given-names></name><name><surname>Ben Assayag</surname><given-names>E.</given-names></name><name><surname>Shabashov-Stone</surname><given-names>D.</given-names></name><name><surname>Liraz-Zaltsman</surname><given-names>S.</given-names></name><name><surname>Mazzitelli</surname><given-names>J.</given-names></name><name><surname>Arenas</surname><given-names>M.</given-names></name><name><surname>Abduljawad</surname><given-names>N.</given-names></name><name><surname>Kliper</surname><given-names>E.</given-names></name><name><surname>Korczyn</surname><given-names>A.D.</given-names></name><name><surname>Thareja</surname><given-names>N.S.</given-names></name><name><surname>Kesner</surname><given-names>E.L.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Silva</surname><given-names>T.K.</given-names></name><name><surname>Katz</surname><given-names>N.</given-names></name><name><surname>Bornstein</surname><given-names>N.M.</given-names></name><name><surname>Silva</surname><given-names>A.J.</given-names></name><name><surname>Shohami</surname><given-names>E.</given-names></name><name><surname>Carmichael</surname><given-names>S.T.</given-names></name></person-group><article-title>CCR5 is a therapeutic target for recovery after stroke and traumatic brain injury</article-title><source>Cell</source><volume>176</volume><year>2019</year><fpage>1143</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.01.044</pub-id><pub-id pub-id-type="pmid">30794775</pub-id></element-citation></ref><ref id="bib0700"><element-citation publication-type="journal" id="sbref0700"><person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>V.L.</given-names></name><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Sandrim</surname><given-names>V.</given-names></name><name><surname>Pontillo</surname><given-names>A.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Influence of NKG2C gene deletion and CCR5&#x00394;32 in pre-eclampsia-Approaching the effect of innate immune gene variants in pregnancy</article-title><source>Int. J. Immunogenet.</source><volume>46</volume><year>2019</year><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1111/iji.12416</pub-id><pub-id pub-id-type="pmid">30786156</pub-id></element-citation></ref><ref id="bib0705"><element-citation publication-type="journal" id="sbref0705"><person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>V.L.</given-names></name><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>Extracellular vesicles in host-pathogen interactions and immune regulation - exosomes as emerging actors in the immunological theater of pregnancy</article-title><source>Heliyon</source><volume>5</volume><year>2019</year><fpage>e02355</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2019.e02355</pub-id><pub-id pub-id-type="pmid">31592031</pub-id></element-citation></ref><ref id="bib0710"><element-citation publication-type="journal" id="sbref0710"><person-group person-group-type="author"><name><surname>Kasztelewicz</surname><given-names>B.</given-names></name><name><surname>Czech-Kowalska</surname><given-names>J.</given-names></name><name><surname>Lipka</surname><given-names>B.</given-names></name><name><surname>Milewska-Bobula</surname><given-names>B.</given-names></name><name><surname>Borszewska-Kornacka</surname><given-names>M.K.</given-names></name><name><surname>Roma&#x00144;ska</surname><given-names>J.</given-names></name><name><surname>Dzier&#x0017c;anowska-Fangrat</surname><given-names>K.</given-names></name></person-group><article-title>Cytokine gene polymorphism associations with congenital cytomegalovirus infection and sensorineural hearing loss</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><volume>36</volume><year>2017</year><fpage>1811</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1007/s10096-017-2996-6</pub-id><pub-id pub-id-type="pmid">28501927</pub-id></element-citation></ref><ref id="bib0715"><element-citation publication-type="book" id="sbref0715"><person-group person-group-type="author"><name><surname>Keohane</surname><given-names>C.</given-names></name><name><surname>Chimelli</surname><given-names>L.</given-names></name><name><surname>Ryan</surname><given-names>A.</given-names></name></person-group><chapter-title>Poliovirus infection and postpolio syndrome</chapter-title><person-group person-group-type="editor"><name><surname>Chr&#x000e9;tien</surname><given-names>F.</given-names></name><name><surname>Wong</surname><given-names>K.T.</given-names></name><name><surname>Sharer</surname><given-names>L.R.</given-names></name><name><surname>Keohane</surname><given-names>C.</given-names></name><name><surname>Gray</surname><given-names>F.</given-names></name></person-group><source>Infections of the Central Nervous System: Pathology and Genetics</source><year>2020</year><publisher-name>John Wiley &#x00026; Sons Ltd.</publisher-name><fpage>195</fpage><lpage>204</lpage></element-citation></ref><ref id="bib0720"><element-citation publication-type="journal" id="sbref0720"><person-group person-group-type="author"><name><surname>Kew</surname><given-names>O.</given-names></name><name><surname>Pallansch</surname><given-names>M.</given-names></name></person-group><article-title>Breaking the last chains of poliovirus transmission: progress and challenges in global polio eradication</article-title><source>Annu. Rev. Virol.</source><volume>5</volume><year>2018</year><fpage>427</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-101416-041749</pub-id><pub-id pub-id-type="pmid">30001183</pub-id></element-citation></ref><ref id="bib0725"><element-citation publication-type="journal" id="sbref0725"><person-group person-group-type="author"><name><surname>Keynan</surname><given-names>Y.</given-names></name><name><surname>Juno</surname><given-names>J.</given-names></name><name><surname>Meyers</surname><given-names>A.</given-names></name><name><surname>Ball</surname><given-names>T.B.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Rubinstein</surname><given-names>E.</given-names></name><name><surname>Fowke</surname><given-names>K.R.</given-names></name></person-group><article-title>Chemokine receptor 5 &#x00394;32 allele in patients with severe pandemic (H1N1) 2009</article-title><source>Emerg Infect Dis</source><volume>16</volume><year>2010</year><fpage>1621</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.3201/eid1610.100108</pub-id><pub-id pub-id-type="pmid">20875295</pub-id></element-citation></ref><ref id="bib0730"><element-citation publication-type="journal" id="sbref0730"><person-group person-group-type="author"><name><surname>Khaiboullina</surname><given-names>S.F.</given-names></name><name><surname>Lopes</surname><given-names>P.</given-names></name><name><surname>de Carvalho</surname><given-names>T.G.</given-names></name><name><surname>Real</surname><given-names>A.L.C.V.</given-names></name><name><surname>Souza</surname><given-names>D.G.</given-names></name><name><surname>Costa</surname><given-names>V.V.</given-names></name><name><surname>Teixeira</surname><given-names>M.M.</given-names></name><name><surname>Bloise</surname><given-names>E.</given-names></name><name><surname>Verma</surname><given-names>S.C.</given-names></name><name><surname>Ribeiro</surname><given-names>F.M.</given-names></name></person-group><article-title>Host immune response to ZIKV in an immunocompetent embryonic mouse model of intravaginal infection</article-title><source>Viruses</source><volume>11</volume><year>2019</year><fpage>558</fpage><pub-id pub-id-type="doi">10.3390/v11060558</pub-id></element-citation></ref><ref id="bib0735"><element-citation publication-type="journal" id="sbref0735"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>Thomas</surname><given-names>S.Y.</given-names></name><name><surname>Moretto</surname><given-names>M.M.</given-names></name><name><surname>Lee</surname><given-names>F.S.</given-names></name><name><surname>Islam</surname><given-names>S.A.</given-names></name><name><surname>Combe</surname><given-names>C.</given-names></name><name><surname>Schwartzman</surname><given-names>J.D.</given-names></name><name><surname>Luster</surname><given-names>A.D.</given-names></name></person-group><article-title>CCR5 is essential for NK cell trafficking and host survival following <italic>Toxoplasma gondii</italic> infection</article-title><source>PLoS Pathog.</source><volume>2</volume><year>2006</year><fpage>e49</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.0020049</pub-id><pub-id pub-id-type="pmid">16789839</pub-id></element-citation></ref><ref id="bib0740"><element-citation publication-type="journal" id="sbref0740"><person-group person-group-type="author"><name><surname>Khorramdelazad</surname><given-names>H.</given-names></name><name><surname>Hakimizadeh</surname><given-names>E.</given-names></name><name><surname>Hassanshahi</surname><given-names>G.</given-names></name><name><surname>Rezayati</surname><given-names>M.</given-names></name><name><surname>Sendi</surname><given-names>H.</given-names></name><name><surname>Arababadi</surname><given-names>M.K.</given-names></name></person-group><article-title>CCR5 &#x00394; 32 mutation is not prevalent in Iranians with chronic HBV infection</article-title><source>J. Med. Virol.</source><volume>85</volume><year>2013</year><fpage>964</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1002/jmv.23510</pub-id><pub-id pub-id-type="pmid">23588722</pub-id></element-citation></ref><ref id="bib0745"><element-citation publication-type="journal" id="sbref0745"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Patil</surname><given-names>A.M.</given-names></name><name><surname>Choi</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>S.B.</given-names></name><name><surname>Uyangaa</surname><given-names>E.</given-names></name><name><surname>Hossain FMA</surname><given-names>Park S.Y.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Eo</surname><given-names>S.K.</given-names></name></person-group><article-title>CCR5 ameliorates Japanese encephalitis via dictating the equilibrium of regulatory CD4<sup>+</sup>Foxp3<sup>+</sup> T and IL-17<sup>+</sup>CD4<sup>+</sup> Th17 cells</article-title><source>J. Neuroinflammation</source><volume>13</volume><year>2016</year><fpage>223</fpage><pub-id pub-id-type="doi">10.1186/s12974-016-0656-x</pub-id><pub-id pub-id-type="pmid">27439902</pub-id></element-citation></ref><ref id="bib0750"><element-citation publication-type="journal" id="sbref0750"><person-group person-group-type="author"><name><surname>King</surname><given-names>C.A.</given-names></name><name><surname>Baillie</surname><given-names>J.</given-names></name><name><surname>Sinclair</surname><given-names>J.H.</given-names></name></person-group><article-title>Human cytomegalovirus modulation of CCR5 expression on myeloid cells affects susceptibility to human immunodeficiency virus type 1 infection</article-title><source>J. Gen. Virol.</source><volume>87</volume><year>2006</year><fpage>2171</fpage><lpage>2180</lpage><pub-id pub-id-type="doi">10.1099/vir.0.81452-0</pub-id><pub-id pub-id-type="pmid">16847113</pub-id></element-citation></ref><ref id="bib0755"><element-citation publication-type="journal" id="sbref0755"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R.S.</given-names></name></person-group><article-title>Discussion on frequency of the HIV-protective CC chemokine receptor 5-&#x00394;32/&#x00394;32 genotype is increased in hepatitis C</article-title><source>Gastroenterology</source><volume>124</volume><year>2003</year><fpage>1558</fpage><pub-id pub-id-type="doi">10.1016/s0016-5085(03)00348-2</pub-id></element-citation></ref><ref id="bib0760"><element-citation publication-type="journal" id="sbref0760"><person-group person-group-type="author"><name><surname>Kletenkov</surname><given-names>K.</given-names></name><name><surname>Martynova</surname><given-names>E.</given-names></name><name><surname>Davidyuk</surname><given-names>Y.</given-names></name><name><surname>Kabwe</surname><given-names>E.</given-names></name><name><surname>Shamsutdinov</surname><given-names>A.</given-names></name><name><surname>Garanina</surname><given-names>E.</given-names></name><name><surname>Shakirova</surname><given-names>V.</given-names></name><name><surname>Khaertynova</surname><given-names>I.</given-names></name><name><surname>Anokhin</surname><given-names>V.</given-names></name><name><surname>Tarlinton</surname><given-names>R.</given-names></name><name><surname>Rizvanov</surname><given-names>A.</given-names></name><name><surname>Khaiboullina</surname><given-names>S.</given-names></name><name><surname>Morzunov</surname><given-names>S.</given-names></name></person-group><article-title>&#x00394;<italic>ccr5</italic> genotype is associated with mild form of nephropathia epidemica</article-title><source>Viruses</source><volume>11</volume><year>2019</year><fpage>675</fpage><pub-id pub-id-type="doi">10.3390/v11070675</pub-id></element-citation></ref><ref id="bib0765"><element-citation publication-type="journal" id="sbref0765"><person-group person-group-type="author"><name><surname>Kodidela</surname><given-names>S.</given-names></name><name><surname>Ranjit</surname><given-names>S.</given-names></name><name><surname>Sinha</surname><given-names>N.</given-names></name><name><surname>McArthur</surname><given-names>C.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name></person-group><article-title>Cytokine profiling of exosomes derived from the plasma of HIV-infected alcohol drinkers and cigarette smokers</article-title><source>PLoS One</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0201144</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0201144</pub-id></element-citation></ref><ref id="bib0770"><element-citation publication-type="journal" id="sbref0770"><person-group person-group-type="author"><name><surname>Kohlmeier</surname><given-names>J.E.</given-names></name><name><surname>Miller</surname><given-names>S.C.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Gerard</surname><given-names>C.</given-names></name><name><surname>Cookenham</surname><given-names>T.</given-names></name><name><surname>Roberts</surname><given-names>A.D.</given-names></name><name><surname>Woodland</surname><given-names>D.L.</given-names></name></person-group><article-title>The chemokine receptor CCR5 plays a key role in the early memory CD8<sup>+</sup> T cell response to respiratory virus infections</article-title><source>Immunity</source><volume>29</volume><year>2008</year><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.05.011</pub-id><pub-id pub-id-type="pmid">18617426</pub-id></element-citation></ref><ref id="bib0775"><element-citation publication-type="journal" id="sbref0775"><person-group person-group-type="author"><name><surname>Konadu</surname><given-names>K.A.</given-names></name><name><surname>Chu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>M.B.</given-names></name><name><surname>Amancha</surname><given-names>P.K.</given-names></name><name><surname>Armstrong</surname><given-names>W.</given-names></name><name><surname>Powell</surname><given-names>M.D.</given-names></name><name><surname>Villinger</surname><given-names>F.</given-names></name><name><surname>Bond</surname><given-names>V.C.</given-names></name></person-group><article-title>Association of cytokines with exosomes in the plasma of HIV-1-seropositive individuals</article-title><source>J. Infect. Dis.</source><volume>211</volume><year>2015</year><fpage>1712</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu676</pub-id><pub-id pub-id-type="pmid">25512626</pub-id></element-citation></ref><ref id="bib0780"><element-citation publication-type="journal" id="sbref0780"><person-group person-group-type="author"><name><surname>Konishi</surname><given-names>I.</given-names></name><name><surname>Horiike</surname><given-names>N.</given-names></name><name><surname>Hiasa</surname><given-names>Y.</given-names></name><name><surname>Michitaka</surname><given-names>K.</given-names></name><name><surname>Onji</surname><given-names>M.</given-names></name></person-group><article-title>CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan</article-title><source>Intervirology</source><volume>47</volume><year>2004</year><fpage>114</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1159/000077835</pub-id><pub-id pub-id-type="pmid">15192276</pub-id></element-citation></ref><ref id="bib0785"><element-citation publication-type="journal" id="sbref0785"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>L.D.</given-names></name><name><surname>Styer</surname><given-names>L.M.</given-names></name><name><surname>Ebel</surname><given-names>G.D.</given-names></name></person-group><article-title>A global perspective on the epidemiology of West Nile virus</article-title><source>Annu. Rev. Entomol.</source><volume>53</volume><year>2008</year><fpage>61</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1146/annurev.ento.53.103106.093258</pub-id><pub-id pub-id-type="pmid">17645411</pub-id></element-citation></ref><ref id="bib0790"><element-citation publication-type="journal" id="sbref0790"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Smith</surname><given-names>G.J.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name><surname>Peiris</surname><given-names>M.</given-names></name><name><surname>Kedzierska</surname><given-names>K.</given-names></name><name><surname>Doherty</surname><given-names>P.C.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Shaw</surname><given-names>M.L.</given-names></name><name><surname>Treanor</surname><given-names>J.</given-names></name><name><surname>Webster</surname><given-names>R.G.</given-names></name><name><surname>Garc&#x000ed;a-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Influenza</article-title><source>Nat. Rev. Dis. Primers</source><volume>4</volume><year>2018</year><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0002-y</pub-id><pub-id pub-id-type="pmid">29955068</pub-id></element-citation></ref><ref id="bib0795"><element-citation publication-type="journal" id="sbref0795"><person-group person-group-type="author"><name><surname>K&#x000fc;hl</surname><given-names>U.</given-names></name><name><surname>Pauschinger</surname><given-names>M.</given-names></name><name><surname>Seeberg</surname><given-names>B.</given-names></name><name><surname>Lassner</surname><given-names>D.</given-names></name><name><surname>Noutsias</surname><given-names>M.</given-names></name><name><surname>Poller</surname><given-names>W.</given-names></name><name><surname>Schultheiss</surname><given-names>H.P.</given-names></name></person-group><article-title>Viral persistence in the myocardium is associated with progressive cardiac dysfunction</article-title><source>Circulation</source><volume>112</volume><year>2005</year><fpage>1965</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.548156</pub-id><pub-id pub-id-type="pmid">16172268</pub-id></element-citation></ref><ref id="bib0800"><element-citation publication-type="journal" id="sbref0800"><person-group person-group-type="author"><name><surname>K&#x000fc;hl</surname><given-names>U.</given-names></name><name><surname>Lassner</surname><given-names>D.</given-names></name><name><surname>von Schlippenbach</surname><given-names>J.</given-names></name><name><surname>Poller</surname><given-names>W.</given-names></name><name><surname>Schultheiss</surname><given-names>H.P.</given-names></name></person-group><article-title>Interferon-Beta improves survival in enterovirus-associated cardiomyopathy</article-title><source>J. Am. Coll. Cardiol.</source><volume>60</volume><year>2012</year><fpage>1295</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.06.026</pub-id><pub-id pub-id-type="pmid">23017536</pub-id></element-citation></ref><ref id="bib0805"><element-citation publication-type="journal" id="sbref0805"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>S.</given-names></name><name><surname>Lied</surname><given-names>A.</given-names></name><name><surname>Kulkarni</surname><given-names>V.</given-names></name><name><surname>Rucevic</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>M.P.</given-names></name><name><surname>Walker-Sperling</surname><given-names>V.</given-names></name><name><surname>Anderson</surname><given-names>S.K.</given-names></name><name><surname>Ewy</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Nguyen</surname><given-names>H.</given-names></name><name><surname>McLaren</surname><given-names>P.J.</given-names></name><name><surname>Viard</surname><given-names>M.</given-names></name><name><surname>Naranbhai</surname><given-names>V.</given-names></name><name><surname>Zou</surname><given-names>C.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Gatanaga</surname><given-names>H.</given-names></name><name><surname>Oka</surname><given-names>S.</given-names></name><name><surname>Takiguchi</surname><given-names>M.</given-names></name><name><surname>Thio</surname><given-names>C.L.</given-names></name><name><surname>Margolick</surname><given-names>J.</given-names></name><name><surname>Kirk</surname><given-names>G.D.</given-names></name><name><surname>Goedert</surname><given-names>J.J.</given-names></name><name><surname>Hoots</surname><given-names>W.K.</given-names></name><name><surname>Deeks</surname><given-names>S.G.</given-names></name><name><surname>Haas</surname><given-names>D.W.</given-names></name><name><surname>Michael</surname><given-names>N.</given-names></name><name><surname>Walker</surname><given-names>B.</given-names></name><name><surname>Le Gall</surname><given-names>S.</given-names></name><name><surname>Chowdhury</surname><given-names>F.Z.</given-names></name><name><surname>Yu</surname><given-names>X.G.</given-names></name><name><surname>Carrington</surname><given-names>M.</given-names></name></person-group><article-title>CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome</article-title><source>Nat. Immunol.</source><volume>20</volume><year>2019</year><fpage>824</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0406-1</pub-id><pub-id pub-id-type="pmid">31209403</pub-id></element-citation></ref><ref id="bib0810"><element-citation publication-type="journal" id="sbref0810"><person-group person-group-type="author"><name><surname>Kulmann-Leal</surname><given-names>B.</given-names></name><name><surname>Ellwanger</surname><given-names>J.H.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>A functional interaction between the CCR5 and CD34 molecules expressed in hematopoietic cells can support (or even promote) the development of cancer</article-title><source>Hematol Transfus Cell Ther</source><volume>42</volume><year>2020</year><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.htct.2019.10.001</pub-id><pub-id pub-id-type="pmid">31822447</pub-id></element-citation></ref><ref id="bib0815"><element-citation publication-type="journal" id="sbref0815"><person-group person-group-type="author"><name><surname>Lacalle</surname><given-names>R.A.</given-names></name><name><surname>Blanco</surname><given-names>R.</given-names></name><name><surname>Carmona-Rodr&#x000ed;guez</surname><given-names>L.</given-names></name><name><surname>Mart&#x000ed;n-Leal</surname><given-names>A.</given-names></name><name><surname>Mira</surname><given-names>E.</given-names></name><name><surname>Ma&#x000f1;es</surname><given-names>S.</given-names></name></person-group><article-title>Chemokine receptor signaling and the hallmarks of cancer</article-title><source>Int. Rev. Cell Mol. Biol.</source><volume>331</volume><year>2017</year><fpage>181</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/bs.ircmb.2016.09.011</pub-id><pub-id pub-id-type="pmid">28325212</pub-id></element-citation></ref><ref id="bib0820"><element-citation publication-type="journal" id="sbref0820"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>J.</given-names></name><name><surname>Neumann-Haefelin</surname><given-names>C.</given-names></name><name><surname>Thimme</surname><given-names>R.</given-names></name></person-group><article-title>Immunological cure of HBV infection</article-title><source>Hepatol. Int.</source><volume>13</volume><year>2019</year><fpage>113</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1007/s12072-018-9912-8</pub-id><pub-id pub-id-type="pmid">30600480</pub-id></element-citation></ref><ref id="bib0825"><element-citation publication-type="journal" id="sbref0825"><person-group person-group-type="author"><name><surname>Larena</surname><given-names>M.</given-names></name><name><surname>Regner</surname><given-names>M.</given-names></name><name><surname>Lobigs</surname><given-names>M.</given-names></name></person-group><article-title>The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e44834</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0044834</pub-id></element-citation></ref><ref id="bib0830"><element-citation publication-type="journal" id="sbref0830"><person-group person-group-type="author"><name><surname>Larrubia</surname><given-names>J.R.</given-names></name><name><surname>Calvino</surname><given-names>M.</given-names></name><name><surname>Benito</surname><given-names>S.</given-names></name><name><surname>Sanz-de-Villalobos</surname><given-names>E.</given-names></name><name><surname>Perna</surname><given-names>C.</given-names></name><name><surname>P&#x000e9;rez-Hornedo</surname><given-names>J.</given-names></name><name><surname>Gonz&#x000e1;lez-Mateos</surname><given-names>F.</given-names></name><name><surname>Garc&#x000ed;a-Garz&#x000f3;n</surname><given-names>S.</given-names></name><name><surname>Bienvenido</surname><given-names>A.</given-names></name><name><surname>Parra</surname><given-names>T.</given-names></name></person-group><article-title>The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection</article-title><source>J. Hepatol.</source><volume>47</volume><year>2007</year><fpage>632</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2007.04.009</pub-id><pub-id pub-id-type="pmid">17560677</pub-id></element-citation></ref><ref id="bib0835"><element-citation publication-type="journal" id="sbref0835"><person-group person-group-type="author"><name><surname>Lassner</surname><given-names>D.</given-names></name><name><surname>Siegismund</surname><given-names>C.S.</given-names></name><name><surname>K&#x000fc;hl</surname><given-names>U.</given-names></name><name><surname>Rohde</surname><given-names>M.</given-names></name><name><surname>Stroux</surname><given-names>A.</given-names></name><name><surname>Escher</surname><given-names>F.</given-names></name><name><surname>Schultheiss</surname><given-names>H.P.</given-names></name></person-group><article-title>CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5</article-title><source>J. Transl. Med.</source><volume>16</volume><year>2018</year><fpage>249</fpage><pub-id pub-id-type="doi">10.1186/s12967-018-1610-8</pub-id><pub-id pub-id-type="pmid">30180856</pub-id></element-citation></ref><ref id="bib0840"><element-citation publication-type="journal" id="sbref0840"><person-group person-group-type="author"><name><surname>Latinovic</surname><given-names>O.S.</given-names></name><name><surname>Reitz</surname><given-names>M.</given-names></name><name><surname>Heredia</surname><given-names>A.</given-names></name></person-group><article-title>CCR5 inhibitors and HIV-1 infection</article-title><source>J AIDS HIV Treat</source><volume>1</volume><year>2019</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.33696/AIDS.1.001</pub-id><pub-id pub-id-type="pmid">31414081</pub-id></element-citation></ref><ref id="bib0845"><element-citation publication-type="journal" id="sbref0845"><person-group person-group-type="author"><name><surname>Law</surname><given-names>H.K.</given-names></name><name><surname>Cheung</surname><given-names>C.Y.</given-names></name><name><surname>Sia</surname><given-names>S.F.</given-names></name><name><surname>Chan</surname><given-names>Y.O.</given-names></name><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Lau</surname><given-names>Y.L.</given-names></name></person-group><article-title>Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells</article-title><source>BMC Immunol.</source><volume>10</volume><year>2009</year><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1471-2172-10-35</pub-id><pub-id pub-id-type="pmid">19505311</pub-id></element-citation></ref><ref id="bib0850"><element-citation publication-type="journal" id="sbref0850"><person-group person-group-type="author"><name><surname>Le Flohic</surname><given-names>G.</given-names></name><name><surname>Porphyre</surname><given-names>V.</given-names></name><name><surname>Barbazan</surname><given-names>P.</given-names></name><name><surname>Gonzalez</surname><given-names>J.P.</given-names></name></person-group><article-title>Review of climate, landscape, and viral genetics as drivers of the Japanese encephalitis virus ecology</article-title><source>PLoS Negl. Trop. Dis.</source><volume>7</volume><year>2013</year><fpage>e2208</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0002208</pub-id><pub-id pub-id-type="pmid">24069463</pub-id></element-citation></ref><ref id="bib0855"><element-citation publication-type="journal" id="sbref0855"><person-group person-group-type="author"><name><surname>Lebecque</surname><given-names>O.</given-names></name><name><surname>Dupont</surname><given-names>M.</given-names></name></person-group><article-title>Puumala hantavirus: an imaging review</article-title><source>Acta Radiol.</source><year>2019</year><pub-id pub-id-type="doi">10.1177/0284185119889564</pub-id><comment>in press</comment></element-citation></ref><ref id="bib0860"><element-citation publication-type="journal" id="sbref0860"><person-group person-group-type="author"><name><surname>Lecointe</surname><given-names>D.</given-names></name><name><surname>Dugas</surname><given-names>N.</given-names></name><name><surname>Leclerc</surname><given-names>P.</given-names></name><name><surname>Hery</surname><given-names>C.</given-names></name><name><surname>Delfraissy</surname><given-names>J.F.</given-names></name><name><surname>Tardieu</surname><given-names>M.</given-names></name></person-group><article-title>Human cytomegalovirus infection reduces surface CCR5 expression in human microglial cells, astrocytes and monocyte-derived macrophages</article-title><source>Microbes Infect.</source><volume>4</volume><year>2002</year><fpage>1401</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1016/s1286-4579(02)00022-9</pub-id><pub-id pub-id-type="pmid">12475630</pub-id></element-citation></ref><ref id="bib0865"><element-citation publication-type="journal" id="sbref0865"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.M.</given-names></name><name><surname>Banini</surname><given-names>B.A.</given-names></name></person-group><article-title>Updates on chronic HBV: current challenges and future goals</article-title><source>Curr. Treat. Options Gastroenterol.</source><volume>17</volume><year>2019</year><fpage>271</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/s11938-019-00236-3</pub-id><pub-id pub-id-type="pmid">31077059</pub-id></element-citation></ref><ref id="bib0870"><element-citation publication-type="journal" id="sbref0870"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>H.Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>W.L.</given-names></name><name><surname>Liang</surname><given-names>T.B.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Zheng</surname><given-names>S.S.</given-names></name></person-group><article-title>Polymorphisms of CCL3L1/CCR5 genes and recurrence of hepatitis B in liver transplant recipients</article-title><source>HBPD INT</source><volume>10</volume><year>2011</year><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1016/S1499-3872(11)60101-X</pub-id><pub-id pub-id-type="pmid">22146622</pub-id></element-citation></ref><ref id="bib0875"><element-citation publication-type="journal" id="sbref0875"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>B.</given-names></name></person-group><article-title>Horizontal transfer of exosomal CXCR4 promotes murine hepatocarcinoma cell migration, invasion and lymphangiogenesis</article-title><source>Gene</source><volume>676</volume><year>2018</year><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2018.07.018</pub-id><pub-id pub-id-type="pmid">30010038</pub-id></element-citation></ref><ref id="bib0880"><element-citation publication-type="journal" id="sbref0880"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Lai</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Pan</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Coronavirus infections and immune responses</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>424</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1002/jmv.25685</pub-id><pub-id pub-id-type="pmid">31981224</pub-id></element-citation></ref><ref id="bib0885"><element-citation publication-type="journal" id="sbref0885"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Qiao</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>Z.</given-names></name><name><surname>Yin</surname><given-names>Y.</given-names></name><name><surname>Liao</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>The chemokine receptor CCR1 is identified in mast cell-derived exosomes</article-title><source>Am. J. Transl. Res.</source><volume>10</volume><year>2018</year><fpage>352</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">29511430</pub-id></element-citation></ref><ref id="bib0890"><element-citation publication-type="journal" id="sbref0890"><person-group person-group-type="author"><name><surname>Lichterfeld</surname><given-names>M.</given-names></name><name><surname>Leifeld</surname><given-names>L.</given-names></name><name><surname>Nischalke</surname><given-names>H.D.</given-names></name><name><surname>Rockstroh</surname><given-names>J.K.</given-names></name><name><surname>Hess</surname><given-names>L.</given-names></name><name><surname>Sauerbruch</surname><given-names>T.</given-names></name><name><surname>Spengler</surname><given-names>U.</given-names></name></person-group><article-title>Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection</article-title><source>J. Infect. Dis.</source><volume>185</volume><year>2002</year><fpage>1803</fpage><lpage>1807</lpage><pub-id pub-id-type="doi">10.1086/340829</pub-id><pub-id pub-id-type="pmid">12085329</pub-id></element-citation></ref><ref id="bib0895"><element-citation publication-type="journal" id="sbref0895"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J.K.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>Chemokine control of West Nile virus infection</article-title><source>Exp. Cell Res.</source><volume>317</volume><year>2011</year><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2011.01.009</pub-id><pub-id pub-id-type="pmid">21376172</pub-id></element-citation></ref><ref id="bib0900"><element-citation publication-type="journal" id="sbref0900"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J.K.</given-names></name><name><surname>Glass</surname><given-names>W.G.</given-names></name><name><surname>McDermott</surname><given-names>D.H.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>CCR5: no longer a &#x02018;good for nothing&#x02019; gene--chemokine control of West Nile virus infection</article-title><source>Trends Immunol.</source><volume>27</volume><year>2006</year><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.it.2006.05.007</pub-id><pub-id pub-id-type="pmid">16753343</pub-id></element-citation></ref><ref id="bib0905"><element-citation publication-type="journal" id="sbref0905"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J.K.</given-names></name><name><surname>Louie</surname><given-names>C.Y.</given-names></name><name><surname>Glaser</surname><given-names>C.</given-names></name><name><surname>Jean</surname><given-names>C.</given-names></name><name><surname>Johnson</surname><given-names>B.</given-names></name><name><surname>Johnson</surname><given-names>H.</given-names></name><name><surname>McDermott</surname><given-names>D.H.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic</article-title><source>J. Infect. Dis.</source><volume>197</volume><year>2008</year><fpage>262</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1086/524691</pub-id><pub-id pub-id-type="pmid">18179388</pub-id></element-citation></ref><ref id="bib0910"><element-citation publication-type="journal" id="sbref0910"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J.K.</given-names></name><name><surname>McDermott</surname><given-names>D.H.</given-names></name><name><surname>Lisco</surname><given-names>A.</given-names></name><name><surname>Foster</surname><given-names>G.A.</given-names></name><name><surname>Krysztof</surname><given-names>D.</given-names></name><name><surname>Follmann</surname><given-names>D.</given-names></name><name><surname>Stramer</surname><given-names>S.L.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission</article-title><source>J. Infect. Dis.</source><volume>201</volume><year>2010</year><fpage>178</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1086/649426</pub-id><pub-id pub-id-type="pmid">20025530</pub-id></element-citation></ref><ref id="bib0915"><element-citation publication-type="journal" id="sbref0915"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>M.C.</given-names></name><name><surname>de Mendon&#x000e7;a</surname><given-names>L.R.</given-names></name><name><surname>Rezende</surname><given-names>A.M.</given-names></name><name><surname>Carrera</surname><given-names>R.M.</given-names></name><name><surname>An&#x000ed;bal-Silva</surname><given-names>C.E.</given-names></name><name><surname>Demers</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Aiuto</surname><given-names>L.</given-names></name><name><surname>Wood</surname><given-names>J.</given-names></name><name><surname>Chowdari</surname><given-names>K.V.</given-names></name><name><surname>Griffiths</surname><given-names>M.</given-names></name><name><surname>Lucena-Araujo</surname><given-names>A.R.</given-names></name><name><surname>Barral-Netto</surname><given-names>M.</given-names></name><name><surname>Azevedo</surname><given-names>E.A.N.</given-names></name><name><surname>Alves</surname><given-names>R.W.</given-names></name><name><surname>Farias</surname><given-names>P.C.S.</given-names></name><name><surname>Marques</surname><given-names>E.T.A.</given-names></name><name><surname>Castanha PMS</surname><given-names>Donald C.L.</given-names></name><name><surname>Kohl</surname><given-names>A.</given-names></name><name><surname>Nimgaonkar</surname><given-names>V.L.</given-names></name><name><surname>Franca</surname><given-names>R.F.O.</given-names></name></person-group><article-title>The transcriptional and protein profile from human infected neuroprogenitor cells is strongly correlated to Zika virus microcephaly cytokines phenotype evidencing a persistent inflammation in the CNS</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>1928</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01928</pub-id><pub-id pub-id-type="pmid">31474994</pub-id></element-citation></ref><ref id="bib0920"><element-citation publication-type="journal" id="sbref0920"><person-group person-group-type="author"><name><surname>Lingala</surname><given-names>S.</given-names></name><name><surname>Ghany</surname><given-names>M.G.</given-names></name></person-group><article-title>Natural history of hepatitis C</article-title><source>Gastroenterol. Clin. North Am.</source><volume>44</volume><year>2015</year><fpage>717</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/j.gtc.2015.07.003</pub-id><pub-id pub-id-type="pmid">26600216</pub-id></element-citation></ref><ref id="bib0925"><element-citation publication-type="journal" id="sbref0925"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>Jj.</given-names></name></person-group><article-title>Exosome-associated hepatitis C virus in cell cultures and patient plasma</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>455</volume><year>2014</year><fpage>218</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.10.146</pub-id><pub-id pub-id-type="pmid">25449270</pub-id></element-citation></ref><ref id="bib0930"><element-citation publication-type="journal" id="sbref0930"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>Y.H.</given-names></name><name><surname>Yang</surname><given-names>Z.Q.</given-names></name></person-group><article-title>The cytokine storm of severe influenza and development of immunomodulatory therapy</article-title><source>Cell. Mol. Immunol.</source><volume>13</volume><year>2016</year><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/cmi.2015.74</pub-id><pub-id pub-id-type="pmid">26189369</pub-id></element-citation></ref><ref id="bib0935"><element-citation publication-type="journal" id="sbref0935"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Xiao</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Xiang</surname><given-names>X.</given-names></name><name><surname>Ou</surname><given-names>A.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Shao</surname><given-names>D.</given-names></name><name><surname>Miao</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Long</surname><given-names>G.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name></person-group><article-title>Chemokine receptor antagonist block inflammation and therapy Japanese encephalitis virus infection in mouse model</article-title><source>Cytokine</source><volume>110</volume><year>2018</year><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2018.04.022</pub-id><pub-id pub-id-type="pmid">29704821</pub-id></element-citation></ref><ref id="bib0940"><element-citation publication-type="journal" id="sbref0940"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>M.</given-names></name><name><surname>Eskandarian</surname><given-names>S.</given-names></name><name><surname>Rupp</surname><given-names>M.</given-names></name><name><surname>Fishman</surname><given-names>N.</given-names></name><name><surname>Gasink</surname><given-names>L.</given-names></name><name><surname>Patterson</surname><given-names>J.</given-names></name><name><surname>Bramson</surname><given-names>J.</given-names></name><name><surname>Hudson</surname><given-names>T.J.</given-names></name><name><surname>Lemire</surname><given-names>M.</given-names></name></person-group><article-title>Genetic variants and susceptibility to neurological complications following West Nile virus infection</article-title><source>J. Infect. Dis.</source><volume>204</volume><year>2011</year><fpage>1031</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir493</pub-id><pub-id pub-id-type="pmid">21881118</pub-id></element-citation></ref><ref id="bib0945"><element-citation publication-type="journal" id="sbref0945"><person-group person-group-type="author"><name><surname>Loeffler</surname><given-names>J.</given-names></name><name><surname>Steffens</surname><given-names>M.</given-names></name><name><surname>Arlt</surname><given-names>E.M.</given-names></name><name><surname>Toliat</surname><given-names>M.R.</given-names></name><name><surname>Mezger</surname><given-names>M.</given-names></name><name><surname>Suk</surname><given-names>A.</given-names></name><name><surname>Wienker</surname><given-names>T.F.</given-names></name><name><surname>Hebart</surname><given-names>H.</given-names></name><name><surname>N&#x000fc;rnberg</surname><given-names>P.</given-names></name><name><surname>Boeckh</surname><given-names>M.</given-names></name><name><surname>Ljungman</surname><given-names>P.</given-names></name><name><surname>Trenschel</surname><given-names>R.</given-names></name><name><surname>Einsele</surname><given-names>H.</given-names></name></person-group><article-title>Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation</article-title><source>J. Clin. Microbiol.</source><volume>44</volume><year>2006</year><fpage>1847</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.1128/JCM.44.5.1847-1850.2006</pub-id><pub-id pub-id-type="pmid">16672419</pub-id></element-citation></ref><ref id="bib0950"><element-citation publication-type="journal" id="sbref0950"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>M.</given-names></name><name><surname>Karrer</surname><given-names>U.</given-names></name><name><surname>Lucas</surname><given-names>A.</given-names></name><name><surname>Klenerman</surname><given-names>P.</given-names></name></person-group><article-title>Viral escape mechanisms - escapology taught by viruses</article-title><source>Int. J. Exp. Pathol.</source><volume>82</volume><year>2001</year><fpage>269</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2613.2001.00204.x</pub-id><pub-id pub-id-type="pmid">11703537</pub-id></element-citation></ref><ref id="bib0955"><element-citation publication-type="journal" id="sbref0955"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>M.</given-names></name><name><surname>Kleinschmidt</surname><given-names>A.</given-names></name><name><surname>Br&#x000fc;hl</surname><given-names>H.</given-names></name><name><surname>Klier</surname><given-names>C.</given-names></name><name><surname>Nelson</surname><given-names>P.J.</given-names></name><name><surname>Cihak</surname><given-names>J.</given-names></name><name><surname>Plach&#x000fd;</surname><given-names>J.</given-names></name><name><surname>Stangassinger</surname><given-names>M.</given-names></name><name><surname>Erfle</surname><given-names>V.</given-names></name><name><surname>Schl&#x000f6;ndorff</surname><given-names>D.</given-names></name></person-group><article-title>Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection</article-title><source>Nat. Med.</source><volume>6</volume><year>2000</year><fpage>769</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1038/77498</pub-id><pub-id pub-id-type="pmid">10888925</pub-id></element-citation></ref><ref id="bib0960"><element-citation publication-type="journal" id="sbref0960"><person-group person-group-type="author"><name><surname>Maestri</surname><given-names>A.</given-names></name><name><surname>dos Santos</surname><given-names>M.C.</given-names></name><name><surname>Ribeiro-Rodrigues</surname><given-names>E.M.</given-names></name><name><surname>de Mello</surname><given-names>W.A.</given-names></name><name><surname>Sousa</surname><given-names>R.C.M.</given-names></name><name><surname>dos Santos</surname><given-names>S.E.</given-names></name><name><surname>Sortica</surname><given-names>V.A.</given-names></name></person-group><article-title>The <italic>CCR5&#x00394;32</italic> (rs333) polymorphism is not a predisposing factor for severe pandemic influenza in the Brazilian admixed population</article-title><source>BMC Res. Notes</source><volume>8</volume><year>2015</year><fpage>326</fpage><pub-id pub-id-type="doi">10.1186/s13104-015-1299-1</pub-id><pub-id pub-id-type="pmid">26223981</pub-id></element-citation></ref><ref id="bib0965"><element-citation publication-type="journal" id="sbref0965"><person-group person-group-type="author"><name><surname>Malvoisin</surname><given-names>E.</given-names></name><name><surname>Livrozet</surname><given-names>J.M.</given-names></name><name><surname>Makloufi</surname><given-names>D.</given-names></name><name><surname>Vincent</surname><given-names>N.</given-names></name></person-group><article-title>Soluble chemokine receptor CXCR4 is present in human sera</article-title><source>Anal. Biochem.</source><volume>414</volume><year>2011</year><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2011.03.022</pub-id><pub-id pub-id-type="pmid">21440527</pub-id></element-citation></ref><ref id="bib0970"><element-citation publication-type="journal" id="sbref0970"><person-group person-group-type="author"><name><surname>Mangia</surname><given-names>A.</given-names></name><name><surname>Santoro</surname><given-names>R.</given-names></name><name><surname>D&#x02019;agruma</surname><given-names>L.</given-names></name><name><surname>Andriulli</surname><given-names>A.</given-names></name></person-group><article-title>HCV chronic infection and CCR5-&#x00394;32/&#x00394;32</article-title><source>Gastroenterology</source><volume>124</volume><year>2003</year><fpage>868</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1053/gast.2003.50134</pub-id><pub-id pub-id-type="pmid">12612938</pub-id></element-citation></ref><ref id="bib0975"><element-citation publication-type="journal" id="sbref0975"><person-group person-group-type="author"><name><surname>Mangieri</surname><given-names>L.F.L.</given-names></name><name><surname>Sena</surname><given-names>M.M.</given-names></name><name><surname>Cezar-Dos-Santos</surname><given-names>F.</given-names></name><name><surname>Trugilo</surname><given-names>K.P.</given-names></name><name><surname>Okuyama</surname><given-names>N.C.M.</given-names></name><name><surname>Pereira</surname><given-names>&#x000c9;R.</given-names></name><name><surname>Maria</surname><given-names>G.C.Q.</given-names></name><name><surname>Watanabe</surname><given-names>M.A.E.</given-names></name><name><surname>de Oliveira</surname><given-names>K.B.</given-names></name></person-group><article-title><italic>CCR5</italic> genetic variants and epidemiological determinants for HPV infection and cervical premalignant lesions</article-title><source>Int. J. Immunogenet.</source><volume>46</volume><year>2019</year><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1111/iji.12444</pub-id><pub-id pub-id-type="pmid">31183980</pub-id></element-citation></ref><ref id="bib0980"><element-citation publication-type="journal" id="sbref0980"><person-group person-group-type="author"><name><surname>Markoti&#x00107;</surname><given-names>A.</given-names></name><name><surname>Hensley</surname><given-names>L.</given-names></name><name><surname>Daddario</surname><given-names>K.</given-names></name><name><surname>Spik</surname><given-names>K.</given-names></name><name><surname>Anderson</surname><given-names>K.</given-names></name><name><surname>Schmaljohn</surname><given-names>C.</given-names></name></person-group><article-title>Pathogenic hantaviruses elicit different immunoreactions in THP-1 cells and primary monocytes and induce differentiation of human monocytes to dendritic-like cells</article-title><source>Coll. Antropol.</source><volume>31</volume><year>2007</year><fpage>1159</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">18217475</pub-id></element-citation></ref><ref id="bib0985"><element-citation publication-type="journal" id="sbref0985"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>R.E.</given-names></name><name><surname>Guabiraba</surname><given-names>R.</given-names></name><name><surname>Del Sarto</surname><given-names>J.L.</given-names></name><name><surname>Rocha</surname><given-names>R.F.</given-names></name><name><surname>Queiroz</surname><given-names>A.L.</given-names></name><name><surname>Cisalpino</surname><given-names>D.</given-names></name><name><surname>Marques</surname><given-names>P.E.</given-names></name><name><surname>Pacca</surname><given-names>C.C.</given-names></name><name><surname>Fagundes</surname><given-names>C.T.</given-names></name><name><surname>Menezes</surname><given-names>G.B.</given-names></name><name><surname>Nogueira</surname><given-names>M.L.</given-names></name><name><surname>Souza</surname><given-names>D.G.</given-names></name><name><surname>Teixeira</surname><given-names>M.M.</given-names></name></person-group><article-title>Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development</article-title><source>Immunology</source><volume>145</volume><year>2015</year><fpage>583</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1111/imm.12476</pub-id><pub-id pub-id-type="pmid">25939314</pub-id></element-citation></ref><ref id="bib0990"><element-citation publication-type="journal" id="sbref0990"><person-group person-group-type="author"><name><surname>Martin-Blondel</surname><given-names>G.</given-names></name><name><surname>Brassat</surname><given-names>D.</given-names></name><name><surname>Bauer</surname><given-names>J.</given-names></name><name><surname>Lassmann</surname><given-names>H.</given-names></name><name><surname>Liblau</surname><given-names>R.S.</given-names></name></person-group><article-title>CCR5 blockade for neuroinflammatory diseases-beyond control of HIV</article-title><source>Nat. Rev. Neurol.</source><volume>12</volume><year>2016</year><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2015.248</pub-id><pub-id pub-id-type="pmid">26782333</pub-id></element-citation></ref><ref id="bib0995"><element-citation publication-type="journal" id="sbref0995"><person-group person-group-type="author"><name><surname>Mascheretti</surname><given-names>S.</given-names></name><name><surname>Hinrichsen</surname><given-names>H.</given-names></name><name><surname>Ross</surname><given-names>S.</given-names></name><name><surname>Buggisch</surname><given-names>P.</given-names></name><name><surname>Hampe</surname><given-names>J.</given-names></name><name><surname>Foelsch</surname><given-names>U.R.</given-names></name><name><surname>Schreiber</surname><given-names>S.</given-names></name></person-group><article-title>Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients</article-title><source>Clin. Exp. Immunol.</source><volume>136</volume><year>2004</year><fpage>328</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2004.02444.x</pub-id><pub-id pub-id-type="pmid">15086398</pub-id></element-citation></ref><ref id="bib1000"><element-citation publication-type="journal" id="sbref1000"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>A.R.</given-names></name><name><surname>Martins</surname><given-names>J.S.C.C.</given-names></name><name><surname>Oliveira</surname><given-names>M.L.A.</given-names></name><name><surname>Garcia</surname><given-names>C.C.</given-names></name><name><surname>Siqueira</surname><given-names>M.M.</given-names></name></person-group><article-title>Human CCR5&#x00394;32 (rs333) polymorphism has no influence on severity and mortality of influenza A(H1N1)pdm09 infection in Brazilian patients from the post pandemic period</article-title><source>Infect. Genet. Evol.</source><volume>67</volume><year>2019</year><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2018.10.024</pub-id><pub-id pub-id-type="pmid">30389547</pub-id></element-citation></ref><ref id="bib1005"><element-citation publication-type="journal" id="sbref1005"><person-group person-group-type="author"><name><surname>Matsukura</surname><given-names>S.</given-names></name><name><surname>Kokubu</surname><given-names>F.</given-names></name><name><surname>Kubo</surname><given-names>H.</given-names></name><name><surname>Tomita</surname><given-names>T.</given-names></name><name><surname>Tokunaga</surname><given-names>H.</given-names></name><name><surname>Kadokura</surname><given-names>M.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Kuroiwa</surname><given-names>Y.</given-names></name><name><surname>Ohno</surname><given-names>T.</given-names></name><name><surname>Suzaki</surname><given-names>H.</given-names></name><name><surname>Adachi</surname><given-names>M.</given-names></name></person-group><article-title>Expression of RANTES by normal airway epithelial cells after influenza virus A infection</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><volume>18</volume><year>1998</year><fpage>255</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1165/ajrcmb.18.2.2822</pub-id><pub-id pub-id-type="pmid">9476913</pub-id></element-citation></ref><ref id="bib1010"><element-citation publication-type="journal" id="sbref1010"><person-group person-group-type="author"><name><surname>Mehlotra</surname><given-names>R.K.</given-names></name></person-group><article-title>CCR5 promoter polymorphism -2459G &#x00026; A: forgotten or ignored?</article-title><source>Cells</source><volume>8</volume><year>2019</year><fpage>651</fpage><pub-id pub-id-type="doi">10.3390/cells8070651</pub-id></element-citation></ref><ref id="bib1015"><element-citation publication-type="journal" id="sbref1015"><person-group person-group-type="author"><name><surname>Michlmayr</surname><given-names>D.</given-names></name><name><surname>Lim</surname><given-names>J.K.</given-names></name></person-group><article-title>Chemokine receptors as important regulators of pathogenesis during arboviral encephalitis</article-title><source>Front. Cell. Neurosci.</source><volume>8</volume><year>2014</year><fpage>264</fpage><pub-id pub-id-type="doi">10.3389/fncel.2014.00264</pub-id><pub-id pub-id-type="pmid">25324719</pub-id></element-citation></ref><ref id="bib1020"><element-citation publication-type="journal" id="sbref1020"><person-group person-group-type="author"><name><surname>Mirzabekov</surname><given-names>T.</given-names></name><name><surname>Bannert</surname><given-names>N.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name><name><surname>Hofmann</surname><given-names>W.</given-names></name><name><surname>Kolchinsky</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Wyatt</surname><given-names>R.</given-names></name><name><surname>Sodroski</surname><given-names>J.</given-names></name></person-group><article-title>Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor</article-title><source>J. Biol. Chem.</source><volume>274</volume><year>1999</year><fpage>28745</fpage><lpage>28750</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.40.28745</pub-id><pub-id pub-id-type="pmid">10497246</pub-id></element-citation></ref><ref id="bib1025"><element-citation publication-type="journal" id="sbref1025"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>R.</given-names></name><name><surname>Lata</surname><given-names>S.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name><name><surname>Banerjea</surname><given-names>A.C.</given-names></name></person-group><article-title>Dengue haemorrhagic fever: a job done via exosomes?</article-title><source>Emerg. Microbes Infect.</source><volume>8</volume><year>2019</year><fpage>1626</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1080/22221751.2019.1685913</pub-id><pub-id pub-id-type="pmid">31711408</pub-id></element-citation></ref><ref id="bib1030"><element-citation publication-type="journal" id="sbref1030"><person-group person-group-type="author"><name><surname>Morard</surname><given-names>I.</given-names></name><name><surname>Cl&#x000e9;ment</surname><given-names>S.</given-names></name><name><surname>Calmy</surname><given-names>A.</given-names></name><name><surname>Mangia</surname><given-names>A.</given-names></name><name><surname>Cerny</surname><given-names>A.</given-names></name><name><surname>De Gottardi</surname><given-names>A.</given-names></name><name><surname>Gorgievski</surname><given-names>M.</given-names></name><name><surname>Heim</surname><given-names>M.</given-names></name><name><surname>Malinverni</surname><given-names>R.</given-names></name><name><surname>Moradpour</surname><given-names>D.</given-names></name><name><surname>M&#x000fc;llhaupt</surname><given-names>B.</given-names></name><name><surname>Semela</surname><given-names>D.</given-names></name><name><surname>Pascarella</surname><given-names>S.</given-names></name><name><surname>Bochud</surname><given-names>P.Y.</given-names></name><name><surname>Negro</surname><given-names>F.</given-names></name><name><surname>Swiss Hepatitis C Cohort Study Group</surname></name></person-group><article-title>Clinical significance of the CCR5delta32 allele in hepatitis C</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e106424</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0106424</pub-id></element-citation></ref><ref id="bib1035"><element-citation publication-type="journal" id="sbref1035"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>C.</given-names></name><name><surname>Gustot</surname><given-names>T.</given-names></name><name><surname>Nicaise</surname><given-names>C.</given-names></name><name><surname>Quertinmont</surname><given-names>E.</given-names></name><name><surname>Nagy</surname><given-names>N.</given-names></name><name><surname>Parmentier</surname><given-names>M.</given-names></name><name><surname>Le Moine</surname><given-names>O.</given-names></name><name><surname>Devi&#x000e8;re</surname><given-names>J.</given-names></name><name><surname>Louis</surname><given-names>H.</given-names></name></person-group><article-title>CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice</article-title><source>Hepatology</source><volume>42</volume><year>2005</year><fpage>854</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1002/hep.20865</pub-id><pub-id pub-id-type="pmid">16175603</pub-id></element-citation></ref><ref id="bib1040"><element-citation publication-type="journal" id="sbref1040"><person-group person-group-type="author"><name><surname>Moudi</surname><given-names>B.</given-names></name><name><surname>Heidari</surname><given-names>Z.</given-names></name><name><surname>Mahmoudzadeh-Sagheb</surname><given-names>H.</given-names></name></person-group><article-title>CCR5, MCP-1 and VDR gene polymorphisms are associated with the susceptibility to HBV infection</article-title><source>Indian J. Clin. Biochem.</source><volume>34</volume><year>2019</year><fpage>407</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1007/s12291-018-0772-8</pub-id><pub-id pub-id-type="pmid">31686727</pub-id></element-citation></ref><ref id="bib1045"><element-citation publication-type="journal" id="sbref1045"><person-group person-group-type="author"><name><surname>Muehling</surname><given-names>L.M.</given-names></name><name><surname>Turner</surname><given-names>R.B.</given-names></name><name><surname>Brown</surname><given-names>K.B.</given-names></name><name><surname>Wright</surname><given-names>P.W.</given-names></name><name><surname>Patrie</surname><given-names>J.T.</given-names></name><name><surname>Lahtinen</surname><given-names>S.J.</given-names></name><name><surname>Lehtinen</surname><given-names>M.J.</given-names></name><name><surname>Kwok</surname><given-names>W.W.</given-names></name><name><surname>Woodfolk</surname><given-names>J.A.</given-names></name></person-group><article-title>Single-cell tracking reveals a role for pre-existing CCR5<sup>+</sup> memory Th1 cells in the control of Rhinovirus-A39 after experimental challenge in humans</article-title><source>J. Infect. Dis.</source><volume>217</volume><year>2018</year><fpage>381</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix514</pub-id><pub-id pub-id-type="pmid">29309618</pub-id></element-citation></ref><ref id="bib1050"><element-citation publication-type="journal" id="sbref1050"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>A.</given-names></name><name><surname>Kelly</surname><given-names>E.</given-names></name><name><surname>Strange</surname><given-names>P.G.</given-names></name></person-group><article-title>Pathways for internalization and recycling of the chemokine receptor CCR5</article-title><source>Blood</source><volume>99</volume><year>2002</year><fpage>785</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1182/blood.v99.3.785</pub-id><pub-id pub-id-type="pmid">11806977</pub-id></element-citation></ref><ref id="bib1055"><element-citation publication-type="journal" id="sbref1055"><person-group person-group-type="author"><name><surname>Muntinghe</surname><given-names>F.L.H.</given-names></name><name><surname>Verduijn</surname><given-names>M.</given-names></name><name><surname>Zuurman</surname><given-names>M.W.</given-names></name><name><surname>Grootendorst</surname><given-names>D.C.</given-names></name><name><surname>Carrero</surname><given-names>J.J.</given-names></name><name><surname>Qureshi</surname><given-names>A.R.</given-names></name><name><surname>Luttropp</surname><given-names>K.</given-names></name><name><surname>Nordfors</surname><given-names>L.</given-names></name><name><surname>Lindholm</surname><given-names>B.</given-names></name><name><surname>Brandenburg</surname><given-names>V.</given-names></name><name><surname>Schalling</surname><given-names>M.</given-names></name><name><surname>Stenvinkel</surname><given-names>P.</given-names></name><name><surname>Boeschoten</surname><given-names>E.W.</given-names></name><name><surname>Krediet</surname><given-names>R.T.</given-names></name><name><surname>Navis</surname><given-names>G.</given-names></name><name><surname>Dekker</surname><given-names>F.W.</given-names></name></person-group><article-title>CCR5 deletion protects against inflammation-associated mortality in dialysis patients</article-title><source>J. Am. Soc. Nephrol.</source><volume>20</volume><year>2009</year><fpage>1641</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008040432</pub-id><pub-id pub-id-type="pmid">19389855</pub-id></element-citation></ref><ref id="bib1060"><element-citation publication-type="journal" id="sbref1060"><person-group person-group-type="author"><name><surname>Muntinghe</surname><given-names>F.L.</given-names></name><name><surname>Abdulahad</surname><given-names>W.H.</given-names></name><name><surname>Huitema</surname><given-names>M.G.</given-names></name><name><surname>Damman</surname><given-names>J.</given-names></name><name><surname>Seelen</surname><given-names>M.A.</given-names></name><name><surname>Lems</surname><given-names>S.P.</given-names></name><name><surname>Hepkema</surname><given-names>B.G.</given-names></name><name><surname>Navis</surname><given-names>G.</given-names></name><name><surname>Westra</surname><given-names>J.</given-names></name></person-group><article-title>CCR5&#x00394;32 genotype leads to a Th2 type directed immune response in ESRD patients</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e31257</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0031257</pub-id></element-citation></ref><ref id="bib1065"><element-citation publication-type="journal" id="sbref1065"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>B.R.</given-names></name><name><surname>Whitehead</surname><given-names>S.S.</given-names></name></person-group><article-title>Immune response to dengue virus and prospects for a vaccine</article-title><source>Annu. Rev. Immunol.</source><volume>29</volume><year>2011</year><fpage>587</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101315</pub-id><pub-id pub-id-type="pmid">21219187</pub-id></element-citation></ref><ref id="bib1070"><element-citation publication-type="journal" id="sbref1070"><person-group person-group-type="author"><name><surname>Mustonen</surname><given-names>J.</given-names></name><name><surname>M&#x000e4;kel&#x000e4;</surname><given-names>S.</given-names></name><name><surname>Outinen</surname><given-names>T.</given-names></name><name><surname>Laine</surname><given-names>O.</given-names></name><name><surname>Jylh&#x000e4;v&#x000e4;</surname><given-names>J.</given-names></name><name><surname>Arstila</surname><given-names>P.T.</given-names></name><name><surname>Hurme</surname><given-names>M.</given-names></name><name><surname>Vaheri</surname><given-names>A.</given-names></name></person-group><article-title>The pathogenesis of nephropathia epidemica: new knowledge and unanswered questions</article-title><source>Antiviral Res.</source><volume>100</volume><year>2013</year><fpage>589</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.10.001</pub-id><pub-id pub-id-type="pmid">24126075</pub-id></element-citation></ref><ref id="bib1075"><element-citation publication-type="journal" id="sbref1075"><person-group person-group-type="author"><name><surname>Nattermann</surname><given-names>J.</given-names></name><name><surname>Timm</surname><given-names>J.</given-names></name><name><surname>Nischalke</surname><given-names>H.D.</given-names></name><name><surname>Olbrich</surname><given-names>A.</given-names></name><name><surname>Michalk</surname><given-names>M.</given-names></name><name><surname>Tillmann</surname><given-names>H.L.</given-names></name><name><surname>Berg</surname><given-names>T.</given-names></name><name><surname>Wedemeyer</surname><given-names>H.</given-names></name><name><surname>Tenckhoff</surname><given-names>H.</given-names></name><name><surname>Wiese</surname><given-names>M.</given-names></name><name><surname>Kullig</surname><given-names>U.</given-names></name><name><surname>G&#x000f6;bel</surname><given-names>U.</given-names></name><name><surname>Capka</surname><given-names>E.</given-names></name><name><surname>Schiefke</surname><given-names>I.</given-names></name><name><surname>G&#x000fc;thof</surname><given-names>W.</given-names></name><name><surname>Gr&#x000fc;ngreiff</surname><given-names>K.</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>I.</given-names></name><name><surname>Roggendorf</surname><given-names>M.</given-names></name><name><surname>Sauerbruch</surname><given-names>T.</given-names></name><name><surname>Spengler</surname><given-names>U.</given-names></name><name><surname>East German HCV Study Group</surname></name></person-group><article-title>The predictive value of <italic>IL28B</italic> gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the <italic>CCR5&#x00394;32</italic> mutation</article-title><source>J. Hepatol.</source><volume>55</volume><year>2011</year><fpage>1201</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.03.011</pub-id><pub-id pub-id-type="pmid">21703201</pub-id></element-citation></ref><ref id="bib1080"><element-citation publication-type="journal" id="sbref1080"><person-group person-group-type="author"><name><surname>Naveca</surname><given-names>F.G.</given-names></name><name><surname>Pontes</surname><given-names>G.S.</given-names></name><name><surname>Chang</surname><given-names>A.Y.</given-names></name><name><surname>da Silva</surname><given-names>G.A.V.</given-names></name><name><surname>do Nascimento</surname><given-names>V.A.</given-names></name></person-group><article-title>Analysis of the immunological biomarker profile during acute Zika virus infection reveals the overexpression of CXCL10, a chemokine linked to neuronal damage</article-title><source>Mem. Inst. Oswaldo Cruz</source><volume>113</volume><year>2018</year><object-id pub-id-type="publisher-id">e170542</object-id><pub-id pub-id-type="doi">10.1590/0074-02760170542</pub-id></element-citation></ref><ref id="bib1085"><element-citation publication-type="journal" id="sbref1085"><person-group person-group-type="author"><name><surname>Nayak</surname><given-names>S.U.</given-names></name><name><surname>Cicalese</surname><given-names>S.</given-names></name><name><surname>Tallarida</surname><given-names>C.</given-names></name><name><surname>Oliver</surname><given-names>C.F.</given-names></name><name><surname>Rawls</surname><given-names>S.M.</given-names></name></person-group><article-title>Chemokine CCR5 and cocaine interactions in the brain: cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist</article-title><source>Brain Behav. Immun.</source><volume>83</volume><year>2020</year><fpage>288</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2019.09.017</pub-id><pub-id pub-id-type="pmid">31557508</pub-id></element-citation></ref><ref id="bib1090"><element-citation publication-type="journal" id="sbref1090"><person-group person-group-type="author"><name><surname>Ndung&#x02019;u</surname><given-names>T.</given-names></name><name><surname>McCune</surname><given-names>J.M.</given-names></name><name><surname>Deeks</surname><given-names>S.G.</given-names></name></person-group><article-title>Why and where an HIV cure is needed and how it might be achieved</article-title><source>Nature</source><volume>576</volume><year>2019</year><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1841-8</pub-id><pub-id pub-id-type="pmid">31853080</pub-id></element-citation></ref><ref id="bib1095"><element-citation publication-type="journal" id="sbref1095"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>H.C.</given-names></name><name><surname>Quah</surname><given-names>B.J.C.</given-names></name></person-group><article-title>Exosomes secreted by bacterially infected macrophages are proinflammatory</article-title><source>Sci. Signal.</source><volume>1</volume><year>2008</year><fpage>pe8</fpage><pub-id pub-id-type="doi">10.1126/stke.16pe8</pub-id><pub-id pub-id-type="pmid">18272468</pub-id></element-citation></ref><ref id="bib1100"><element-citation publication-type="journal" id="sbref1100"><person-group person-group-type="author"><name><surname>Omran</surname><given-names>M.H.</given-names></name><name><surname>Khamis</surname><given-names>M.</given-names></name><name><surname>Nasr</surname><given-names>N.</given-names></name><name><surname>Massoud</surname><given-names>A.A.</given-names></name><name><surname>Youssef</surname><given-names>S.S.</given-names></name><name><surname>Bader El Din</surname><given-names>N.G.</given-names></name><name><surname>Dawood</surname><given-names>R.M.</given-names></name><name><surname>Atef</surname><given-names>K.</given-names></name><name><surname>Moustafa</surname><given-names>R.I.</given-names></name><name><surname>Nabil</surname><given-names>W.</given-names></name><name><surname>Tabll</surname><given-names>A.A.</given-names></name><name><surname>El Awady</surname><given-names>M.K.</given-names></name></person-group><article-title>A study of CC-Chemokine Receptor 5 (CCR5) polymorphism on the outcome of HCV therapy in Egyptian patients</article-title><source>Hepat. Mon.</source><volume>13</volume><year>2013</year><object-id pub-id-type="publisher-id">e13721</object-id><pub-id pub-id-type="doi">10.5812/hepatmon.13721</pub-id></element-citation></ref><ref id="bib1105"><element-citation publication-type="journal" id="sbref1105"><person-group person-group-type="author"><name><surname>Ornelas</surname><given-names>A.M.M.</given-names></name><name><surname>Xavier-de-Carvalho</surname><given-names>C.</given-names></name><name><surname>Alvarado-Arnez</surname><given-names>L.E.</given-names></name><name><surname>Ribeiro-Alves</surname><given-names>M.</given-names></name><name><surname>Rossi</surname><given-names>&#x000c1;D.</given-names></name><name><surname>Tanuri</surname><given-names>A.</given-names></name><name><surname>de Aguiar</surname><given-names>R.S.</given-names></name><name><surname>Moraes</surname><given-names>M.O.</given-names></name><name><surname>Cardoso</surname><given-names>C.C.</given-names></name></person-group><article-title>Association between <italic>MBL2</italic> haplotypes and dengue severity in children from Rio de Janeiro, Brazil</article-title><source>Mem. Inst. Oswaldo Cruz</source><volume>114</volume><year>2019</year><object-id pub-id-type="publisher-id">e190004</object-id><pub-id pub-id-type="doi">10.1590/0074-02760190004</pub-id></element-citation></ref><ref id="bib1110"><element-citation publication-type="journal" id="sbref1110"><person-group person-group-type="author"><name><surname>Oslund</surname><given-names>K.L.</given-names></name><name><surname>Baumgarth</surname><given-names>N.</given-names></name></person-group><article-title>Influenza-induced innate immunity: regulators of viral replication, respiratory tract pathology &#x00026; adaptive immunity</article-title><source>Future Virol.</source><volume>6</volume><year>2011</year><fpage>951</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.2217/fvl.11.63</pub-id><pub-id pub-id-type="pmid">21909336</pub-id></element-citation></ref><ref id="bib1115"><element-citation publication-type="journal" id="sbref1115"><person-group person-group-type="author"><name><surname>Pareek</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>S.</given-names></name><name><surname>Kumari</surname><given-names>B.</given-names></name><name><surname>Jain</surname><given-names>P.</given-names></name><name><surname>Banerjee</surname><given-names>A.</given-names></name><name><surname>Vrati</surname><given-names>S.</given-names></name></person-group><article-title>MiR-155 induction in microglial cells suppresses Japanese encephalitis virus replication and negatively modulates innate immune responses</article-title><source>J. Neuroinflammation</source><volume>2014</volume><issue>11</issue><year>2014</year><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-11-97</pub-id></element-citation></ref><ref id="bib1120"><element-citation publication-type="journal" id="sbref1120"><person-group person-group-type="author"><name><surname>Parmentier</surname><given-names>M.</given-names></name></person-group><article-title>CCR5 and HIV infection, a view from Brussels</article-title><source>Front. Immunol.</source><volume>6</volume><year>2015</year><fpage>295</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00295</pub-id><pub-id pub-id-type="pmid">26106394</pub-id></element-citation></ref><ref id="bib1125"><element-citation publication-type="journal" id="sbref1125"><person-group person-group-type="author"><name><surname>Pauvolid-Corr&#x000ea;a</surname><given-names>A.</given-names></name><name><surname>Campos</surname><given-names>Z.</given-names></name><name><surname>Juliano</surname><given-names>R.</given-names></name><name><surname>Velez</surname><given-names>J.</given-names></name><name><surname>Nogueira</surname><given-names>R.M.R.</given-names></name><name><surname>Komar</surname><given-names>N.</given-names></name></person-group><article-title>Serological evidence of widespread circulation of West Nile virus and other flaviviruses in equines of the Pantanal</article-title><source>Brazil. PLoS Negl Trop Dis</source><volume>8</volume><year>2014</year><fpage>e2706</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0002706</pub-id><pub-id pub-id-type="pmid">24551266</pub-id></element-citation></ref><ref id="bib1130"><element-citation publication-type="journal" id="sbref1130"><person-group person-group-type="author"><name><surname>Pena</surname><given-names>S.D.J.</given-names></name><name><surname>Di Pietro</surname><given-names>G.</given-names></name><name><surname>Fuchshuber-Moraes</surname><given-names>M.</given-names></name><name><surname>Genro</surname><given-names>J.P.</given-names></name><name><surname>Hutz</surname><given-names>M.H.</given-names></name></person-group><article-title>The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><object-id pub-id-type="publisher-id">e17063</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017063</pub-id></element-citation></ref><ref id="bib1135"><element-citation publication-type="journal" id="sbref1135"><person-group person-group-type="author"><name><surname>Pervaiz</surname><given-names>A.</given-names></name><name><surname>Zepp</surname><given-names>M.</given-names></name><name><surname>Mahmood</surname><given-names>S.</given-names></name><name><surname>Ali</surname><given-names>D.M.</given-names></name><name><surname>Berger</surname><given-names>M.R.</given-names></name><name><surname>Adwan</surname><given-names>H.</given-names></name></person-group><article-title>CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer</article-title><source>Cell. Oncol. Dordr. (Dordr)</source><volume>42</volume><year>2019</year><fpage>93</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1007/s13402-018-0415-3</pub-id></element-citation></ref><ref id="bib1140"><element-citation publication-type="journal" id="sbref1140"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>L.R.</given-names></name><name><surname>Brault</surname><given-names>A.C.</given-names></name><name><surname>Nasci</surname><given-names>R.S.</given-names></name></person-group><article-title>West Nile virus: review of the literature</article-title><source>JAMA</source><volume>310</volume><year>2013</year><fpage>308</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.8042</pub-id><pub-id pub-id-type="pmid">23860989</pub-id></element-citation></ref><ref id="bib1145"><element-citation publication-type="journal" id="sbref1145"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>V.N.</given-names></name><name><surname>Russell</surname><given-names>C.A.</given-names></name></person-group><article-title>The evolution of seasonal influenza viruses</article-title><source>Nat. Rev. Microbiol.</source><volume>16</volume><year>2018</year><fpage>60</fpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.146</pub-id><pub-id pub-id-type="pmid">29109554</pub-id></element-citation></ref><ref id="bib1150"><element-citation publication-type="journal" id="sbref1150"><person-group person-group-type="author"><name><surname>Picton</surname><given-names>A.C.P.</given-names></name><name><surname>Shalekoff</surname><given-names>S.</given-names></name><name><surname>Paximadis</surname><given-names>M.</given-names></name><name><surname>Tiemessen</surname><given-names>C.T.</given-names></name></person-group><article-title>Marked differences in CCR5 expression and activation levels in two South African populations</article-title><source>Immunology</source><volume>136</volume><year>2012</year><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2012.03592.x</pub-id><pub-id pub-id-type="pmid">22509959</pub-id></element-citation></ref><ref id="bib1155"><element-citation publication-type="journal" id="sbref1155"><person-group person-group-type="author"><name><surname>Pietschmann</surname><given-names>T.</given-names></name><name><surname>Brown</surname><given-names>R.J.P.</given-names></name></person-group><article-title>Hepatitis C virus</article-title><source>Trends Microbiol.</source><volume>27</volume><year>2019</year><fpage>379</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2019.01.001</pub-id><pub-id pub-id-type="pmid">30709707</pub-id></element-citation></ref><ref id="bib1160"><element-citation publication-type="journal" id="sbref1160"><person-group person-group-type="author"><name><surname>Piovan</surname><given-names>E.</given-names></name><name><surname>Tosello</surname><given-names>V.</given-names></name><name><surname>Indraccolo</surname><given-names>S.</given-names></name><name><surname>Cabrelle</surname><given-names>A.</given-names></name><name><surname>Baesso</surname><given-names>I.</given-names></name><name><surname>Trentin</surname><given-names>L.</given-names></name><name><surname>Zamarchi</surname><given-names>R.</given-names></name><name><surname>Tamamura</surname><given-names>H.</given-names></name><name><surname>Fujii</surname><given-names>N.</given-names></name><name><surname>Semenzato</surname><given-names>G.</given-names></name><name><surname>Chieco-Bianchi</surname><given-names>L.</given-names></name><name><surname>Amadori</surname><given-names>A.</given-names></name></person-group><article-title>Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation</article-title><source>Blood</source><volume>105</volume><year>2005</year><fpage>931</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-03-0799</pub-id><pub-id pub-id-type="pmid">15454484</pub-id></element-citation></ref><ref id="bib1165"><element-citation publication-type="journal" id="sbref1165"><person-group person-group-type="author"><name><surname>Pirozyan</surname><given-names>M.R.</given-names></name><name><surname>Nguyen</surname><given-names>N.</given-names></name><name><surname>Cameron</surname><given-names>B.</given-names></name><name><surname>Luciani</surname><given-names>F.</given-names></name><name><surname>Bull</surname><given-names>R.A.</given-names></name><name><surname>Zekry</surname><given-names>A.</given-names></name><name><surname>Lloyd</surname><given-names>A.R.</given-names></name></person-group><article-title>Chemokine-regulated recruitment of antigen-specific T-cell subpopulations to the liver in acute and chronic hepatitis C infection</article-title><source>J. Infect. Dis.</source><volume>219</volume><year>2019</year><fpage>1430</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy679</pub-id><pub-id pub-id-type="pmid">30496498</pub-id></element-citation></ref><ref id="bib1170"><element-citation publication-type="journal" id="sbref1170"><person-group person-group-type="author"><name><surname>Poljak</surname><given-names>M.</given-names></name><name><surname>Seme</surname><given-names>K.</given-names></name><name><surname>Marin</surname><given-names>I.J.</given-names></name><name><surname>Babi&#x0010d;</surname><given-names>D.Z.</given-names></name><name><surname>Mat&#x0010d;i&#x0010d;</surname><given-names>M.</given-names></name><name><surname>Megli&#x0010d;</surname><given-names>J.</given-names></name></person-group><article-title>Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increased in hepatitis C patients</article-title><source>Gastroenterology</source><volume>124</volume><year>2003</year><fpage>1558</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.1016/s0016-5085(03)00349-4</pub-id></element-citation></ref><ref id="bib1175"><element-citation publication-type="journal" id="sbref1175"><person-group person-group-type="author"><name><surname>Promrat</surname><given-names>K.</given-names></name><name><surname>McDermott</surname><given-names>D.H.</given-names></name><name><surname>Gonzalez</surname><given-names>C.M.</given-names></name><name><surname>Kleiner</surname><given-names>D.E.</given-names></name><name><surname>Koziol</surname><given-names>D.E.</given-names></name><name><surname>Lessie</surname><given-names>M.</given-names></name><name><surname>Merrell</surname><given-names>M.</given-names></name><name><surname>Soza</surname><given-names>A.</given-names></name><name><surname>Heller</surname><given-names>T.</given-names></name><name><surname>Ghany</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Alter</surname><given-names>H.J.</given-names></name><name><surname>Hoofnagle</surname><given-names>J.H.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name><name><surname>Liang</surname><given-names>T.J.</given-names></name></person-group><article-title>Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C</article-title><source>Gastroenterology</source><volume>124</volume><year>2003</year><fpage>352</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1053/gast.2003.50061</pub-id><pub-id pub-id-type="pmid">12557141</pub-id></element-citation></ref><ref id="bib1180"><element-citation publication-type="journal" id="sbref1180"><person-group person-group-type="author"><name><surname>Proudfoot</surname><given-names>A.E.</given-names></name></person-group><article-title>Chemokine receptors: multifaceted therapeutic targets</article-title><source>Nat. Rev. Immunol.</source><volume>2</volume><year>2002</year><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/nri722</pub-id><pub-id pub-id-type="pmid">11910892</pub-id></element-citation></ref><ref id="bib1185"><element-citation publication-type="journal" id="sbref1185"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>K.</given-names></name><name><surname>Shang</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Tian</surname><given-names>D.S.</given-names></name></person-group><article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa248</pub-id><comment>in press</comment></element-citation></ref><ref id="bib1190"><element-citation publication-type="journal" id="sbref1190"><person-group person-group-type="author"><name><surname>Racaniello</surname><given-names>V.R.</given-names></name></person-group><article-title>One hundred years of poliovirus pathogenesis</article-title><source>Virology</source><volume>344</volume><year>2006</year><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.09.015</pub-id><pub-id pub-id-type="pmid">16364730</pub-id></element-citation></ref><ref id="bib1195"><element-citation publication-type="journal" id="sbref1195"><person-group person-group-type="author"><name><surname>Rajan</surname><given-names>D.</given-names></name><name><surname>McCracken</surname><given-names>C.E.</given-names></name><name><surname>Kopleman</surname><given-names>H.B.</given-names></name><name><surname>Kyu</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>F.E.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Anderson</surname><given-names>L.J.</given-names></name></person-group><article-title>Human rhinovirus induced cytokine/chemokine responses in human airway epithelial and immune cells</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e114322</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0114322</pub-id></element-citation></ref><ref id="bib1200"><element-citation publication-type="journal" id="sbref1200"><person-group person-group-type="author"><name><surname>Rautenbach</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>A.A.</given-names></name></person-group><article-title>Metabolomics as an approach to characterise the contrasting roles of CCR5 in the presence and absence of disease</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><year>2020</year><fpage>1472</fpage><pub-id pub-id-type="doi">10.3390/ijms21041472</pub-id></element-citation></ref><ref id="bib1205"><element-citation publication-type="journal" id="sbref1205"><person-group person-group-type="author"><name><surname>Renovato-Martins</surname><given-names>M.</given-names></name><name><surname>Matheus</surname><given-names>M.E.</given-names></name><name><surname>de Andrade</surname><given-names>I.R.</given-names></name><name><surname>Moraes</surname><given-names>J.A.</given-names></name><name><surname>da Silva</surname><given-names>S.V.</given-names></name><name><surname>Citelli Dos Reis</surname><given-names>M.</given-names></name><name><surname>de Souza</surname><given-names>A.A.P.</given-names></name><name><surname>da Silva</surname><given-names>C.C.</given-names></name><name><surname>Bouskela</surname><given-names>E.</given-names></name><name><surname>Barja-Fidalgo</surname><given-names>C.</given-names></name></person-group><article-title>Microparticles derived from obese adipose tissue elicit a pro-inflammatory phenotype of CD16<sup>+</sup>, CCR5<sup>+</sup> and TLR8<sup>+</sup> monocytes</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><volume>1863</volume><year>2017</year><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2016.09.016</pub-id><pub-id pub-id-type="pmid">27677832</pub-id></element-citation></ref><ref id="bib1210"><element-citation publication-type="journal" id="sbref1210"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>A.</given-names></name><name><surname>Falcon</surname><given-names>A.</given-names></name><name><surname>Cuevas</surname><given-names>M.T.</given-names></name><name><surname>Pozo</surname><given-names>F.</given-names></name><name><surname>Guerra</surname><given-names>S.</given-names></name><name><surname>Garc&#x000ed;a-Barreno</surname><given-names>B.</given-names></name><name><surname>Martinez-Orellana</surname><given-names>P.</given-names></name><name><surname>P&#x000e9;rez-Bre&#x000f1;a</surname><given-names>P.</given-names></name><name><surname>Montoya</surname><given-names>M.</given-names></name><name><surname>Melero</surname><given-names>J.A.</given-names></name><name><surname>Pizarro</surname><given-names>M.</given-names></name><name><surname>Ortin</surname><given-names>J.</given-names></name><name><surname>Casas</surname><given-names>I.</given-names></name><name><surname>Nieto</surname><given-names>A.</given-names></name></person-group><article-title>Characterization <italic>in vitro</italic> and <italic>in vivo</italic> of a pandemic H1N1 influenza virus from a fatal case</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e53515</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0053515</pub-id></element-citation></ref><ref id="bib1215"><element-citation publication-type="journal" id="sbref1215"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>C.</given-names></name><name><surname>Cuomo</surname><given-names>G.</given-names></name><name><surname>Ferrara</surname><given-names>R.</given-names></name><name><surname>Del Mastro</surname><given-names>A.</given-names></name><name><surname>Esposito</surname><given-names>S.</given-names></name><name><surname>Sellitto</surname><given-names>A.</given-names></name><name><surname>Adinolfi</surname><given-names>L.E.</given-names></name></person-group><article-title>Uncommon immune-mediated extrahepatic manifestations of HCV infection</article-title><source>Expert Rev. Clin. Immunol.</source><volume>14</volume><year>2018</year><fpage>1089</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1080/1744666X.2018.1538790</pub-id><pub-id pub-id-type="pmid">30338718</pub-id></element-citation></ref><ref id="bib1220"><element-citation publication-type="journal" id="sbref1220"><person-group person-group-type="author"><name><surname>Rosenbaum</surname><given-names>L.</given-names></name></person-group><article-title>The future of gene editing - toward scientific and social consensus</article-title><source>N. Engl. J. Med.</source><volume>380</volume><year>2019</year><fpage>971</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1056/NEJMms1817082</pub-id><pub-id pub-id-type="pmid">30649992</pub-id></element-citation></ref><ref id="bib1225"><element-citation publication-type="journal" id="sbref1225"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>A.S.</given-names></name><name><surname>Roivainen</surname><given-names>M.</given-names></name><name><surname>Hovi</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>CCR5 deficiency and severe polio infection in the 1984 outbreak in Finland</article-title><source>J. Med. Virol.</source><volume>85</volume><year>2013</year><fpage>2139</fpage><lpage>2140</lpage><pub-id pub-id-type="doi">10.1002/jmv.23739</pub-id><pub-id pub-id-type="pmid">24037958</pub-id></element-citation></ref><ref id="bib1230"><element-citation publication-type="journal" id="sbref1230"><person-group person-group-type="author"><name><surname>Rozmyslowicz</surname><given-names>T.</given-names></name><name><surname>Majka</surname><given-names>M.</given-names></name><name><surname>Kijowski</surname><given-names>J.</given-names></name><name><surname>Murphy</surname><given-names>S.L.</given-names></name><name><surname>Conover</surname><given-names>D.O.</given-names></name><name><surname>Poncz</surname><given-names>M.</given-names></name><name><surname>Ratajczak</surname><given-names>J.</given-names></name><name><surname>Gaulton</surname><given-names>G.N.</given-names></name><name><surname>Ratajczak</surname><given-names>M.Z.</given-names></name></person-group><article-title>Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV</article-title><source>AIDS</source><volume>17</volume><year>2003</year><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1097/00002030-200301030-00006</pub-id><pub-id pub-id-type="pmid">12478067</pub-id></element-citation></ref><ref id="bib1235"><element-citation publication-type="journal" id="sbref1235"><person-group person-group-type="author"><name><surname>Rudd</surname><given-names>J.M.</given-names></name><name><surname>Pulavendran</surname><given-names>S.</given-names></name><name><surname>Ashar</surname><given-names>H.K.</given-names></name><name><surname>Ritchey</surname><given-names>J.W.</given-names></name><name><surname>Snider</surname><given-names>T.A.</given-names></name><name><surname>Malayer</surname><given-names>J.R.</given-names></name><name><surname>Marie</surname><given-names>M.</given-names></name><name><surname>Chow</surname><given-names>V.T.K.</given-names></name><name><surname>Narasaraju</surname><given-names>T.</given-names></name></person-group><article-title>Neutrophils induce a novel chemokine receptors repertoire during Influenza pneumonia</article-title><source>Front. Cell. Infect. Microbiol.</source><volume>9</volume><year>2019</year><fpage>108</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2019.00108</pub-id><pub-id pub-id-type="pmid">31041196</pub-id></element-citation></ref><ref id="bib1240"><element-citation publication-type="journal" id="sbref1240"><person-group person-group-type="author"><name><surname>Ruiz-Ferrer</surname><given-names>M.</given-names></name><name><surname>Barroso</surname><given-names>N.</given-names></name><name><surname>Anti&#x000f1;olo</surname><given-names>G.</given-names></name><name><surname>Aguilar-Reina</surname><given-names>J.</given-names></name></person-group><article-title>Analysis of <italic>CCR5</italic>-&#x00394;32 and <italic>CCR2</italic>-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies</article-title><source>J. Viral Hepat.</source><volume>11</volume><year>2004</year><fpage>319</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2004.00510.x</pub-id><pub-id pub-id-type="pmid">15230854</pub-id></element-citation></ref><ref id="bib1245"><element-citation publication-type="journal" id="sbref1245"><person-group person-group-type="author"><name><surname>Rustemoglu</surname><given-names>A.</given-names></name><name><surname>Ekinci</surname><given-names>D.</given-names></name><name><surname>Nursal</surname><given-names>A.F.</given-names></name><name><surname>Barut</surname><given-names>S.</given-names></name><name><surname>Duygu</surname><given-names>F.</given-names></name><name><surname>G&#x000fc;nal</surname><given-names>&#x000d6;.</given-names></name></person-group><article-title>The possible role of CCR5&#x00394;32 mutation in Crimean-Congo hemorrhagic fever infection</article-title><source>J. Med. Virol.</source><volume>89</volume><year>2017</year><fpage>1714</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1002/jmv.24865</pub-id><pub-id pub-id-type="pmid">28547880</pub-id></element-citation></ref><ref id="bib1250"><element-citation publication-type="journal" id="sbref1250"><person-group person-group-type="author"><name><surname>Safari</surname><given-names>H.</given-names></name><name><surname>Sarab</surname><given-names>G.A.</given-names></name><name><surname>Fereidouni</surname><given-names>M.</given-names></name><name><surname>Ziaee</surname><given-names>M.</given-names></name><name><surname>Mahavar</surname><given-names>N.</given-names></name><name><surname>Naghizadeh</surname><given-names>M.S.</given-names></name><name><surname>Taene</surname><given-names>A.</given-names></name><name><surname>Mahdavi</surname><given-names>R.</given-names></name><name><surname>Naseri</surname><given-names>M.</given-names></name></person-group><article-title>The CCR5-&#x00394;32 mutation: impact on disease outcome in individuals with Hepatitis B infection in the Southern Khorasan population (East of Iran)</article-title><source>Hepat. Mon.</source><volume>17</volume><year>2017</year><object-id pub-id-type="publisher-id">e55014</object-id><pub-id pub-id-type="doi">10.5812/hepatmon.55014</pub-id></element-citation></ref><ref id="bib1255"><element-citation publication-type="journal" id="sbref1255"><person-group person-group-type="author"><name><surname>Sagar</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>P.P.</given-names></name><name><surname>Cooper</surname><given-names>L.T.Jr.</given-names></name></person-group><article-title>Myocarditis</article-title><source>Lancet</source><volume>379</volume><year>2012</year><fpage>738</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60648-X</pub-id><pub-id pub-id-type="pmid">22185868</pub-id></element-citation></ref><ref id="bib1260"><element-citation publication-type="journal" id="sbref1260"><person-group person-group-type="author"><name><surname>Saksida</surname><given-names>A.</given-names></name><name><surname>Duh</surname><given-names>D.</given-names></name><name><surname>Wraber</surname><given-names>B.</given-names></name><name><surname>Dedushaj</surname><given-names>I.</given-names></name><name><surname>Ahmeti</surname><given-names>S.</given-names></name><name><surname>Av&#x00161;i&#x0010d;-&#x0017d;upanc</surname><given-names>T.</given-names></name></person-group><article-title>Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever</article-title><source>Clin. Vaccine Immunol.</source><volume>17</volume><year>2010</year><fpage>1086</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1128/CVI.00530-09</pub-id><pub-id pub-id-type="pmid">20484568</pub-id></element-citation></ref><ref id="bib1265"><element-citation publication-type="journal" id="sbref1265"><person-group person-group-type="author"><name><surname>Salentin</surname><given-names>R.</given-names></name><name><surname>Gemsa</surname><given-names>D.</given-names></name><name><surname>Sprenger</surname><given-names>H.</given-names></name><name><surname>Kaufmann</surname><given-names>A.</given-names></name></person-group><article-title>Chemokine receptor expression and chemotactic responsiveness of human monocytes after influenza A virus infection</article-title><source>J. Leukoc. Biol.</source><volume>74</volume><year>2003</year><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1189/jlb.1102565</pub-id><pub-id pub-id-type="pmid">12885942</pub-id></element-citation></ref><ref id="bib1270"><element-citation publication-type="journal" id="sbref1270"><person-group person-group-type="author"><name><surname>Sales</surname><given-names>K.J.</given-names></name><name><surname>Adefuye</surname><given-names>A.</given-names></name><name><surname>Nicholson</surname><given-names>L.</given-names></name><name><surname>Katz</surname><given-names>A.A.</given-names></name></person-group><article-title>CCR5 expression is elevated in cervical cancer cells and is up-regulated by seminal plasma</article-title><source>Mol. Hum. Reprod.</source><volume>20</volume><year>2014</year><fpage>1144</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1093/molehr/gau063</pub-id><pub-id pub-id-type="pmid">25103627</pub-id></element-citation></ref><ref id="bib1275"><element-citation publication-type="journal" id="sbref1275"><person-group person-group-type="author"><name><surname>Salnikova</surname><given-names>L.E.</given-names></name><name><surname>Smelaya</surname><given-names>T.V.</given-names></name><name><surname>Moroz</surname><given-names>V.V.</given-names></name><name><surname>Golubev</surname><given-names>A.M.</given-names></name><name><surname>Rubanovich</surname><given-names>A.V.</given-names></name></person-group><article-title>Host genetic risk factors for community-acquired pneumonia</article-title><source>Gene</source><volume>518</volume><year>2013</year><fpage>449</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2012.10.027</pub-id><pub-id pub-id-type="pmid">23107763</pub-id></element-citation></ref><ref id="bib1280"><element-citation publication-type="journal" id="sbref1280"><person-group person-group-type="author"><name><surname>Samson</surname><given-names>M.</given-names></name><name><surname>Libert</surname><given-names>F.</given-names></name><name><surname>Doranz</surname><given-names>B.J.</given-names></name><name><surname>Rucker</surname><given-names>J.</given-names></name><name><surname>Liesnard</surname><given-names>C.</given-names></name><name><surname>Farber</surname><given-names>C.M.</given-names></name><name><surname>Saragosti</surname><given-names>S.</given-names></name><name><surname>Lapoum&#x000e9;roulie</surname><given-names>C.</given-names></name><name><surname>Cognaux</surname><given-names>J.</given-names></name><name><surname>Forceille</surname><given-names>C.</given-names></name><name><surname>Muyldermans</surname><given-names>G.</given-names></name><name><surname>Verhofstede</surname><given-names>C.</given-names></name><name><surname>Burtonboy</surname><given-names>G.</given-names></name><name><surname>Georges</surname><given-names>M.</given-names></name><name><surname>Imai</surname><given-names>T.</given-names></name><name><surname>Rana</surname><given-names>S.</given-names></name><name><surname>Yi</surname><given-names>Y.</given-names></name><name><surname>Smyth</surname><given-names>R.J.</given-names></name><name><surname>Collman</surname><given-names>R.G.</given-names></name><name><surname>Doms</surname><given-names>R.W.</given-names></name><name><surname>Vassart</surname><given-names>G.</given-names></name><name><surname>Parmentier</surname><given-names>M.</given-names></name></person-group><article-title>Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene</article-title><source>Nature</source><volume>382</volume><year>1996</year><fpage>722</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1038/382722a0</pub-id><pub-id pub-id-type="pmid">8751444</pub-id></element-citation></ref><ref id="bib1285"><element-citation publication-type="journal" id="sbref1285"><person-group person-group-type="author"><name><surname>Samson</surname><given-names>M.</given-names></name><name><surname>LaRosa</surname><given-names>G.</given-names></name><name><surname>Libert</surname><given-names>F.</given-names></name><name><surname>Paindavoine</surname><given-names>P.</given-names></name><name><surname>Detheux</surname><given-names>M.</given-names></name><name><surname>Vassart</surname><given-names>G.</given-names></name><name><surname>Parmentier</surname><given-names>M.</given-names></name></person-group><article-title>The second extracellular loop of CCR5 is the major determinant of ligand specificity</article-title><source>J. Biol. Chem.</source><volume>272</volume><year>1997</year><fpage>24934</fpage><lpage>24941</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.40.24934</pub-id><pub-id pub-id-type="pmid">9312096</pub-id></element-citation></ref><ref id="bib1290"><element-citation publication-type="journal" id="sbref1290"><person-group person-group-type="author"><name><surname>Sanchooli</surname><given-names>J.</given-names></name><name><surname>Sanadgol</surname><given-names>N.</given-names></name><name><surname>Kazemi Arababadi</surname><given-names>M.</given-names></name><name><surname>Kennedy</surname><given-names>D.</given-names></name></person-group><article-title>CCR5 plays important roles in hepatitis B infection</article-title><source>Viral Immunol.</source><volume>27</volume><year>2014</year><fpage>2</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1089/vim.2013.0067</pub-id><pub-id pub-id-type="pmid">24405101</pub-id></element-citation></ref><ref id="bib1295"><element-citation publication-type="journal" id="sbref1295"><person-group person-group-type="author"><name><surname>Sanjos&#x000e9;</surname><given-names>S.</given-names></name><name><surname>Brotons</surname><given-names>M.</given-names></name><name><surname>Pav&#x000f3;n</surname><given-names>M.A.</given-names></name></person-group><article-title>The natural history of human papillomavirus infection</article-title><source>Best Pract. Res. Clin. Obstet. Gynaecol.</source><volume>47</volume><year>2018</year><fpage>2</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.bpobgyn.2017.08.015</pub-id><pub-id pub-id-type="pmid">28964706</pub-id></element-citation></ref><ref id="bib1300"><element-citation publication-type="journal" id="sbref1300"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>E.U.D.</given-names></name><name><surname>Lima</surname><given-names>G.D.C.</given-names></name><name><surname>Oliveira</surname><given-names>M.L.</given-names></name><name><surname>Her&#x000e1;clio</surname><given-names>S.A.</given-names></name><name><surname>Silva HDA</surname><given-names>Crovella S.</given-names></name><name><surname>Maia</surname><given-names>M.M.D.</given-names></name><name><surname>Souza</surname><given-names>P.R.E.</given-names></name></person-group><article-title><italic>CCR2</italic> and <italic>CCR5</italic> genes polymorphisms in women with cervical lesions from Pernambuco, Northeast Region of Brazil: a case-control study</article-title><source>Mem. Inst. Oswaldo Cruz</source><volume>111</volume><year>2016</year><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1590/0074-02760150367</pub-id><pub-id pub-id-type="pmid">26982176</pub-id></element-citation></ref><ref id="bib1305"><element-citation publication-type="journal" id="sbref1305"><person-group person-group-type="author"><name><surname>Schauren</surname><given-names>J.S.</given-names></name><name><surname>Marasca</surname><given-names>J.A.</given-names></name><name><surname>Veit</surname><given-names>T.D.</given-names></name><name><surname>Monticielo</surname><given-names>O.A.</given-names></name><name><surname>Xavier</surname><given-names>R.M.</given-names></name><name><surname>Brenol</surname><given-names>J.C.T.</given-names></name><name><surname>Chies</surname><given-names>J.A.B.</given-names></name></person-group><article-title>CCR5delta32 in systemic lupus erythematosus: implications for disease susceptibility and outcome in a Brazilian population</article-title><source>Lupus</source><volume>22</volume><year>2013</year><fpage>802</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1177/0961203313491848</pub-id><pub-id pub-id-type="pmid">23753295</pub-id></element-citation></ref><ref id="bib1310"><element-citation publication-type="journal" id="sbref1310"><person-group person-group-type="author"><name><surname>Schiffman</surname><given-names>M.</given-names></name><name><surname>Doorbar</surname><given-names>J.</given-names></name><name><surname>Wentzensen</surname><given-names>N.</given-names></name><name><surname>de Sanjos&#x000e9;</surname><given-names>S.</given-names></name><name><surname>Fakhry</surname><given-names>C.</given-names></name><name><surname>Monk</surname><given-names>B.J.</given-names></name><name><surname>Stanley</surname><given-names>M.A.</given-names></name><name><surname>Franceschi</surname><given-names>S.</given-names></name></person-group><article-title>Carcinogenic human papillomavirus infection</article-title><source>Nat. Rev. Dis. Primers</source><volume>2</volume><year>2016</year><fpage>16086</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2016.86</pub-id><pub-id pub-id-type="pmid">27905473</pub-id></element-citation></ref><ref id="bib1315"><element-citation publication-type="journal" id="sbref1315"><person-group person-group-type="author"><name><surname>Schlabe</surname><given-names>S.</given-names></name><name><surname>Rockstroh</surname><given-names>J.K.</given-names></name></person-group><article-title>Advances in the treatment of HIV/HCV coinfection in adults</article-title><source>Expert Opin. Pharmacother.</source><volume>19</volume><year>2018</year><fpage>49</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1080/14656566.2017.1419185</pub-id><pub-id pub-id-type="pmid">29252031</pub-id></element-citation></ref><ref id="bib1320"><element-citation publication-type="journal" id="sbref1320"><person-group person-group-type="author"><name><surname>Sejvar</surname><given-names>J.J.</given-names></name></person-group><article-title>West Nile virus infection</article-title><source>Microbiol. Spectr.</source><volume>4</volume><year>2016</year><pub-id pub-id-type="doi">10.1128/microbiolspec.EI10-0021-2016</pub-id></element-citation></ref><ref id="bib1325"><element-citation publication-type="journal" id="sbref1325"><person-group person-group-type="author"><name><surname>Settergren</surname><given-names>B.</given-names></name></person-group><article-title>Clinical aspects of nephropathia epidemica (Puumala virus infection) in Europe: a review</article-title><source>Scand. J. Infect. Dis.</source><volume>32</volume><year>2000</year><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1080/003655400750045204</pub-id><pub-id pub-id-type="pmid">10826895</pub-id></element-citation></ref><ref id="bib1330"><element-citation publication-type="journal" id="sbref1330"><person-group person-group-type="author"><name><surname>Sezgin</surname><given-names>E.</given-names></name><name><surname>van Natta</surname><given-names>M.L.</given-names></name><name><surname>Ahuja</surname><given-names>A.</given-names></name><name><surname>Lyon</surname><given-names>A.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Troyer</surname><given-names>J.L.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S.J.</given-names></name><name><surname>Jabs</surname><given-names>D.A.</given-names></name><name><surname>Studies of the Ocular Complications of AIDS Research Group</surname></name></person-group><article-title>Association of host genetic risk factors with the course of cytomegalovirus retinitis in patients infected with human immunodeficiency virus</article-title><source>Am. J. Ophthalmol.</source><volume>151</volume><year>2011</year><fpage>999</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2010.11.029</pub-id><comment>e4</comment><pub-id pub-id-type="pmid">21396623</pub-id></element-citation></ref><ref id="bib1335"><element-citation publication-type="journal" id="sbref1335"><person-group person-group-type="author"><name><surname>Shaheen</surname><given-names>Z.R.</given-names></name><name><surname>Naatz</surname><given-names>A.</given-names></name><name><surname>Corbett</surname><given-names>J.A.</given-names></name></person-group><article-title>CCR5-dependent activation of mTORC1 regulates translation of inducible NO synthase and COX-2 during Encephalomyocarditis virus infection</article-title><source>J. Immunol.</source><volume>195</volume><year>2015</year><fpage>4406</fpage><lpage>4414</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500704</pub-id><pub-id pub-id-type="pmid">26408666</pub-id></element-citation></ref><ref id="bib1340"><element-citation publication-type="journal" id="sbref1340"><person-group person-group-type="author"><name><surname>Shaik</surname><given-names>M.M.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Rits-Volloch</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Liao</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>Structural basis of coreceptor recognition by HIV-1 envelope spike</article-title><source>Nature</source><volume>565</volume><year>2019</year><fpage>318</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0804-9</pub-id><pub-id pub-id-type="pmid">30542158</pub-id></element-citation></ref><ref id="bib1345"><element-citation publication-type="journal" id="sbref1345"><person-group person-group-type="author"><name><surname>Shelfoon</surname><given-names>C.</given-names></name><name><surname>Shariff</surname><given-names>S.</given-names></name><name><surname>Traves</surname><given-names>S.L.</given-names></name><name><surname>Kooi</surname><given-names>C.</given-names></name><name><surname>Leigh</surname><given-names>R.</given-names></name><name><surname>Proud</surname><given-names>D.</given-names></name></person-group><article-title>Chemokine release from human rhinovirus-infected airway epithelial cells promotes fibroblast migration</article-title><source>J. Allergy Clin. Immunol.</source><volume>138</volume><year>2016</year><fpage>114</fpage><pub-id pub-id-type="doi">10.1016/j.jaci.2015.12.1308</pub-id><comment>e4-122.e4</comment><pub-id pub-id-type="pmid">26883463</pub-id></element-citation></ref><ref id="bib1350"><element-citation publication-type="journal" id="sbref1350"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Qiu</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name></person-group><article-title>CCR2 positive exosome released by mesenchymal stem cells suppresses macrophage functions and alleviates ischemia/reperfusion-induced renal injury</article-title><source>Stem Cells Int.</source><volume>2016</volume><year>2016</year><object-id pub-id-type="publisher-id">1240301</object-id><pub-id pub-id-type="doi">10.1155/2016/1240301</pub-id></element-citation></ref><ref id="bib1355"><element-citation publication-type="journal" id="sbref1355"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shao</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Gan</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Bucci</surname><given-names>E.</given-names></name><name><surname>Piacentini</surname><given-names>M.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Melino</surname><given-names>G.</given-names></name></person-group><article-title>COVID-19 infection: the perspectives on immune responses</article-title><source>Cell Death Differ.</source><volume>27</volume><year>2020</year><fpage>1451</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-0530-3</pub-id><pub-id pub-id-type="pmid">32205856</pub-id></element-citation></ref><ref id="bib1360"><element-citation publication-type="journal" id="sbref1360"><person-group person-group-type="author"><name><surname>Shirvani</surname><given-names>H.</given-names></name><name><surname>Achour</surname><given-names>L.</given-names></name><name><surname>Scott</surname><given-names>M.G.</given-names></name><name><surname>Thuret</surname><given-names>A.</given-names></name><name><surname>Labb&#x000e9;-Julli&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Bismuth</surname><given-names>G.</given-names></name><name><surname>Marullo</surname><given-names>S.</given-names></name></person-group><article-title>Evidence for internal stores of CCR5 in blood cells</article-title><source>Blood</source><volume>118</volume><year>2011</year><fpage>1175</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-02-330886</pub-id><pub-id pub-id-type="pmid">21799100</pub-id></element-citation></ref><ref id="bib1365"><element-citation publication-type="journal" id="sbref1365"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>B.</given-names></name><name><surname>Perez</surname><given-names>A.B.</given-names></name><name><surname>Garcia</surname><given-names>G.</given-names></name><name><surname>Aguirre</surname><given-names>E.</given-names></name><name><surname>Alvarez</surname><given-names>M.</given-names></name><name><surname>Gonzalez</surname><given-names>D.</given-names></name><name><surname>Guzman</surname><given-names>M.G.</given-names></name></person-group><article-title>Role of CC chemokine receptor 1 and two of its ligands in human dengue infection. Three approaches under the Cuban situation</article-title><source>Microbes Infect.</source><volume>16</volume><year>2014</year><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2013.10.011</pub-id><pub-id pub-id-type="pmid">24157267</pub-id></element-citation></ref><ref id="bib1370"><element-citation publication-type="journal" id="sbref1370"><person-group person-group-type="author"><name><surname>Signoret</surname><given-names>N.</given-names></name><name><surname>Pelchen-Matthews</surname><given-names>A.</given-names></name><name><surname>Mack</surname><given-names>M.</given-names></name><name><surname>Proudfoot</surname><given-names>A.E.</given-names></name><name><surname>Marsh</surname><given-names>M.</given-names></name></person-group><article-title>Endocytosis and recycling of the HIV coreceptor CCR5</article-title><source>J. Cell Biol.</source><volume>151</volume><year>2000</year><fpage>1281</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1083/jcb.151.6.1281</pub-id><pub-id pub-id-type="pmid">11121442</pub-id></element-citation></ref><ref id="bib1375"><element-citation publication-type="journal" id="sbref1375"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>J.R.</given-names></name><name><surname>Romeiro</surname><given-names>M.F.</given-names></name><name><surname>Souza</surname><given-names>W.M.</given-names></name><name><surname>Munhoz</surname><given-names>T.D.</given-names></name><name><surname>Borges</surname><given-names>G.P.</given-names></name><name><surname>Soares</surname><given-names>O.A.B.</given-names></name><name><surname>Campos</surname><given-names>C.H.C.</given-names></name><name><surname>Machado</surname><given-names>R.Z.</given-names></name><name><surname>Silva</surname><given-names>M.L.C.R.</given-names></name><name><surname>Faria</surname><given-names>J.L.M.</given-names></name><name><surname>Ch&#x000e1;vez</surname><given-names>J.H.</given-names></name><name><surname>Figueiredo</surname><given-names>L.T.M.</given-names></name></person-group><article-title>A Saint Louis encephalitis and Rocio virus serosurvey in Brazilian horses</article-title><source>Rev. Soc. Bras. Med. Trop.</source><volume>47</volume><year>2014</year><fpage>414</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1590/0037-8682-0117-2014</pub-id><pub-id pub-id-type="pmid">25229279</pub-id></element-citation></ref><ref id="bib1380"><element-citation publication-type="journal" id="sbref1380"><person-group person-group-type="author"><name><surname>Silva-Carvalho</surname><given-names>W.H.V.</given-names></name><name><surname>de Moura</surname><given-names>R.R.</given-names></name><name><surname>Coelho</surname><given-names>A.V.C.</given-names></name><name><surname>Crovella</surname><given-names>S.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>R.L.</given-names></name></person-group><article-title>Frequency of the <italic>CCR5</italic>-delta32 allele in Brazilian populations: a systematic literature review and meta-analysis</article-title><source>Infect. Genet. Evol.</source><volume>43</volume><year>2016</year><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2016.05.024</pub-id><pub-id pub-id-type="pmid">27208805</pub-id></element-citation></ref><ref id="bib1385"><element-citation publication-type="journal" id="sbref1385"><person-group person-group-type="author"><name><surname>Simonetta</surname><given-names>F.</given-names></name><name><surname>Bourgeois</surname><given-names>C.</given-names></name></person-group><article-title>CD4+FOXP3+ regulatory T-cell subsets in Human immunodeficiency virus infection</article-title><source>Front. Immunol.</source><volume>4</volume><year>2013</year><fpage>215</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00215</pub-id><pub-id pub-id-type="pmid">23908654</pub-id></element-citation></ref><ref id="bib1390"><element-citation publication-type="journal" id="sbref1390"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>H.</given-names></name><name><surname>Sachan</surname><given-names>R.</given-names></name><name><surname>Jain</surname><given-names>M.</given-names></name><name><surname>Mittal</surname><given-names>B.</given-names></name></person-group><article-title><italic>CCR5</italic>-&#x00394;<italic>32</italic> polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer</article-title><source>Oncol. Res.</source><volume>17</volume><year>2008</year><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.3727/096504008784523667</pub-id><pub-id pub-id-type="pmid">18543610</pub-id></element-citation></ref><ref id="bib1395"><element-citation publication-type="journal" id="sbref1395"><person-group person-group-type="author"><name><surname>Sironi</surname><given-names>M.</given-names></name><name><surname>Cagliani</surname><given-names>R.</given-names></name><name><surname>Pontremoli</surname><given-names>C.</given-names></name><name><surname>Rossi</surname><given-names>M.</given-names></name><name><surname>Migliorino</surname><given-names>G.</given-names></name><name><surname>Clerici</surname><given-names>M.</given-names></name><name><surname>Gori</surname><given-names>A.</given-names></name></person-group><article-title>The CCR5&#x00394;32 allele is not a major predisposing factor for severe H1N1pdm09 infection</article-title><source>BMC Res. Notes</source><volume>7</volume><year>2014</year><fpage>504</fpage><pub-id pub-id-type="doi">10.1186/1756-0500-7-504</pub-id><pub-id pub-id-type="pmid">25100510</pub-id></element-citation></ref><ref id="bib1400"><element-citation publication-type="journal" id="sbref1400"><person-group person-group-type="author"><name><surname>Sl&#x000e1;dkov&#x000e1;</surname><given-names>T.</given-names></name><name><surname>Kostolansk&#x000fd;</surname><given-names>F.</given-names></name></person-group><article-title>The role of cytokines in the immune response to influenza A virus infection</article-title><source>Acta Virol.</source><volume>50</volume><year>2006</year><fpage>151</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">17131933</pub-id></element-citation></ref><ref id="bib1405"><element-citation publication-type="journal" id="sbref1405"><person-group person-group-type="author"><name><surname>Solloch</surname><given-names>U.V.</given-names></name><name><surname>Lang</surname><given-names>K.</given-names></name><name><surname>Lange</surname><given-names>V.</given-names></name><name><surname>B&#x000f6;hme</surname><given-names>I.</given-names></name><name><surname>Schmidt</surname><given-names>A.H.</given-names></name><name><surname>Sauter</surname><given-names>J.</given-names></name></person-group><article-title>Frequencies of gene variant CCR5-&#x00394;32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers</article-title><source>Hum. Immunol.</source><volume>78</volume><year>2017</year><fpage>710</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2017.10.001</pub-id><pub-id pub-id-type="pmid">28987960</pub-id></element-citation></ref><ref id="bib1410"><element-citation publication-type="journal" id="sbref1410"><person-group person-group-type="author"><name><surname>St John</surname><given-names>A.L.</given-names></name><name><surname>Rathore</surname><given-names>A.P.S.</given-names></name></person-group><article-title>Adaptive immune responses to primary and secondary dengue virus infections</article-title><source>Nat. Rev. Immunol.</source><volume>19</volume><year>2019</year><fpage>218</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0123-x</pub-id><pub-id pub-id-type="pmid">30679808</pub-id></element-citation></ref><ref id="bib1415"><element-citation publication-type="journal" id="sbref1415"><person-group person-group-type="author"><name><surname>Stanaway</surname><given-names>J.D.</given-names></name><name><surname>Shepard</surname><given-names>D.S.</given-names></name><name><surname>Undurraga</surname><given-names>E.A.</given-names></name><name><surname>Halasa</surname><given-names>Y.A.</given-names></name><name><surname>Coffeng</surname><given-names>L.E.</given-names></name><name><surname>Brady</surname><given-names>O.J.</given-names></name><name><surname>Hay</surname><given-names>S.I.</given-names></name><name><surname>Bedi</surname><given-names>N.</given-names></name><name><surname>Bensenor</surname><given-names>I.M.</given-names></name><name><surname>Casta&#x000f1;eda-Orjuela</surname><given-names>C.A.</given-names></name><name><surname>Chuang</surname><given-names>T.W.</given-names></name><name><surname>Gibney</surname><given-names>K.B.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Rafay</surname><given-names>A.</given-names></name><name><surname>Ukwaja</surname><given-names>K.N.</given-names></name><name><surname>Yonemoto</surname><given-names>N.</given-names></name><name><surname>Murray</surname><given-names>C.J.L.</given-names></name></person-group><article-title>The global burden of dengue: an analysis from the Global Burden of Disease Study 2013</article-title><source>Lancet Infect. Dis.</source><volume>16</volume><year>2016</year><fpage>712</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)00026-8</pub-id><pub-id pub-id-type="pmid">26874619</pub-id></element-citation></ref><ref id="bib1420"><element-citation publication-type="journal" id="sbref1420"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>K.E.</given-names></name><name><surname>Thio</surname><given-names>C.L.</given-names></name><name><surname>Osburn</surname><given-names>W.O.</given-names></name></person-group><article-title>CCR5 deficiency enhances hepatic innate immune cell recruitment and inflammation in a murine model of acute hepatitis B infection</article-title><source>Immunol. Cell Biol.</source><volume>97</volume><year>2019</year><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1111/imcb.12221</pub-id><pub-id pub-id-type="pmid">30536991</pub-id></element-citation></ref><ref id="bib1425"><element-citation publication-type="journal" id="sbref1425"><person-group person-group-type="author"><name><surname>Stumbryt&#x00117;-Kaminskien&#x00117;</surname><given-names>A.</given-names></name><name><surname>Gudlevi&#x0010d;ien&#x00117;</surname><given-names>&#x0017d;</given-names></name><name><surname>Dabkevi&#x0010d;ien&#x00117;</surname><given-names>D.</given-names></name><name><surname>Mackevi&#x0010d;ien&#x00117;</surname><given-names>I.</given-names></name></person-group><article-title>Combined effect of HPV and several gene SNPs in laryngeal cancer</article-title><source>Medicina Kaunas (Kaunas)</source><volume>56</volume><year>2020</year><fpage>81</fpage><pub-id pub-id-type="doi">10.3390/medicina56020081</pub-id></element-citation></ref><ref id="bib1430"><element-citation publication-type="journal" id="sbref1430"><person-group person-group-type="author"><name><surname>Suneetha</surname><given-names>P.V.</given-names></name><name><surname>Sarin</surname><given-names>S.K.</given-names></name><name><surname>Goyal</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>G.T.</given-names></name><name><surname>Shukla</surname><given-names>D.K.</given-names></name><name><surname>Hissar</surname><given-names>S.</given-names></name></person-group><article-title>Association between vitamin D receptor, CCR5, TNF-&#x003b1; and TNF-&#x003b2; gene polymorphisms and HBV infection and severity of liver disease</article-title><source>J. Hepatol.</source><volume>44</volume><year>2006</year><fpage>856</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2006.01.028</pub-id><pub-id pub-id-type="pmid">16545485</pub-id></element-citation></ref><ref id="bib1435"><element-citation publication-type="journal" id="sbref1435"><person-group person-group-type="author"><name><surname>Suppiah</surname><given-names>V.</given-names></name><name><surname>Armstrong</surname><given-names>N.J.</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>K.S.</given-names></name><name><surname>Berg</surname><given-names>T.</given-names></name><name><surname>Weltman</surname><given-names>M.</given-names></name><name><surname>Abate</surname><given-names>M.L.</given-names></name><name><surname>Spengler</surname><given-names>U.</given-names></name><name><surname>Bassendine</surname><given-names>M.</given-names></name><name><surname>Dore</surname><given-names>G.J.</given-names></name><name><surname>Irving</surname><given-names>W.L.</given-names></name><name><surname>Powell</surname><given-names>E.</given-names></name><name><surname>Nattermann</surname><given-names>J.</given-names></name><name><surname>Mueller</surname><given-names>T.</given-names></name><name><surname>Riordan</surname><given-names>S.</given-names></name><name><surname>Stewart</surname><given-names>G.J.</given-names></name><name><surname>George</surname><given-names>J.</given-names></name><name><surname>Booth</surname><given-names>D.R.</given-names></name><name><surname>Ahlenstiel</surname><given-names>G.</given-names></name><name><surname>International Hepatitis C Genetics Consortium (IHCGC)</surname></name></person-group><article-title>CCR5-&#x00394;32 genotype does not improve predictive value of <italic>IL28B</italic> polymorphisms for treatment response in chronic HCV infection</article-title><source>Genes Immun.</source><volume>14</volume><year>2013</year><fpage>286</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1038/gene.2013.15</pub-id><pub-id pub-id-type="pmid">23594959</pub-id></element-citation></ref><ref id="bib1440"><element-citation publication-type="journal" id="sbref1440"><person-group person-group-type="author"><name><surname>Suthar</surname><given-names>M.S.</given-names></name><name><surname>Diamond</surname><given-names>M.S.</given-names></name><name><surname>Gale</surname><given-names>M.Jr.</given-names></name></person-group><article-title>West Nile virus infection and immunity</article-title><source>Nat. Rev. Microbiol.</source><volume>11</volume><year>2013</year><fpage>115</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2950</pub-id><pub-id pub-id-type="pmid">23321534</pub-id></element-citation></ref><ref id="bib1445"><element-citation publication-type="journal" id="sbref1445"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>P.S.</given-names></name><name><surname>de Oliveira</surname><given-names>K.B.</given-names></name><name><surname>Aoki</surname><given-names>M.N.</given-names></name><name><surname>Tatakihara VLH</surname><given-names>Borelli S.D.</given-names></name><name><surname>Watanabe</surname><given-names>M.A.E.</given-names></name></person-group><article-title>Investigating the association of chemokine receptor 5 (CCR5) polymorphism with cervical cancer in human papillomavirus (HPV) positive patients</article-title><source>Acta Sci Health Sci</source><volume>30</volume><year>2008</year><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.4025/actascihealthsci.v30i2.944</pub-id></element-citation></ref><ref id="bib1450"><element-citation publication-type="journal" id="sbref1450"><person-group person-group-type="author"><name><surname>Tadagaki</surname><given-names>K.</given-names></name><name><surname>Tudor</surname><given-names>D.</given-names></name><name><surname>Gbahou</surname><given-names>F.</given-names></name><name><surname>Tschische</surname><given-names>P.</given-names></name><name><surname>Waldhoer</surname><given-names>M.</given-names></name><name><surname>Bomsel</surname><given-names>M.</given-names></name><name><surname>Jockers</surname><given-names>R.</given-names></name><name><surname>Kamal</surname><given-names>M.</given-names></name></person-group><article-title>Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and CXCR4 impairing their HIV coreceptor activity</article-title><source>Blood</source><volume>119</volume><year>2012</year><fpage>4908</fpage><lpage>4918</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-08-372516</pub-id><pub-id pub-id-type="pmid">22496149</pub-id></element-citation></ref><ref id="bib1455"><element-citation publication-type="journal" id="sbref1455"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>M.C.B.</given-names></name><name><surname>Goedegebuure</surname><given-names>P.S.</given-names></name><name><surname>Belt</surname><given-names>B.A.</given-names></name><name><surname>Flaherty</surname><given-names>B.</given-names></name><name><surname>Sankpal</surname><given-names>N.</given-names></name><name><surname>Gillanders</surname><given-names>W.E.</given-names></name><name><surname>Eberlein</surname><given-names>T.J.</given-names></name><name><surname>Hsieh</surname><given-names>C.S.</given-names></name><name><surname>Linehan</surname><given-names>D.C.</given-names></name></person-group><article-title>Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer</article-title><source>J. Immunol.</source><volume>182</volume><year>2009</year><fpage>1746</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.182.3.1746</pub-id><pub-id pub-id-type="pmid">19155524</pub-id></element-citation></ref><ref id="bib1460"><element-citation publication-type="journal" id="sbref1460"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Q.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Han</surname><given-names>G.W.</given-names></name><name><surname>Kufareva</surname><given-names>I.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Fenalti</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>W.W.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Cherezov</surname><given-names>V.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Stevens</surname><given-names>R.C.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name></person-group><article-title>Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex</article-title><source>Science</source><volume>341</volume><year>2013</year><fpage>1387</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1126/science.1241475</pub-id><pub-id pub-id-type="pmid">24030490</pub-id></element-citation></ref><ref id="bib1465"><element-citation publication-type="journal" id="sbref1465"><person-group person-group-type="author"><name><surname>Tapparel</surname><given-names>C.</given-names></name><name><surname>Siegrist</surname><given-names>F.</given-names></name><name><surname>Petty</surname><given-names>T.J.</given-names></name><name><surname>Kaiser</surname><given-names>L.</given-names></name></person-group><article-title>Picornavirus and enterovirus diversity with associated human diseases</article-title><source>Infect. Genet. Evol.</source><volume>14</volume><year>2013</year><fpage>282</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2012.10.016</pub-id><pub-id pub-id-type="pmid">23201849</pub-id></element-citation></ref><ref id="bib1470"><element-citation publication-type="journal" id="sbref1470"><person-group person-group-type="author"><name><surname>Tavares</surname><given-names>L.P.</given-names></name><name><surname>Garcia</surname><given-names>C.C.</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>A.P.F.</given-names></name><name><surname>Kraemer</surname><given-names>L.R.</given-names></name><name><surname>Melo</surname><given-names>E.M.</given-names></name><name><surname>Oliveira</surname><given-names>F.M.S.</given-names></name><name><surname>Freitas</surname><given-names>C.S.</given-names></name><name><surname>Lopes</surname><given-names>G.A.O.</given-names></name><name><surname>Reis</surname><given-names>D.C.</given-names></name><name><surname>Cassali</surname><given-names>G.D.</given-names></name><name><surname>Machado</surname><given-names>A.M.</given-names></name><name><surname>Mantovani</surname><given-names>A.</given-names></name><name><surname>Locati</surname><given-names>M.</given-names></name><name><surname>Teixeira</surname><given-names>M.M.</given-names></name><name><surname>Russo</surname><given-names>R.C.</given-names></name></person-group><article-title>ACKR2 contributes to pulmonary dysfunction by shaping CCL5:CCR5-dependent recruitment of lymphocytes during Influenza A infection in mice</article-title><source>Am. J. Physiol. Lung Cell Mol. Physiol.</source><volume>318</volume><year>2020</year><fpage>L655</fpage><lpage>L670</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00134.2019</pub-id><pub-id pub-id-type="pmid">31995405</pub-id></element-citation></ref><ref id="bib1475"><element-citation publication-type="journal" id="sbref1475"><person-group person-group-type="author"><name><surname>Th&#x000e9;ry</surname><given-names>C.</given-names></name><name><surname>Witwer</surname><given-names>K.W.</given-names></name><name><surname>Aikawa</surname><given-names>E.</given-names></name><name><surname>Alcaraz</surname><given-names>M.J.</given-names></name><name><surname>Anderson</surname><given-names>J.D.</given-names></name></person-group><article-title>Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines</article-title><source>J. Extracell. Vesicles</source><volume>7</volume><year>2018</year><object-id pub-id-type="publisher-id">1535750</object-id><pub-id pub-id-type="doi">10.1080/20013078.2018.1535750</pub-id></element-citation></ref><ref id="bib1480"><element-citation publication-type="journal" id="sbref1480"><person-group person-group-type="author"><name><surname>Thio</surname><given-names>C.L.</given-names></name><name><surname>Astemborski</surname><given-names>J.</given-names></name><name><surname>Bashirova</surname><given-names>A.</given-names></name><name><surname>Mosbruger</surname><given-names>T.</given-names></name><name><surname>Greer</surname><given-names>S.</given-names></name><name><surname>Witt</surname><given-names>M.D.</given-names></name><name><surname>Goedert</surname><given-names>J.J.</given-names></name><name><surname>Hilgartner</surname><given-names>M.</given-names></name><name><surname>Majeske</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S.J.</given-names></name><name><surname>Thomas</surname><given-names>D.L.</given-names></name><name><surname>Carrington</surname><given-names>M.</given-names></name></person-group><article-title>Genetic protection against hepatitis B virus conferred by <italic>CCR5</italic>&#x00394;<italic>32</italic>: evidence that CCR5 contributes to viral persistence</article-title><source>J. Virol.</source><volume>81</volume><year>2007</year><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1128/JVI.01897-06</pub-id><pub-id pub-id-type="pmid">17079285</pub-id></element-citation></ref><ref id="bib1485"><element-citation publication-type="journal" id="sbref1485"><person-group person-group-type="author"><name><surname>Thio</surname><given-names>C.L.</given-names></name><name><surname>Astemborski</surname><given-names>J.</given-names></name><name><surname>Thomas</surname><given-names>R.</given-names></name><name><surname>Mosbruger</surname><given-names>T.</given-names></name><name><surname>Witt</surname><given-names>M.D.</given-names></name><name><surname>Goedert</surname><given-names>J.J.</given-names></name><name><surname>Hoots</surname><given-names>K.</given-names></name><name><surname>Winkler</surname><given-names>C.</given-names></name><name><surname>Thomas</surname><given-names>D.L.</given-names></name><name><surname>Carrington</surname><given-names>M.</given-names></name></person-group><article-title>Interaction between <italic>RANTES</italic> promoter variant and <italic>CCR5</italic>&#x00394;<italic>32</italic> favors recovery from hepatitis B</article-title><source>J. Immunol.</source><volume>181</volume><year>2008</year><fpage>7944</fpage><lpage>7947</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.11.7944</pub-id><pub-id pub-id-type="pmid">19017985</pub-id></element-citation></ref><ref id="bib1490"><element-citation publication-type="journal" id="sbref1490"><person-group person-group-type="author"><name><surname>Thoelen</surname><given-names>I.</given-names></name><name><surname>Verbeeck</surname><given-names>J.</given-names></name><name><surname>Wollants</surname><given-names>E.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Robaeys</surname><given-names>G.</given-names></name><name><surname>Mathe&#x000ef;</surname><given-names>C.</given-names></name><name><surname>Buntinx</surname><given-names>F.</given-names></name><name><surname>Nevens</surname><given-names>F.</given-names></name><name><surname>Van Ranst</surname><given-names>M.</given-names></name></person-group><article-title>Frequency of the CCR5-&#x00394;32 mutant allele is not increased in Belgian hepatitis C virus-infected patients</article-title><source>Viral Immunol.</source><volume>18</volume><year>2005</year><fpage>232</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1089/vim.2005.18.232</pub-id><pub-id pub-id-type="pmid">15802968</pub-id></element-citation></ref><ref id="bib1495"><element-citation publication-type="journal" id="sbref1495"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name><name><surname>Tiwari</surname><given-names>R.</given-names></name><name><surname>Dhole</surname><given-names>T.N.</given-names></name></person-group><article-title>Japanese encephalitis: a review of the Indian perspective</article-title><source>Braz. J. Infect. Dis.</source><volume>16</volume><year>2012</year><fpage>564</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1016/j.bjid.2012.10.004</pub-id><pub-id pub-id-type="pmid">23141974</pub-id></element-citation></ref><ref id="bib1500"><element-citation publication-type="journal" id="sbref1500"><person-group person-group-type="author"><name><surname>Tokarz</surname><given-names>A.</given-names></name><name><surname>Konkolewska</surname><given-names>M.</given-names></name><name><surname>Ku&#x0015b;nierz-Cabala</surname><given-names>B.</given-names></name><name><surname>Maziarz</surname><given-names>B.</given-names></name><name><surname>Hanarz</surname><given-names>P.</given-names></name><name><surname>&#x0017b;urakowski</surname><given-names>A.</given-names></name><name><surname>Szu&#x0015b;cik</surname><given-names>I.</given-names></name><name><surname>St&#x00119;pie&#x00144;</surname><given-names>E.&#x00141;.</given-names></name></person-group><article-title>Retinopathy severity correlates with RANTES concentrations and CCR 5-positive microvesicles in diabetes</article-title><source>Folia Med. Cracov.</source><volume>59</volume><year>2019</year><fpage>95</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.24425/fmc.2019.131139</pub-id></element-citation></ref><ref id="bib1505"><element-citation publication-type="journal" id="sbref1505"><person-group person-group-type="author"><name><surname>TrehanPati</surname><given-names>N.</given-names></name><name><surname>Geffers</surname><given-names>R.</given-names></name><name><surname>Sukriti</surname><given-names>Hissar S.</given-names></name><name><surname>Riese</surname><given-names>P.</given-names></name><name><surname>Toepfer</surname><given-names>T.</given-names></name><name><surname>Buer</surname><given-names>J.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name><name><surname>Guzman</surname><given-names>C.A.</given-names></name><name><surname>Sarin</surname><given-names>S.K.</given-names></name></person-group><article-title>Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection</article-title><source>Hepatology</source><volume>49</volume><year>2009</year><fpage>781</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1002/hep.22696</pub-id><pub-id pub-id-type="pmid">19185001</pub-id></element-citation></ref><ref id="bib1510"><element-citation publication-type="journal" id="sbref1510"><person-group person-group-type="author"><name><surname>Tsimanis</surname><given-names>A.</given-names></name><name><surname>Kalinkovich</surname><given-names>A.</given-names></name><name><surname>Bentwich</surname><given-names>Z.</given-names></name></person-group><article-title>Soluble chemokine CCR5 receptor is present in human plasma</article-title><source>Immunol. Lett.</source><volume>96</volume><year>2005</year><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2004.07.014</pub-id><pub-id pub-id-type="pmid">15585308</pub-id></element-citation></ref><ref id="bib1515"><element-citation publication-type="journal" id="sbref1515"><person-group person-group-type="author"><name><surname>Tyner</surname><given-names>J.W.</given-names></name><name><surname>Uchida</surname><given-names>O.</given-names></name><name><surname>Kajiwara</surname><given-names>N.</given-names></name><name><surname>Kim</surname><given-names>E.Y.</given-names></name><name><surname>Patel</surname><given-names>A.C.</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>M.P.</given-names></name><name><surname>Walter</surname><given-names>M.J.</given-names></name><name><surname>Schwendener</surname><given-names>R.A.</given-names></name><name><surname>Cook</surname><given-names>D.N.</given-names></name><name><surname>Danoff</surname><given-names>T.M.</given-names></name><name><surname>Holtzman</surname><given-names>M.J.</given-names></name></person-group><article-title>CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection</article-title><source>Nat. Med.</source><volume>11</volume><year>2005</year><fpage>1180</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1038/nm1303</pub-id><pub-id pub-id-type="pmid">16208318</pub-id></element-citation></ref><ref id="bib1520"><element-citation publication-type="journal" id="sbref1520"><person-group person-group-type="author"><name><surname>Ungv&#x000e1;ri</surname><given-names>I.</given-names></name><name><surname>T&#x000f6;lgyesi</surname><given-names>G.</given-names></name><name><surname>Semsei</surname><given-names>A.F.</given-names></name><name><surname>Nagy</surname><given-names>A.</given-names></name><name><surname>Radosits</surname><given-names>K.</given-names></name><name><surname>Keszei</surname><given-names>M.</given-names></name><name><surname>Kozma</surname><given-names>G.T.</given-names></name><name><surname>Falus</surname><given-names>A.</given-names></name><name><surname>Szalai</surname><given-names>C.</given-names></name></person-group><article-title>CCR5&#x00394;32 mutation, <italic>Mycoplasma pneumoniae</italic> infection, and asthma</article-title><source>J. Allergy Clin. Immunol.</source><volume>119</volume><year>2007</year><fpage>1545</fpage><lpage>1547</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2007.02.038</pub-id><pub-id pub-id-type="pmid">17445875</pub-id></element-citation></ref><ref id="bib1525"><element-citation publication-type="journal" id="sbref1525"><person-group person-group-type="author"><name><surname>Valaperti</surname><given-names>A.</given-names></name><name><surname>Nishii</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Naito</surname><given-names>K.</given-names></name><name><surname>Chan</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Skurk</surname><given-names>C.</given-names></name><name><surname>Schultheiss</surname><given-names>H.P.</given-names></name><name><surname>Wells</surname><given-names>G.A.</given-names></name><name><surname>Eriksson</surname><given-names>U.</given-names></name><name><surname>Liu</surname><given-names>P.P.</given-names></name></person-group><article-title>Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5<sup>+</sup>CD11b<sup>+</sup> monocyte migration and impairing interferon production</article-title><source>Circulation</source><volume>128</volume><year>2013</year><fpage>1542</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.002275</pub-id><pub-id pub-id-type="pmid">24030499</pub-id></element-citation></ref><ref id="bib1530"><element-citation publication-type="journal" id="sbref1530"><person-group person-group-type="author"><name><surname>van den Hurk</surname><given-names>A.F.</given-names></name><name><surname>Ritchie</surname><given-names>S.A.</given-names></name><name><surname>Mackenzie</surname><given-names>J.S.</given-names></name></person-group><article-title>Ecology and geographical expansion of Japanese encephalitis virus</article-title><source>Annu. Rev. Entomol.</source><volume>54</volume><year>2009</year><fpage>17</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1146/annurev.ento.54.110807.090510</pub-id><pub-id pub-id-type="pmid">19067628</pub-id></element-citation></ref><ref id="bib1535"><element-citation publication-type="journal" id="sbref1535"><person-group person-group-type="author"><name><surname>Van Der Ryst</surname><given-names>E.</given-names></name></person-group><article-title>Maraviroc - A CCR5 antagonist for the treatment of HIV-1 infection</article-title><source>Front. Immunol.</source><volume>6</volume><year>2015</year><fpage>277</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00277</pub-id><pub-id pub-id-type="pmid">26097475</pub-id></element-citation></ref><ref id="bib1540"><element-citation publication-type="journal" id="sbref1540"><person-group person-group-type="author"><name><surname>Varani</surname><given-names>S.</given-names></name><name><surname>Frascaroli</surname><given-names>G.</given-names></name><name><surname>Homman-Loudiyi</surname><given-names>M.</given-names></name><name><surname>Feld</surname><given-names>S.</given-names></name><name><surname>Landini</surname><given-names>M.P.</given-names></name><name><surname>S&#x000f6;derberg-Naucl&#x000e9;r</surname><given-names>C.</given-names></name></person-group><article-title>Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5</article-title><source>J. Leukoc. Biol.</source><volume>77</volume><year>2005</year><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1189/jlb.0504301</pub-id><pub-id pub-id-type="pmid">15522919</pub-id></element-citation></ref><ref id="bib1545"><element-citation publication-type="journal" id="sbref1545"><person-group person-group-type="author"><name><surname>Veiga-Parga</surname><given-names>T.</given-names></name><name><surname>Sehrawat</surname><given-names>S.</given-names></name><name><surname>Rouse</surname><given-names>B.T.</given-names></name></person-group><article-title>Role of regulatory T cells during virus infection</article-title><source>Immunol. Rev.</source><volume>255</volume><year>2013</year><fpage>182</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1111/imr.12085</pub-id><pub-id pub-id-type="pmid">23947355</pub-id></element-citation></ref><ref id="bib1550"><element-citation publication-type="journal" id="sbref1550"><person-group person-group-type="author"><name><surname>Venkatesan</surname><given-names>S.</given-names></name><name><surname>Petrovic</surname><given-names>A.</given-names></name><name><surname>Van Ryk</surname><given-names>D.I.</given-names></name><name><surname>Locati</surname><given-names>M.</given-names></name><name><surname>Weissman</surname><given-names>D.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>Reduced cell surface expression of CCR5 in CCR5&#x00394;32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration</article-title><source>J. Biol. Chem.</source><volume>277</volume><year>2002</year><fpage>2287</fpage><lpage>2301</lpage><pub-id pub-id-type="doi">10.1074/jbc.M108321200</pub-id><pub-id pub-id-type="pmid">11604406</pub-id></element-citation></ref><ref id="bib1555"><element-citation publication-type="journal" id="sbref1555"><person-group person-group-type="author"><name><surname>Venuti</surname><given-names>A.</given-names></name><name><surname>Pastori</surname><given-names>C.</given-names></name><name><surname>Siracusano</surname><given-names>G.</given-names></name><name><surname>Riva</surname><given-names>A.</given-names></name><name><surname>Sciortino</surname><given-names>M.T.</given-names></name><name><surname>Lopalco</surname><given-names>L.</given-names></name></person-group><article-title>ERK1-based pathway as a new selective mechanism to modulate CCR5 with natural antibodies</article-title><source>J. Immunol.</source><volume>195</volume><year>2015</year><fpage>3045</fpage><lpage>3057</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500708</pub-id><pub-id pub-id-type="pmid">26324779</pub-id></element-citation></ref><ref id="bib1560"><element-citation publication-type="journal" id="sbref1560"><person-group person-group-type="author"><name><surname>Venuti</surname><given-names>A.</given-names></name><name><surname>Pastori</surname><given-names>C.</given-names></name><name><surname>Pennisi</surname><given-names>R.</given-names></name><name><surname>Riva</surname><given-names>A.</given-names></name><name><surname>Sciortino</surname><given-names>M.T.</given-names></name><name><surname>Lopalco</surname><given-names>L.</given-names></name></person-group><article-title>Class B &#x003b2;-arrestin2-dependent CCR5 signalosome retention with natural antibodies to CCR5</article-title><source>Sci. Rep.</source><volume>6</volume><year>2016</year><fpage>39382</fpage><pub-id pub-id-type="doi">10.1038/srep39382</pub-id><pub-id pub-id-type="pmid">28008933</pub-id></element-citation></ref><ref id="bib1565"><element-citation publication-type="journal" id="sbref1565"><person-group person-group-type="author"><name><surname>Venuti</surname><given-names>A.</given-names></name><name><surname>Pastori</surname><given-names>C.</given-names></name><name><surname>Lopalco</surname><given-names>L.</given-names></name></person-group><article-title>The role of natural antibodies to CC chemokine receptor 5 in HIV infection</article-title><source>Front. Immunol.</source><volume>8</volume><year>2017</year><fpage>1358</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01358</pub-id><pub-id pub-id-type="pmid">29163468</pub-id></element-citation></ref><ref id="bib1570"><element-citation publication-type="journal" id="sbref1570"><person-group person-group-type="author"><name><surname>Venuti</surname><given-names>A.</given-names></name><name><surname>Pastori</surname><given-names>C.</given-names></name><name><surname>Siracusano</surname><given-names>G.</given-names></name><name><surname>Pennisi</surname><given-names>R.</given-names></name><name><surname>Riva</surname><given-names>A.</given-names></name><name><surname>Tommasino</surname><given-names>M.</given-names></name><name><surname>Sciortino</surname><given-names>M.T.</given-names></name><name><surname>Lopalco</surname><given-names>L.</given-names></name></person-group><article-title>The abrogation of phosphorylation plays a relevant role in the CCR5 signalosome formation with natural antibodies to CCR5</article-title><source>Viruses</source><volume>10</volume><year>2018</year><fpage>9</fpage><pub-id pub-id-type="doi">10.3390/v10010009</pub-id></element-citation></ref><ref id="bib1575"><element-citation publication-type="journal" id="sbref1575"><person-group person-group-type="author"><name><surname>Vigan&#x000f2;</surname><given-names>M.</given-names></name><name><surname>Andreoni</surname><given-names>M.</given-names></name><name><surname>Perno</surname><given-names>C.F.</given-names></name><name><surname>Crax&#x000ec;</surname><given-names>A.</given-names></name><name><surname>Aghemo</surname><given-names>A.</given-names></name><name><surname>Alberti</surname><given-names>A.</given-names></name><name><surname>Andreone</surname><given-names>P.</given-names></name><name><surname>Babudieri</surname><given-names>S.</given-names></name><name><surname>Bonora</surname><given-names>S.</given-names></name><name><surname>Brunetto</surname><given-names>M.R.</given-names></name><name><surname>Bruno</surname><given-names>R.</given-names></name><name><surname>Bruno</surname><given-names>S.</given-names></name><name><surname>Calvaruso</surname><given-names>V.</given-names></name><name><surname>Caporaso</surname><given-names>N.</given-names></name><name><surname>Cartabellotta</surname><given-names>F.</given-names></name><name><surname>Ceccherini-Silberstein</surname><given-names>F.</given-names></name><name><surname>Cento</surname><given-names>V.</given-names></name><name><surname>Ciancio</surname><given-names>A.</given-names></name><name><surname>Colombatto</surname><given-names>P.</given-names></name><name><surname>Coppola</surname><given-names>N.</given-names></name><name><surname>Di Marco</surname><given-names>V.</given-names></name><name><surname>Di Perri</surname><given-names>G.</given-names></name><name><surname>Fagiuoli</surname><given-names>S.</given-names></name><name><surname>Gaeta</surname><given-names>G.B.</given-names></name><name><surname>Gasbarrini</surname><given-names>A.</given-names></name><name><surname>Lampertico</surname><given-names>P.</given-names></name><name><surname>Pellicelli</surname><given-names>A.</given-names></name><name><surname>Prestileo</surname><given-names>T.</given-names></name><name><surname>Puoti</surname><given-names>M.</given-names></name><name><surname>Raimondo</surname><given-names>G.</given-names></name><name><surname>Rizzardini</surname><given-names>G.</given-names></name><name><surname>Taliani</surname><given-names>G.</given-names></name><name><surname>Zignego</surname><given-names>A.L.</given-names></name></person-group><article-title>Real life experiences in HCV management in 2018</article-title><source>Expert Rev. Anti. Ther.</source><volume>17</volume><year>2019</year><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1080/14787210.2019.1563755</pub-id></element-citation></ref><ref id="bib1580"><element-citation publication-type="journal" id="sbref1580"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>T.</given-names></name><name><surname>Portales</surname><given-names>P.</given-names></name><name><surname>Baillat</surname><given-names>V.</given-names></name><name><surname>de Boever</surname><given-names>C.M.</given-names></name><name><surname>Le Moing</surname><given-names>V.</given-names></name><name><surname>Vidal</surname><given-names>M.</given-names></name><name><surname>Ducos</surname><given-names>J.</given-names></name><name><surname>Clot</surname><given-names>J.</given-names></name><name><surname>Reynes</surname><given-names>J.</given-names></name><name><surname>Corbeau</surname><given-names>P.</given-names></name></person-group><article-title>T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists</article-title><source>J. Acquir. Immune Defic. Syndr.</source><volume>38</volume><year>2005</year><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1097/01.qai.0000149793.14334.6c</pub-id><pub-id pub-id-type="pmid">15735449</pub-id></element-citation></ref><ref id="bib1585"><element-citation publication-type="journal" id="sbref1585"><person-group person-group-type="author"><name><surname>Vomaske</surname><given-names>J.</given-names></name><name><surname>Denton</surname><given-names>M.</given-names></name><name><surname>Kreklywich</surname><given-names>C.</given-names></name><name><surname>Andoh</surname><given-names>T.</given-names></name><name><surname>Osborn</surname><given-names>J.M.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Messaoudi</surname><given-names>I.</given-names></name><name><surname>Orloff</surname><given-names>S.L.</given-names></name><name><surname>Streblow</surname><given-names>D.N.</given-names></name></person-group><article-title>Cytomegalovirus CC chemokine promotes immune cell migration</article-title><source>J. Virol.</source><volume>86</volume><year>2012</year><fpage>11833</fpage><lpage>11844</lpage><pub-id pub-id-type="doi">10.1128/JVI.00452-12</pub-id><pub-id pub-id-type="pmid">22915808</pub-id></element-citation></ref><ref id="bib1590"><element-citation publication-type="journal" id="sbref1590"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>O.</given-names></name><name><surname>Pappo</surname><given-names>O.</given-names></name><name><surname>Ari</surname><given-names>Z.B.</given-names></name><name><surname>Azzaria</surname><given-names>E.</given-names></name><name><surname>Wiess</surname><given-names>I.D.</given-names></name><name><surname>Gafnovitch</surname><given-names>I.</given-names></name><name><surname>Wald</surname><given-names>H.</given-names></name><name><surname>Spengler</surname><given-names>U.</given-names></name><name><surname>Galun</surname><given-names>E.</given-names></name><name><surname>Peled</surname><given-names>A.</given-names></name></person-group><article-title>The CCR5&#x00394;32 allele is associated with reduced liver inflammation in hepatitis C virus infection</article-title><source>Eur. J. Immunogenet.</source><volume>31</volume><year>2004</year><fpage>249</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2370.2004.00482.x</pub-id><pub-id pub-id-type="pmid">15548261</pub-id></element-citation></ref><ref id="bib1595"><element-citation publication-type="journal" id="sbref1595"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Gene-edited babies: what went wrong and what could go wrong</article-title><source>PLoS Biol.</source><volume>17</volume><year>2019</year><object-id pub-id-type="publisher-id">e3000224</object-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000224</pub-id></element-citation></ref><ref id="bib1600"><element-citation publication-type="journal" id="sbref1600"><person-group person-group-type="author"><name><surname>Wasmuth</surname><given-names>H.E.</given-names></name><name><surname>Werth</surname><given-names>A.</given-names></name><name><surname>Mueller</surname><given-names>T.</given-names></name><name><surname>Berg</surname><given-names>T.</given-names></name><name><surname>Dietrich</surname><given-names>C.G.</given-names></name><name><surname>Geier</surname><given-names>A.</given-names></name><name><surname>Schirin-Sokhan</surname><given-names>R.</given-names></name><name><surname>Gartung</surname><given-names>C.</given-names></name><name><surname>Lorenzen</surname><given-names>J.</given-names></name><name><surname>Matern</surname><given-names>S.</given-names></name><name><surname>Lammert</surname><given-names>F.</given-names></name></person-group><article-title>CC chemokine receptor 5 &#x00394;32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia</article-title><source>J. Mol. Med.</source><volume>82</volume><year>2004</year><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s00109-003-0505-0</pub-id><pub-id pub-id-type="pmid">14673528</pub-id></element-citation></ref><ref id="bib1605"><element-citation publication-type="journal" id="sbref1605"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>R.G.</given-names></name><name><surname>Semsarian</surname><given-names>C.</given-names></name><name><surname>Macdonald</surname><given-names>P.</given-names></name></person-group><article-title>Dilated cardiomyopathy</article-title><source>Lancet</source><volume>390</volume><year>2017</year><fpage>400</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31713-5</pub-id><pub-id pub-id-type="pmid">28190577</pub-id></element-citation></ref><ref id="bib1610"><element-citation publication-type="journal" id="sbref1610"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>I.D.</given-names></name><name><surname>Shoham</surname><given-names>H.</given-names></name><name><surname>Wald</surname><given-names>O.</given-names></name><name><surname>Wald</surname><given-names>H.</given-names></name><name><surname>Beider</surname><given-names>K.</given-names></name><name><surname>Abraham</surname><given-names>M.</given-names></name><name><surname>Barashi</surname><given-names>N.</given-names></name><name><surname>Galun</surname><given-names>E.</given-names></name><name><surname>Nagler</surname><given-names>A.</given-names></name><name><surname>Peled</surname><given-names>A.</given-names></name></person-group><article-title>Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditions</article-title><source>Cytokine</source><volume>54</volume><year>2011</year><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2011.01.011</pub-id><pub-id pub-id-type="pmid">21376626</pub-id></element-citation></ref><ref id="bib1615"><element-citation publication-type="journal" id="sbref1615"><person-group person-group-type="author"><name><surname>Woitas</surname><given-names>R.P.</given-names></name><name><surname>Ahlenstiel</surname><given-names>G.</given-names></name><name><surname>Iwan</surname><given-names>A.</given-names></name><name><surname>Rockstroh</surname><given-names>J.K.</given-names></name><name><surname>Brackmann</surname><given-names>H.H.</given-names></name><name><surname>Kupfer</surname><given-names>B.</given-names></name><name><surname>Matz</surname><given-names>B.</given-names></name><name><surname>Offergeld</surname><given-names>R.</given-names></name><name><surname>Sauerbruch</surname><given-names>T.</given-names></name><name><surname>Spengler</surname><given-names>U.</given-names></name></person-group><article-title>Frequency of the HIV-protective CC chemokine receptor 5-&#x00394;32/&#x00394;32 genotype is increased in hepatitis C</article-title><source>Gastroenterology</source><volume>122</volume><year>2002</year><fpage>1721</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.33660</pub-id><pub-id pub-id-type="pmid">12055576</pub-id></element-citation></ref><ref id="bib1620"><element-citation publication-type="journal" id="sbref1620"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Paxton</surname><given-names>W.A.</given-names></name><name><surname>Kassam</surname><given-names>N.</given-names></name><name><surname>Ruffing</surname><given-names>N.</given-names></name><name><surname>Rottman</surname><given-names>J.B.</given-names></name><name><surname>Sullivan</surname><given-names>N.</given-names></name><name><surname>Choe</surname><given-names>H.</given-names></name><name><surname>Sodroski</surname><given-names>J.</given-names></name><name><surname>Newman</surname><given-names>W.</given-names></name><name><surname>Koup</surname><given-names>R.A.</given-names></name><name><surname>Mackay</surname><given-names>C.R.</given-names></name></person-group><article-title>CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro</article-title><source>J. Exp. Med.</source><volume>185</volume><year>1997</year><fpage>1681</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1084/jem.185.9.1681</pub-id><pub-id pub-id-type="pmid">9151905</pub-id></element-citation></ref><ref id="bib1625"><element-citation publication-type="journal" id="sbref1625"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.G.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>Z.W.</given-names></name><name><surname>Tian</surname><given-names>J.H.</given-names></name><name><surname>Pei</surname><given-names>Y.Y.</given-names></name><name><surname>Yuan</surname><given-names>M.L.</given-names></name><name><surname>Zhang</surname><given-names>Y.L.</given-names></name><name><surname>Dai</surname><given-names>F.H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.M.</given-names></name><name><surname>Zheng</surname><given-names>J.J.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Holmes</surname><given-names>E.C.</given-names></name><name><surname>Zhang</surname><given-names>Y.L.Z.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="bib1630"><element-citation publication-type="journal" id="sbref1630"><person-group person-group-type="author"><name><surname>Wysocki</surname><given-names>C.A.</given-names></name><name><surname>Jiang</surname><given-names>Q.</given-names></name><name><surname>Panoskaltsis-Mortari</surname><given-names>A.</given-names></name><name><surname>Taylor</surname><given-names>P.A.</given-names></name><name><surname>McKinnon</surname><given-names>K.P.</given-names></name><name><surname>Su</surname><given-names>L.</given-names></name><name><surname>Blazar</surname><given-names>B.R.</given-names></name><name><surname>Serody</surname><given-names>J.S.</given-names></name></person-group><article-title>Critical role for CCR5 in the function of donor CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells during acute graft-versus-host disease</article-title><source>Blood</source><volume>106</volume><year>2005</year><fpage>3300</fpage><lpage>3307</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-04-1632</pub-id><pub-id pub-id-type="pmid">16002422</pub-id></element-citation></ref><ref id="bib1635"><element-citation publication-type="journal" id="sbref1635"><person-group person-group-type="author"><name><surname>Xavier-Carvalho</surname><given-names>C.</given-names></name><name><surname>Gibson</surname><given-names>G.</given-names></name><name><surname>Brasil</surname><given-names>P.</given-names></name><name><surname>Ferreira</surname><given-names>R.X.</given-names></name><name><surname>de Souza Santos</surname><given-names>R.</given-names></name><name><surname>Gon&#x000e7;alves Cruz</surname><given-names>O.</given-names></name><name><surname>de Oliveira</surname><given-names>S.A.</given-names></name><name><surname>de S&#x000e1; Carvalho</surname><given-names>M.</given-names></name><name><surname>Pacheco</surname><given-names>A.G.</given-names></name><name><surname>Kubelka</surname><given-names>C.F.</given-names></name><name><surname>Moraes</surname><given-names>M.O.</given-names></name></person-group><article-title>Single nucleotide polymorphisms in candidate genes and dengue severity in children: a case-control, functional and meta-analysis study</article-title><source>Infect. Genet. Evol.</source><volume>20</volume><year>2013</year><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2013.08.017</pub-id><pub-id pub-id-type="pmid">24016730</pub-id></element-citation></ref><ref id="bib1640"><element-citation publication-type="journal" id="sbref1640"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Zhan</surname><given-names>S.</given-names></name><name><surname>Ge</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>P.</given-names></name></person-group><article-title>The potential risks of C-C chemokine receptor 5-edited babies in bone development</article-title><source>Bone Res.</source><volume>7</volume><year>2019</year><fpage>4</fpage><pub-id pub-id-type="doi">10.1038/s41413-019-0044-0</pub-id><pub-id pub-id-type="pmid">30701110</pub-id></element-citation></ref><ref id="bib1645"><element-citation publication-type="journal" id="sbref1645"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhong</surname><given-names>Z.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name></person-group><article-title>Bioinformatic identification of key genes and pathways that maY. be involved in the pathogenesis of HBV-associated acute liver failure</article-title><source>Genes Dis.</source><volume>5</volume><year>2018</year><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2018.02.005</pub-id><pub-id pub-id-type="pmid">30591937</pub-id></element-citation></ref><ref id="bib1650"><element-citation publication-type="journal" id="sbref1650"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>A.</given-names></name><name><surname>Alagozlu</surname><given-names>H.</given-names></name><name><surname>Ozdemir</surname><given-names>O.</given-names></name><name><surname>Arici</surname><given-names>S.</given-names></name></person-group><article-title>Effects of the chemokine receptor 5 (CCR5)-delta32 mutation on hepatitis C virus-specific immune responses and liver tissue pathology in HCV infected patients</article-title><source>Hepat. Mon.</source><volume>14</volume><year>2014</year><object-id pub-id-type="publisher-id">e11283</object-id><pub-id pub-id-type="doi">10.5812/hepatmon.11283</pub-id></element-citation></ref><ref id="bib1655"><element-citation publication-type="journal" id="sbref1655"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>M.F.</given-names></name><name><surname>Chen</surname><given-names>D.S.</given-names></name><name><surname>Dusheiko</surname><given-names>G.M.</given-names></name><name><surname>Janssen</surname><given-names>H.L.A.</given-names></name><name><surname>Lau</surname><given-names>D.T.Y.</given-names></name><name><surname>Locarnini</surname><given-names>S.A.</given-names></name><name><surname>Peters</surname><given-names>M.G.</given-names></name><name><surname>Lai</surname><given-names>C.L.</given-names></name></person-group><article-title>Hepatitis B virus infection</article-title><source>Nat. Rev. Dis. Primers</source><volume>4</volume><year>2018</year><fpage>18035</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2018.35</pub-id><pub-id pub-id-type="pmid">29877316</pub-id></element-citation></ref><ref id="bib1660"><element-citation publication-type="journal" id="sbref1660"><person-group person-group-type="author"><name><surname>Zachova</surname><given-names>K.</given-names></name><name><surname>Kosztyu</surname><given-names>P.</given-names></name><name><surname>Zadrazil</surname><given-names>J.</given-names></name><name><surname>Matousovic</surname><given-names>K.</given-names></name><name><surname>Vondrak</surname><given-names>K.</given-names></name><name><surname>Hubacek</surname><given-names>P.</given-names></name><name><surname>Kostovcikova</surname><given-names>K.</given-names></name><name><surname>Tlaskalova Hogenova</surname><given-names>H.</given-names></name><name><surname>Mestecky</surname><given-names>J.</given-names></name><name><surname>Raska</surname><given-names>M.</given-names></name></person-group><article-title>Multiparametric flow cytometry analysis of peripheral blood B cell trafficking differences among Epstein-Barr virus infected and uninfected subpopulations</article-title><source>Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech.</source><year>2019</year><pub-id pub-id-type="doi">10.5507/bp.2019.052</pub-id><comment>in press</comment></element-citation></ref><ref id="bib1665"><element-citation publication-type="journal" id="sbref1665"><person-group person-group-type="author"><name><surname>Zahran</surname><given-names>A.M.</given-names></name><name><surname>Hetta</surname><given-names>H.F.</given-names></name><name><surname>Rayan</surname><given-names>A.</given-names></name><name><surname>Eldin</surname><given-names>A.S.</given-names></name><name><surname>Hassan</surname><given-names>E.A.</given-names></name><name><surname>Fakhry</surname><given-names>H.</given-names></name><name><surname>Soliman</surname><given-names>A.</given-names></name><name><surname>El&#x02011;Badawy</surname><given-names>O.</given-names></name></person-group><article-title>Differential expression of Tim&#x02011;3, PD&#x02011;1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus&#x02011;related hepatocellular carcinoma and their impact on treatment outcomes</article-title><source>Cancer Immunol. Immunother.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00262-019-02465-y</pub-id><comment>in press</comment></element-citation></ref><ref id="bib1670"><element-citation publication-type="journal" id="sbref1670"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Goedert</surname><given-names>J.J.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>T.R.</given-names></name></person-group><article-title>High frequency of <italic>CCR5</italic>-&#x00394;32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1</article-title><source>Gastroenterology</source><volume>124</volume><year>2003</year><fpage>867</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1053/gast.2003.50132</pub-id><pub-id pub-id-type="pmid">12612937</pub-id></element-citation></ref><ref id="bib1675"><element-citation publication-type="journal" id="sbref1675"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Shan</surname><given-names>K.R.</given-names></name><name><surname>Tan</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>C.J.</given-names></name><name><surname>Guan</surname><given-names>Z.Z.</given-names></name></person-group><article-title>Correlations between polymorphisms in the uridine diphosphate-glucuronosyltransferase 1A and C-C motif chemokine receptor 5 genes and infection with the hepatitis B virus in three ethnic groups in China</article-title><source>J. Int. Med. Res.</source><volume>46</volume><year>2018</year><fpage>739</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1177/0300060517730174</pub-id><pub-id pub-id-type="pmid">29239247</pub-id></element-citation></ref><ref id="bib1680"><element-citation publication-type="journal" id="sbref1680"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Qi</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Cao</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>B.</given-names></name></person-group><article-title>PD1<sup>+</sup>CCR2<sup>+</sup>CD8<sup>+</sup> T cells infiltrate the central nervous system during acute Japanese encephalitis virus infection</article-title><source>Virol. Sin.</source><volume>34</volume><year>2019</year><fpage>538</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1007/s12250-019-00134-z</pub-id><pub-id pub-id-type="pmid">31215000</pub-id></element-citation></ref><ref id="bib1685"><element-citation publication-type="journal" id="sbref1685"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Wiklund</surname><given-names>F.</given-names></name><name><surname>Gharizadeh</surname><given-names>B.</given-names></name><name><surname>Sadat</surname><given-names>M.</given-names></name><name><surname>Gambelunghe</surname><given-names>G.</given-names></name><name><surname>Hallmans</surname><given-names>G.</given-names></name><name><surname>Dillner</surname><given-names>J.</given-names></name><name><surname>Wallin</surname><given-names>K.L.</given-names></name><name><surname>Ghaderi</surname><given-names>M.</given-names></name></person-group><article-title>Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients</article-title><source>Anticancer Res.</source><volume>26</volume><year>2006</year><fpage>3669</fpage><lpage>3674</lpage><pub-id pub-id-type="pmid">17094383</pub-id></element-citation></ref><ref id="bib1690"><element-citation publication-type="journal" id="sbref1690"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>G.W.</given-names></name><name><surname>Abagyan</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Stevens</surname><given-names>R.C.</given-names></name><name><surname>Cherezov</surname><given-names>V.</given-names></name><name><surname>Kufareva</surname><given-names>I.</given-names></name><name><surname>Handel</surname><given-names>T.M.</given-names></name></person-group><article-title>Structure of CC chemokine receptor 5 with a potent chemokine antagonist reveals mechanisms of chemokine recognition and molecular mimicry by HIV</article-title><source>Immunity</source><volume>46</volume><year>2017</year><fpage>1005</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.05.002</pub-id><pub-id pub-id-type="pmid">28636951</pub-id></element-citation></ref><ref id="bib1695"><element-citation publication-type="journal" id="sbref1695"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Host microRNAs and exosomes that modulate influenza virus infection</article-title><source>Virus Res.</source><volume>279</volume><year>2020</year><object-id pub-id-type="publisher-id">197885</object-id><pub-id pub-id-type="doi">10.1016/j.virusres.2020.197885</pub-id></element-citation></ref><ref id="bib1700"><element-citation publication-type="journal" id="sbref1700"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Woodson</surname><given-names>M.</given-names></name><name><surname>Neupane</surname><given-names>B.</given-names></name><name><surname>Bai</surname><given-names>F.</given-names></name><name><surname>Sherman</surname><given-names>M.B.</given-names></name><name><surname>Choi</surname><given-names>K.H.</given-names></name><name><surname>Neelakanta</surname><given-names>G.</given-names></name><name><surname>Sultana</surname><given-names>H.</given-names></name></person-group><article-title>Exosomes serve as novel modes of tick-borne flavivirus transmission from arthropod to human cells and facilitates dissemination of viral RNA and proteins to the vertebrate neuronal cells</article-title><source>PLoS Pathog.</source><volume>14</volume><year>2018</year><object-id pub-id-type="publisher-id">e1006764</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006764</pub-id></element-citation></ref><ref id="bib1705"><element-citation publication-type="journal" id="sbref1705"><person-group person-group-type="author"><name><surname>Zlotnik</surname><given-names>A.</given-names></name><name><surname>Yoshie</surname><given-names>O.</given-names></name></person-group><article-title>Chemokines: a new classification system and their role in immunity</article-title><source>Immunity</source><volume>12</volume><year>2000</year><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(00)80165-x</pub-id><pub-id pub-id-type="pmid">10714678</pub-id></element-citation></ref><ref id="bib1710"><element-citation publication-type="journal" id="sbref1710"><person-group person-group-type="author"><name><surname>Zwoli&#x00144;ska</surname><given-names>K.</given-names></name><name><surname>Knysz</surname><given-names>B.</given-names></name><name><surname>Rybka</surname><given-names>K.</given-names></name><name><surname>Pazgan-Simon</surname><given-names>M.</given-names></name><name><surname>G&#x00105;siorowski</surname><given-names>J.</given-names></name><name><surname>Sobczy&#x00144;ski</surname><given-names>M.</given-names></name><name><surname>G&#x00142;adysz</surname><given-names>A.</given-names></name><name><surname>Piasecki</surname><given-names>E.</given-names></name></person-group><article-title>Protective effect of <italic>CCR5-&#x00394;32</italic> against HIV infection by the heterosexual mode of transmission in a Polish population</article-title><source>AIDS Res. Hum. Retroviruses</source><volume>29</volume><year>2013</year><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1089/AID.2011.0362</pub-id><pub-id pub-id-type="pmid">22957692</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements and Funding</title><p>This work was supported by Brazilian funding agencies: JHE receives a postdoctoral fellowship from <funding-source id="gs0005">Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior (CAPES, Brazil)</funding-source>; BKL receives a master scholarship from <funding-source id="gs0010">Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq, Brazil)</funding-source>; VLK received a doctoral scholarship from CAPES (Brazil) and currently receives a postdoctoral fellowship from <funding-source id="gs0015">Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo (FAPESP, Brazil)</funding-source>; AGR received a scholarship from <funding-source id="gs0020">Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado do Rio Grande do Sul (FAPERGS, Brazil)</funding-source>; MASB receives a doctoral scholarship from CAPES (Brazil); JABC receives a research fellowship from CNPq (Brazil).</p></ack></back></article>